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There is now strong evidence to suggest that prostaglandin (PG)-F2ct acts as a
uterine luteolysin in a number of sub-primate mammalian species. The purpose of
the experiments reported here was to investigate whether PGF2ct acts as a uterine
luteolysin in the pseudopregnant rabbit and to examine the effects of pregnancy and
hormone treatment on PGF2ct secretion by the uterus.
Measurements of plasma progesterone and measurements of PGF2a, PGE2 and 6-keto-
PGFia concentrations in plasma and uterine and placental tissue were made by radio¬
immunoassay following solvent extraction. The presence of PGF2ct, PGE2 and 6-keto-
PGFia was confirmed by combined gas chromatography - mass spectrometry wherever
possible.
Peripheral plasma progesterone concentrations in intact and hysterectomised
rabbits decreased from Day 14. The rate of decrease in intact, but not in
hysterectomised rabbits was accelerated on Days 17 and 18 and was associated
with an increase in PGF2c( levels in the uterine venous plasma. There was no change
in uterine PGE2 output during pseudopregnancy. The endogenous uterine tissue con¬
centration of PGF2a was significantly higher on Day 17 than on earlier days of
pseudopregnancy but neither this nor the increase in uterine PGF2a secretion on
Day 17 could be related to an increase in the ability of uterine tissue homogenates
to synthesise PGF2a in vitro, or to an increase in substrate availability or a
decrease in the ability of uterine tissue to metabolise PGF2a.
In the pregnant rabbit the peripheral plasma progesterone concentrations
remained elevated up to Day 31 and there was no increase in uterine venous plasma
levels of .PGF2a on Days 17 and 18. PGF2a levels in the uterine venous plasma were
elevated on Days 24 to 26 of pregnancy but this increase was not associated with a
decrease in plasma progesterone concentrations. There was no significant difference
in the ability of uterine tissue from Day 17 pregnant or Day 17 pseudopregnant
rabbits to synthesise or metabolise PGF2c( in vitro. The uterine venous plasma
levels of PGE2 increased markedly after Day 11 of pregnancy and was positively
correlated with the number of foetuses present in the uterus. The Day 17 pregnant
uterus synthesised significantly more PGE2 than the Day 17 pseudopregnant uterus
and synthesised significantly less PGE2 than the Day 17 foetal-placenta.
In ovariectomised rabbits the in vivo administration of progesterone signifi¬
cantly increased the ability of uterine tissue homogenates to synthesise PGF2c( when
compared with oestrogen administration. This effect is due to a lack of substrate
availability. The synthetic potential of the uterus is greatest following the
sequential exposure of uterine tissue to progesterone followed by oestrogen.
It is concluded that PGF2a does act as a uterine luteolysin in the pseudo¬
pregnant rabbit and that prostaglandin production by the pregnant uterus and its
contents is important in maintaining placental function and is also involved in the
process of parturition.
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INTRODUCTION
The field of prostaglandin research has been closely linked with
that of reproductive physiology since the 1930s. Kurzrok and Lieb
(1930) showed that fresh human semen was capable of affecting the
motility of the human uterus, in vitro, and that the response of the
tissue depended on its reproductive state. The effects of human
and sheep semen on various biological systems were examined by Von
Euler (1934) and Goldblatt (1935), and in 1935, in the same journal
in which the name 'progesterone' was suggested for the hormone pro¬
duced by the corpus luteum (Allen, Corner, Butenandt and Slotta,
1935), Von Euler proposed that the name 'prostaglandin' be given to
the constituents of human semen that are responsible for its vaso¬
depressor and smooth-muscle stimulating activity. However, it was
not until the early 1960s, following the isolation and determination
of the absolute configuration of prostaglandin E^ (PGEj^), prosta¬
glandin Fia and prostaglandin F2a (PGF2a) (Bergstrom, Ryhage,
Samuelsson and Sjovall, 1962), that it was proved that these proper¬
ties of seminal fluid were attributable to a new group of compounds.
Chemically, the primary prostaglandins are C20 unsaturated,
hydroxy fatty acids comprising two chains joined by a cyclopentane
ring. They are formed from certain essential fatty acids by the
action of a membrane bound enzyme complex, prostaglandin synthetase.
In mammalian tissues, the most prominent substrate for this enzyme
complex is free arachidonic acid. The majority of arachidonic acid
in tissues is in the form of phospholipids, cholesterol esters or
triglycerides. The first stage in prostaglandin biosynthesis
therefore requires the liberation of arachidonic acid by the action















































Since the original studies of Bergstr8m and his co-workers in the
early 1960s, several pathways in the oxidative biotransformation of
arachidonic acid have been characterised. Some of these pathways
are summarised in Figs 1 and 2.
Prostaglandins are not stored in tissues, so their release is
prec^eded by their immediate synthesis. It is possible that every
cell in the body has the capacity to synthesis and release prosta¬
glandins, and will do so if damaged. The release of prostaglandins
from many intact tissues has been examined and one organ which has
received much attention is the uterus. The main reason for this is
that in many mammalian species the uterus influences ovarian
function.
Uterine luteolytic hormone (luteolysin)
In 1923, Loeb showed that the removal of the uterus during the
luteal phase of the cycle in the guinea-pig, extended the life span
of the corpus luteum for a period equivalent to, or longer than,
pregnancy. In 1927, Loeb wrote "It is possible that the uterus, in
particular its mucosa, produces an internal secretion which exerts a
specific abbreviating effect on the life of the corpus luteum."
Since that time hysterectomy has been shown to prolong luteal function
in the cycling sheep (Wiltbank and Casida, 1956), pig (Anderson,
Butcher and Melampy, 1963), cow (Wiltbank and Casida, 1956; Anderson,
Neal and Melampy, 1962) and mare (Hughes, Stabenfeldt and Evans, 1977)
and in the pseudopregnant hamster (Duby, McDaniel, Spilman and Black,
1969), rabbit (Asdell and Hammond, 1933; Chu, Lee and You, 1946), rat
(Melampy, Anderson and Kragt, 1964; Bradbury, 1937), vole (Eloff
and Milligan, 1980) and mouse (Crister, Rutledge and Evans,
1980). However, in certain other species including the ferret
(Deanesly and Parkes, 1933), monkey (Burford and Diddle, 1936; TeLinde
and Wharton, 1960) and human (Beling, Stewart, Marcus and Markham,
1970) hysterectomy does not appear to affect luteal function. This
suggests that, in those species, the control of the life span of the
corpus luteum is independent of the uterus.
Between 1927 and 1969 much evidence for the existence of a
uterine luteolysin accumulated. Although attempts to isolate and
identify the principle involved failed, several important character¬
istics of the uterine-luteal relationship were revealed. One of
the most striking features of this relationship is that in many
species it acts primarily on a local basis, each uterine horn exerting
its influence over the ipsilateral ovary only. Inskeep and Butcher
(1966) showed that in bilaterally ovulating ewes, hemihysterectomy
only prolonged the oestrous cycle when combined with contralateral
ovariectomy. Cycle length was not affected if the ipsilateral ovary
was removed. However, if the remaining uterine horn was separated
and retracted from its physical connections with the overy, luteal
maintenance occurred. Similar results were reported in the cycling
guinea-pig (Bland and Donovan, 1969a; Butcher, Barley and Inskeep,
1969; Fischer, 1974) and in the pseudopregnant rat (Barley, Butcher
and Inskeep, 1966) and hamster (Orsini, 1968). In the cycling pig
unilateral regression also occurs but only when all but one quarter
of one uterine horn has been removed (Anderson, Butcher and Melampy,
1961).
Experiments involving the removal of the uterus at different
stages of the luteal phase showed that the luteolytic factor was secre¬
ted around the time of luteal regression. The exact timing of onset
and the duration of secretion of luteolysin needed to bring about
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luteal regression shows considerable species variation. In the
pseudopregnant hamster and cycling guinea-pig, hysterectomy will
prolong luteal function if performed as late as the morning of Day 8
(pseudopregnancy 9 days) or Day 14 (cycle length approximately 16
days) respectively (Caldwell, Mazer and Wright, 1967; Bland and
Donovan, 1969a). In sheep, the removal of the uterus as late as
Day 15 (cycle length approximately 17 days), will arrest involutionary
changes in the luteal cells providing the corpora lutea are still
functional (Moor, Hay, Short and Rowson, 1970; Kiracofe and Spies, 1964).
Uterine venous blood from donor ewes on Day 15 of the cycle will also
cause a 50% decrease in progesterone levels in recipient animals with
an autotransplanted ovary. (McCracken, Carlson, Glew, Goding, Baird,
Green and Samuelsson, 1972). In the pig hysterectomy on Day 16 will
maintain luteal function in 50% of animals (Anderson, Bowerman and
Melampy, 1963).
Premature, uterine medicated luteolysis can also be induced by
a variety of stimuli. The insertion of a foreign body into the
uterine horn(s) adjacent to the functional corpus luteum in the
guinea-pig (Bland and Donovan, 1965), cow (Chatterjee and Luktuke,
1961) and sheep (Ginther, Pope and Casida, 1966) is one such stimulus.
The foreign body probably acts by causing local irritation or infla-
mation of the endometrium and thereby releasing the uterine luteoly-
sin. Treatments which result in the destruction of the endometrium
\
however, are often associated with luteal maintenance (Anderson
et al., 1961).
Oestrogen is luteolytic in the cow when given on Days 2 to 12
of the cycle, in the sheep when given after Day 10 and in the
guinea-pig when administered on Days 4 to 6 (Greenstein, Murray and
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Folley, 1958; Stormshak, Kelley and Hawk, 1968; 1969; Bland and
Donovan, 1968; Choudary and Greenwald, 1968). Progesterone
treatment begun on Day 1 of the cycle and continued for several days
also decreases cycle length in the sheep, cow, and guinea-pig (Loy,
Zimbleman and Casida, 1960; Woody, First and Pope, 1967) providing
the uterus is intact (Bolt and Hawk, 1972a; Stormshak et al. , 1968;
1969; Bland and Donovan, 1970; Rowlands, 1962; Brunner, Donaldson
and Hansel, 1969; Kaltenbach, Niswender, Zimmerman and Wiltbank,
1964). Oxytocin treatment will also induce precocious oestrus in
the cow providing the uterine horn adjacent to the corpus luteum is
left intact (Ginther, Woody, Mahajan, Janakiraman and Casida, 1967).
Before the role of a uterine luteolytic hormone can be ascribed
to a compound, the pattern of secretion and metabolism of that com¬
pound by the uterus and other relevant tissues should be able to
account for the above observations and satisfy the following criteria.
1) The exogenous administration of this compound should induce
luteal regression and be accompanied by a decrease in the
circulating plasma levels of progesterone.
2) The compound should be produced by the uterus, in amounts
sufficient to cause luteolysis, at the time luteal regression
occurs.
3) It should pass from the uterus to the ovary in a localised
manner.
4) Factors which affect its synthesis, metabolism and/or mode
of action, should affect luteal function in the appropriate
manner.
These criteria will be considered separately :-
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1) In 1969, Phariss and Wyngarden reported that the daily, sub¬
cutaneous administration of 1 mg kg-1 PGF2a to pseudopregnant rats
reduced the duration of pseudopregnancy from a mean length of 14 days
to 7 days. Since this initial study PGF2a has been shown to be
luteolytic in many non-primate, mammalian species including the sheep
(McCracken, Glew and Scaramuzzi, 1970), cow (Liehr, Marion and Olsen,
1972; Lauderdale, 1972), pig (Gleeson, 1974) , guinea-pig (Blatchley
and Donovan, 1969), mare (Noden, Oxender and Hafs, 1974), and pseudo-
pregnant rabbit (Gutknecht, Duncan and Wyngarden, 1970).
The mechanism by which PGF2a induces luteolysis is not fully
known although much data has accumulated in the past lOyrs. Because
PGF2a is a potent venoconstrictor (Du Charme, Weeks and Montgomery,
1968), Pharriss, Cornette and Gutknecht (1970) proposed that the
luteolytic effect of PGF2a was due to constriction of the utero-
ovarian vein, resulting in a reduced ovarian blood flow and luteolysis
ensuing as a consequence of anoxia. This theory gained support when
Speroff and Ramwell (1970) showed that, during a three hour incuba¬
tion period, PGF2a stimulated the in vitro production of progesterone
by the ovary. This suggested that PGF2a did not have a direct
'luteolytic effect on the ovary. However, subsequent experiments
showed that when the incubation time was doubled, PGF2a did inhibit
progesterone production (0fGrady, Kohorn, Glass, Caldwell, Brock
and Speroff, 1972). Prostaglandins of the E series stimulate
ovarian progesterone production in vitro by increasing the intra¬
cellular levels of adenosine 3',51-monophosphate (c-AMP). The
stimulatory effect of PGF2a in vitro is probably due to a PGE-like
action. The initial increase in progesterone production followed by
its inhibition is also seen in vivo when PGF2a is infused into the
9
autotransplanted sheep ovary at a low dose level. If the dose of
PGF2a is increased the initial stimulant effect is not seen. More¬
over, the decrease in progesterone production occurs without any
corresponding reduction in the total ovarian blood flow (McCracken,
et at., 1970; Baird, 1974) suggesting that PGF2a is capable of
exerting a direct, biochemical effect on the luteal cell. Niswender,
Diekman, Nett and Akbor (1973) have reported a selective reduction in
the blood flow to the corpus luteum in the sheep ovary, and PGF2cx has
been observed to selectively reduce blood flow to the corpus luteum
of the sheep (Thorburn and Hales, 1972) and rabbit (Novy and Cook, 1973).
However, Einer-Jenson and McCracken (1977) found that the decrease in
progesterone output from the corpus luteum preceded the reduction in
blood flow. Similar results have also been reported for pseudo-
pregnant (Janson, Albrecht and Ahren, 1975) and pregnant (Bruce and
Hillier, 1974) rabbits. It is clear that pharmacological doses of
PGF2a will decrease ovarian blood flow but, at lower doses, the de¬
crease in progesterone secretion appears to precede any decrease in
blood flow. The latter may occur as a consequence, as opposed to a
cause, of luteolysis.
Steroid production by the luteal cell is stimulated by lutein¬
izing hormone (LH). LH binds to specific receptors in the plasma-
membrane of the granulosa cell and stimulates the production of c-AMP
by activation of the enzyme adenylate cyclase. The c-AMP then
interacts with protein receptors to activate a protein kinase (Garren,
Gill, Masui and Walton, 1971) which in turn activates various enzymes,
including cholesterol esterase. The cholesterol esterase converts
the cholesterol esters stored in the lipid droplets into free choles¬
terol which is then converted into progesterone.
10
The first indications that PGF2a might be exerting its effect
Via antagonism of gonadotropin action arose from the work of Behrman,
Yoshinaga and Greep (1971). They showed that in the Day 5 pseudo-
pregnant rat, LH administration (20yg i.v.) could reverse the acute
inhibition of progesterone secretion caused by the i.v. injection of
lOyg PGF2ct. Further studies demonstrated that PGF2a also blocked
luteal maintenance in hypophysectomised rats maintained on prolactin
(Behrman, Macdonald and Greep, 1971). In the rat there is a sig¬
nificant reduction in LH receptor number at the time of luteal
regression (Lee, Tateishi, Ryan and Jiang, 1975). Hichens, Grinwich
and Behrman (1974) have shown that PGF2a treatment causes a signifi¬
cant decrease in luteal LH receptor number within 24 hr in the rat
but does not affect LH binding to isolated luteal membranes. Since
similar effects can be induced by ergocryptine treatment (Grinwich,
Hichens and Behrman, 1976) and by hypophysectomy (Behrman, Grinwich,
Hichens and Macdonald, 1978) these authors concluded that PGF2a acted
Via the inhibition of prolactin. This conclusion is supported by
the fact that prolactin treatment prevents the loss in LH receptor
number produced by PGF2(X, ergocryptine or hypophysectomy (Berhman
et al., 1978; Grinwich et al., 1976). The luteolytic
effect of PGF2ct treatment is, however, unlikely to be mediated via
the reduction in LH receptor number alone since the fall in serum
progesterone precedes the fall in LH receptor binding capacity by
some 6 hrs (Grinwich et al., 1976). The latter, however, does
coincide with a marked elevation in serum 20a-dihydroprogesterone
(20a-ol) which is generally thought to signal the onset of functional
luteolysis in the rat. The loss of LH receptors would ensure the
final demise in luteal function.
The more rapid effect of PGF2a on progesterone secretion could
be mediated in a number of ways. Behrman and Hichens (1976) observed
that following PGF2a treatment there was a marked fall in the uptake
of radiolabelled LH and radiolabelled prolactin by the rat corpus
luteum, in vivo, within 30 min. The mechanism by which this occurs
is, at present, unknown.
A direct antagonism of gonadotrophin action by PGF2a in vitvo
has also been demonstrated. Henderson and McNatty (1975) suggested
that the rapid effect of PGF2a on progesterone secretion is due to
the PGF2ct interfering with the coupling mechanism by which the LH
receptor activation stimulates adenylate cyclase activity. This
would result in a decrease in intracellular c-AMP which in turn
would reduce the availability of cholesterol for conversion into
progesterone. Behrman et at., (1971) have shown that the
treatment of rats in vivo with PGF2a depresses cholesterol ester
synthetase activity in the rat ovary. Cholesterol esterase activity
was also reduced but to a lesser degree. Again this action appears
to be mediated via the antagonism of the action of prolactin (Behrman
et at,, 1971). Lahav, Freud and Lindner (1976) have shown that
-PGF2ct inhibits the accumulation of c-AMP induced by LH in slices in
rat luteal tissue but has no effect on LH-stimulated adenylate
cyclase activity in rat isolated luteal plasma membranes (Dorflinger
and Behrman, 1978). The fact that PGF2a only exerts its rapid anti-
LH action in the intact cell supports the idea of Henderson and
McNatty (1975) that it exerts its effect by interfering with the
coupling mechanism by which LH receptor activation stimulates adeny¬
late cyclase. The mechanism by which this occurs is not known but
the calcium ionophore A23187 has been found to mimic the action of
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PGF2a in dispersed luteal cells. Also, the addition of calcium to
isolated plasma membranes produced a dose dependent inhibition of
LH-stimulated adenylate cyclase activity (Dorflinger and Behrman as
reported in Behrman, 1979). The preliminary evidence therefore
indicates that one of the initial actions of PGF2a in the luteal cell
is to increase the intracellular content of free calcium which in
turn inhibits adenylate cyclase activity and thereby reduces proges¬
terone production.
Binding sites for PGF2a have been found in the corpora lutea of.
the sheep (Powell, Hammarstrom and Samuelsson, 1974a), cow (Powell
e~b al. , 1974b) , mare (Kimball and Wyngarden, 1977) , rat (Wright,
Luborsky-Moore and Behrman, 1979) and human (Powell, Hammarstrom,
Samuelsson and Sjoberg, 1974). Whether the combination of PGF2ct with
these binding sites is important for luteolysis is not known. Kimball
and Wyngarden (1977) were unable to show any cyclical changes in the
number of high affinity PGF2a-binding sites in equine corpora lutea.
Similarly, Wright, Pang and Behrman (1980) could show no difference in
the PGF2a binding capacity of rat corpora lutea on Days 4 and 8 of
pseudopregnancy. On the other hand Rao, Estergreen, Carmen and Moss
1,1979) have reported that there is a progressive increase in the
specific binding of ^H-PGF2a by bovine corpora lutea between Day 13
and Day 20, the time at which functional luteolysis occurs, and that
binding decreases between Days 21 and 24 when both structural and
functional luteolysis are complete. The increase in PGF2ct-binding
between Days 13 and 20 was also accompanied by a 203-fold increase
in receptor affinity. It appears, therefore, that there is a large
degree of species variation in the ability of corpora lutea to bind
PGF2a. in species in which PGF2a~receptor levels and/or affinity
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do show cyclical changes, it is possible that these changes may also
be under hormonal control.
2) PGF2a is found as a major PG in the uterine tissues of a large
number of animals. In the sheep the concentration of PGF2a in the
endometrial tissue is significantly higher on Day 14 of the cycle
and Inskeep
than on Days 3, 5 or 11 (Wilson, Cenedella and Butchery 1972).
Similarly, in the cow the endometrial levels of PGF2c( are approxi¬
mately three times higher on Days 15 to 20 of the cycle than on Days
(Shemesh and Hansel,1975)
1 to 14. ^ In the guinea-pig, Poyser (1972) has shown that the level
of PGF2a in the uterine tissue on Days 13, 14 and 15 are higher than
on earlier days of the cycle, while in the hamster the highest con¬
centrations of PGF2a occur on Day 8 of pseudopregnancy (Lukaszewska,
Wilson and Hansel, 1972).
In all these species, therefore, there is a significant increase
in the endogenous concentration of PGF2a in uterine tissue immediately
prior to the onset of luteolysis. This increase in uterine tissue
levels is accompanied by an increase in the concentration of PGF2a i-n
the uterine venous plasma. In fact, since prostaglandins are not
stored intracellularly but are synthesised de novo, the increase in
uterine venous plasma concentrations of PGF2a probably gives a more
accurate measure of the synthetic activity of the uterus than
measurements of endogenous tissue levels. In the sheep, uterine
venous blood collected on Day 15 of the cycle induces luteal regres¬
sion when infused into donor ewes in which the ovaries have been
autotransplanted to the neck. Blood taken on earlier days of the
cycle had no such effect (McCracken et al,, 1972). PGF2a has been
identified by combined gas chromatography-mass spectrometry, (g.c.-
m.s.) in the uterine venous plasma of sheep (Bland, Horton and
Poyser, 1971; McCracken et at., 1972; Harrison, Heap, Horton and
Poyser, 1972), guinea-pigs (Blatchley, Donovan, Horton and Poyser,
1972) and pigs (Hunter and Poyser, as reported by Horton and Poyser,
1976). In all these species as well as in the cow (Shemesh and
Hansel, 1975) and mare (Douglas and Ginther, 1976), the concentration
of PGF2ct in the uterine vein begins to increase from about Day 11 of
the cycle and tends to increase further until Days 16 to 18, by which
time luteal regression is complete. PGF2a release from the uterus
occurs in a pulsatile fashion in the sheep (Thorburn et at., 1973),
cow (Nancarrow, Buckmaster, Chamley, Cox, Cumming, Cummings, Drinan,
Findlay, Goding, Restall, Schneider and Thorburn, 1973) and pig
(Gleeson and Thorburn, 1973). The peaks of PGF2a vary from 8 to
25 ng ml-*, they are of short duration and tend to increase in fre¬
quency and amplitude towards the end of the luteal phase. Although
measuring PGF2a in samples of utero-ovarian venous plasma allows the
determination of sequential changes in the concentration of -the
prostaglandin in the plasma, these concentrations cannot really be
related to uterine production rates without measuring the blood flow.
The high levels of PGF2a found in the uterine effluent at the time of
luteolysis could arise as a consequence of a decrease in blood flow.
Measurements of the peripheral plasma levels of PGF2a are n°t open
to this bias. However, peripheral plasma levels of PGF2a tend to be
low due to the rapid removal of prostaglandins from the circulation
by the lung. One way of overcoming these problems is to measure the
peripheral plasma levels of 13,14-dihydro-15-keto-prostaglandin F2a (13,
14-dihydro-15-keto-PGF2cc) the main circulating metabolite of PGF2a-
In the sheep (Peterson, Tervit, Fairclough, Hawick and Smith, 1976),
cow (Kindahl, Edqvist, Bane and Granstrom) and pig (Shille, Karlbom,
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Einarsson, Larsson, Kindahl and Edqvist, 1979) the peripheral plasma
levels of 13,14-dihydro-15-keto-PGF2a increase around the time of
luteolysis in accordance with the proposed increase in uterine PGF2a
output. In the guinea-pig the urinary levels of 5a,7a-dihydroxy-
11-oxotetraner-prostanoic acid increase at the end of the oestrous
cycle (Granstrom and Kindahl, 1976). These results suggest that
the increases in uterine venous plasma PGF2ct around the time of
luteolysis reflect an increase in PGF2ct synthesis and secretion
(providing that the pattern of prostaglandin metabolism does not vary
greatly during the cycle).
In order to establish that PGF2a acts as the luteolytic hormone
in these species, it is necessary to establish that the amounts of
PGF2cx released by the uterus are sufficient to bring about luteolysis.
Thorburn and Nicol (1971) showed that the infusion of PGF2ct at a rate
of 40 or lOyg h-^ into the ovarian artery on Day 5, 6 or 7 of the
oestrous cycle resulted in a decrease in the peripheral plasma pro¬
gesterone levels and a return to oestr^Sus 72h later in 50% of the
animals treated. The authors calculated that an infusion rate of
40yg h-^ into the ovarian artery corresponds to a concentration of
lOng ml-* blood. This probably represents a pharmacological dose
in terms of the ovarian arterial blood supply, but a similar infusion
into the utero-ovarian vein which represents physiological concentra¬
tions, also induced luteolysis in 3 out of 4 animals. When PGF2a
was infused into the jugular vein there was a slight, but transient
fall in the circulating level of progesterone and cycle length was
not affected. McCracken et at, (1972) confirmed these results.
They calculated that immediately prior to oestrus the uterus releases
25yg h-1 PGF2a into the uterine vein. When PGF2a is infused at a
rate of 25yg h-1 into the right uterine vein of the uterus of a ewe
on Days 6, 10 or 14 of the cycle,progesterone secretion decreased,
reaching very low levels by the end of the infusion period. These
results show that the luteolytic effect of PGF2a occurs at physio¬
logical concentrations and acts in a highly localised manner. The
failure of PGF2a infusions into the jugular vein to induce luteolysis
can probably be attributed in part to a dilution effect and, more
importantly, to the fact that, following a single passage of blood
through the lungs, 95-99% of the PGF2a in the blood is metabolised
(Ferriera and Vane, 1967). This highly efficient mechanism of
removing prostaglandins from the systemic circulation probably
accounts for the highly localised action of PGF2a-
3) Uterine ligation experiments have shown that the luteolytic sub¬
stance in uterine vein blood reaches the ovary via the vascular
system (Bland and Donovan, 1966; Butcher et aZ., 1969; Kiracofe,
Menzies, Gier and Spies, 1966). In the sheep the ovarian artery is
highly convoluted and, before it enters the hilus °f ovar-7'
it is closely apposed to the utero-ovarian vein . Hansel (personal
communication quoted in McCracken et at. , 1972) considered that it
would be possible for substances to diffuse from the vein into the
artery and thereby pass directly into the ovary.
In the sheep, separation of the utero-ovarian vein and the
ovarian artery prevented regression of the corpus luteum at the
expected time (Kifacofe et aZ., 1966; Baird and Land, 1973).
McCracken et aZ. (1972) reported that following the infusion of
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tritiated PGF2a ( H-PGF2a) into the uterine vein of a sheep at a point
proximal to its confluence with the utero-ovarian vein, there was a
small but significant increase in 3H-PGF2K in the ovarian arterial
blood within 20 minutes. This increase continued oyer the next 60
minutes to reach peak levels approximately 20 to 30 minutes after
termination of the infusion. The efficiency of transfer was esti¬
mated to be about 2%. Land, Baird and Scaramuzzi (1976) found that
the concentration of 3H-PGF2a in the ovarian artery was proportional
to the log of the concentration of 3H~PGF2a in the uterine vein, but
estimated that the efficiency of transfer was in the order of 0.2%.
There is also evidence to suggest that the vascular plexus in the
ovarian pedicle may also be involved in the transfer of PGF2a from
the uterus to the ovary. Baird and Land (1973) found that luteal
maintenance only occurred in 4 out of 10 ewes in which the main
uterine vein alone had been ligated and severed, but occurred in 6
out of 7 ewes in which the tubal arcade of veins anastomosing between
the uterine and ovarian veins was severed. Measurements of PGF2a
concentrations in the uterine vein and oviducal vein of sheep from
Days 12 to 16 of the cycle are not significantly different from one
another but are significantly higher than those recorded in the
mammary vein and ovarian vein (Alwachi, Bland and Poyser, 1981). To
what extent this system contributes to the transfer of PGF2a from
the uterus to the ovary ~Ln ViVO is not known. There appears to be
a substantial variation in the diameter of the oviducal veins from
different animals and Ginther (1974) has suggested that the relative
amount of venous effluent discharging through the oviducal vein,
although probably small in normal ewes, may be considerable after
ligation or constriction of the main uterine vein.
The existence of the counter-current mechanism in the sheep for
the transfer of PGF2a has been disputed by Coudert, Phillips, Faiman,
Chernecki and Palmer (1974). They failed to demonstrate any transfer
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of 3H-PGF2a from the utero-ovarian vein to the ovarian artery.
However, the sensitivity of the experimental system employed by
Coudert et al. (1974) had a maximum efficiency of 0.7% and this could
explain their failure to detect an increase in 3H-PGF2a in the
ovarian artery. Whether the low efficiency of transfer recorded by
Baird et al. (1976) enables sufficient PGF2a to enter the ovarian
artery and initiate luteolysis is not clear. However, as Horton
and Poyser (1976) point out, the ability of most tissues, with the
exception of the lungs, liver and kidney, to metabolise prostaglan¬
dins is very low so that most of the PGF2a leaving the ovary will
pass into the utero-ovarian vein and mix with the freshly secreted
PGF2ct from the uterus. A low efficiency of transfer would therefore
help to maintain a steady and 'moderate' level of PGF2a in the
ovarian arterial blood. Any PGF2a not captured by the ovarian
artery/utero-ovarian vein counter-current loop, would pass into the
systemic circulation and be inactivated by the lungs.
A similar counter-current mechanism has been reported to exist
in the cow (Hixon and Hansel, 1974), but whether it operates in other
species with a highly localised utero/ovarian relationship is not
known. Del Campo and Ginther (1972, 1973) have shown that in species
in which a unilateral pathway has been demonstrated, the uterus and
the ovaries share common arteries and veins which would allow such a
mechanism to operate. In species in which no unilateral pathway has
been demonstrated, such as the rabbit (Hunter and Casida, 1967) the
uterine vasculature is anatomically more independent from the ovarian
vasculature and a counter-current mechanism is not feasible.
4) If PGF2a is indeed the uterine luteolytic hormone, stimuli which
induce premature luteal regression, with a concomitant shortening of
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the oestrous cycle, should stimulate the early production of PGF2a.
Using data on luteal size, Bland and Donovan (1966) showed that the
insertion of glass beads into the uterine lumen of guinea-pigs on
Days 2 to 4 of the cycle caused luteal regression to occur between
Days 9 to 11. This is accompanied by an increase in utero-ovarian
PGF2ot levels by Day 8, but this increase in the levels of utero-
ovarian PGF2ct does not become significant until Day 12 when the
utero-ovarian plasma progesterone levels are also greatly reduced
(Blatchley, Donovan and Poyser, 1976). The pattern of PGF2a secre¬
tion is similar to, and of the same order of magnitude as that found
during the normal oestrous cycle (Earthy, Bishop and Flack, 1975).
The delay between bead insertion and luteal regression which occurs
in the guinea-pig is not observed in the sheep. Bead insertion
between Days 2 to 4 of the cycle results in increased endometrial
and uterine venous plasma levels of PGF2ct, and in greatly reduced
peripheral plasma progesterone levels 3 to 4 days later (Spilman and
Duby, 1972; Pexton, Ford, Wilson, Butcher and Inskeep, 1975).
Again, the levels of PGF2K recorded were as high as those found at
the end of the oestrous cycle. The presence of an intra-uterine
device (I.U.D.) has also been reported to raise the endometrial PGF
content in the rat, hamster and rabbit (Saksena, Lau and Castracane,
1974; Harper and Saksena, 1974).
If PGF2ct is the uterine luteolysin, then drugs which inhibit
prostaglandin synthesis or inhibit the action of PGF2ct should
prevent normal luteal regression. Unfortunately, no chemical antag¬
onists, in the pharmacological sense of the word, to prevent the
action of PGF2a are yet available. However, much useful informa¬
tion has been gained by active immunisation against PGF2a an<i by the
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use of indomethacin, a potent inhibitor of the cycloxygenase
enzyme (Vane, 1971).
Indomethctcin inhibits the in vitro synthesis of prostaglandins
by the guinea-pig uterus (Poyser, 1972) and increases cycle length
when incorporated into a slow-release preparation and placed in the
uterine lumen (Horton and Poyser, 1973; Marley, 1973). The
increase in cycle length following indomethacin treatment was similar
to that observed following hysterectomy and measurements of periph¬
eral plasma progesterone levels show that the corpus luteum is well
maintained throughout this period (Poyser and Horton, 1975). Since
oral or parenteral administration of indomethacin to guinea-pigs, in
near toxic doses, only increased cycle length by 3 to 4 days (Marley,
1972; Horton and Poyser, 1973), it seems likely that the increase in
cycle length induced by indomethacin treatment results specifically
from the inhibition of uterine prostaglandin synthesis. However,
this has not been verified experimentally by measuring uterine
venous plasma levels of PGF2a following the local administration of
indomethacin to the uterus. Mellin and Busch (1976) were unable to
show an increased oestrous cycle length in sheep following the oral
administration of indomethacin (20 mg kg-*),aspirin (100 mg kg-!) or
flufenamic acid (10 mg kg-*), whereas the daily, intrauterine
administration of indomethacin, from Days 12 to 17 of the cycle,
inhibited luteal regression (Lewis and Warren, 1975). In the pseudo-
pregnant rat and rabbit, the systemic administration of indomethacin
prolongs the duration of pseudopregnancy (0'Grady, Caldwell, Auletta
and Speroff, 1972; Chaterjee, 1973).
Active immunisation against PGF2a prolongs the oestrous cycle in
both sheep (Scaramuzzi, Baird, Wheeler and Land, 1973) and guinea-
pigs (Horton and Poyser, 1974; Hildebrandt-Stark, Marcus, Yoshinaga,
Behrman and Greep, 1975). In the sheep, following the primary
immunisation, the concentration of antibodies directed against PGF2a
in the blood rose steadily over a period of 90 days and cyclic
activity halted within the first month. Thereafter surgical
removal of the corpus luteum resulted in a return to oestrus, within
3 days (Scaramuzzi et at. , 1973). These findings suggest that the
corpus luteum was active during these elongated 'cycles'. In the
guinea-pig, animals with high PGF^ titres had their oestrous cycles
elongated to a greater extent than those animals with lower antibody
titres. Measurements of the peripheral plasma progesterone levels
again showed that the corpora lutea were still functional (Horton
and Poyser, 1974). The most attractive explanation for these
observations is that the PGF antibodies effectively neutralise the
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PGF 2 a secreted by the uterus. However, there is evidence to suggest
that prostaglandins are also involved in the process of ovulation
both at the hypothalamic (Carlson, Barcikowski and McCracken, 1973;
Harms, Oyeda and McCann, 1974; Tsafriri, Koch and Lindner, 1973) and
ovarian level (Ainsworth, Baker and Armstrong, 1975; LeMaire, Yang,
Behrman and Marsh, 1973; Tsafriri, Lindner, Zor and Lamprecht, 1972).
The observed increase in cycle length could therefore arise from the
inhibition of ovulation. Moreover, if the inhibition occurs at the
ovarian level, the mature follicles can become luteinised and secrete
progesterone. Under these circumstances, the levels of circulating
progesterone would not accurately reflect luteal function.
Hildebrandt-Stark et at. (1975) have reported the presence of lutein¬
ised, unovulated follicles, in the ovaries of animals immunised
against PGF2a- It would be of interest to know whether the original
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corpora lutea in such animals were still functional. Horton and
Poyser (1976) reported that one guinea-pig immunised against PGF2a
did become pregnant when mated, indicating that ovulation had not
been blocked completely. However, only one foetus was present and
this did not survive beyond mid-term. The mother also failed to
abort it.
The next point that must be considered is how the synthesis,
metabolism and action of PGF2ct is normally regulated. The cyclical
pattern of release suggests that this may be under hormonal control.
In the guinea-pig, administration of oestradiol (lOyg day-1)
on Days 4 to 6 of the cycle increases the amount of PGF2a measured
in the utero-ovarian venous plasma on Day 7 (Blatchley, Donovan,
Poyser, Horton and Thompson, 1971). This could explain the uterine
mediated, luteolytic effect of oestradiol reported by Bland and
Donovan (1970). Blatchley, Donovan, Horton and Poyser (1972) have
suggested that oestradiol released from the maturing ovary after
Day 10 of the cycle might form the physiological trigger for the
increase in uterine PGF2a secretion seen towards the end of the
oestrous cycle. Blatchley and Poyser (1974) showed that following
the ~in vivo treatment of ovariectomised guinea-pigs with either
progesterone or oestradiol benzoate both PGF-like and PGE-like
activity can be detected in the utero-ovarian venous plasma. The
levels of PGF^ tended to be higher following oestradiol benzoate
treatment than after progesterone treatment but the wide scatter of
individual results meant that there was no significant difference
between the two treatments. When oestradiol benzoate treatment was
preceded by a period of progesterone priming however, the increase
in utero-ovarian vein levels of PGF2a was significantly higher than
when either hormone was administered alone. This suggests that a
period of progesterone priming may also be important.
In the sheep, administration of oestradiol for a period of 2 to
4 days after the middle of the cycle also induces luteolysis in
intact animals but not in hysterectomised (Hawk and Bolt, 1970;
Stormshak e~b al. , 1968; Ginther, 1970) or in indomethctcin-
treated animals (Lewis and Warren, 1977). Injection of oestradiol
or progesterone on Days 1 to 8 of the cycle has no effect on the
weight or progesterone content of ovine corpora lutea. However, if
progesterone is administered on Days 1 to 4 of the cycle, the injec¬
tion of oestradiol as early as Day 5 or 6, induces luteolysis.
Caldwell, Tillson, Brock and Speroff (1972) showed that in proges¬
terone-primed, ovariectomised sheep, oestradiol treatment increases
the peripheral plasma levels of PGF2a to values similar to those
observed at the end of the oestrous cycle. This effect was abolished
by hysterectomy or by active immunisation against oestradiol. The
importance of progesterone priming is further supported by the
experiments of Barcikowski, Carlson, Wilson and McCracken (1974) who
showed that the infusion of physiological amounts of oestradiol into
the arterial supply of an autotransplanted uterus on different days
of the cycle caused a significant increase in PGF2a release only when
the infusion was performed during the late luteal phase of the cycle.
The increase in PGF2a release could be blocked by the simultaneous
infusion of indomethacin, demonstrating that oestradiol stimulated
de novo synthesis of PGF2a« Further support for the role of oestra¬
diol in controlling ovarian cyclicity comes from the observation that
destruction of the follicles in the sheep ovary, either by X-irradia-
tion or cauterisation, delays luteal regression (Karsch, Noveroske,
24
Roche, Norton and Nalbandov, 1970; Ginther, 1971).
In animals in which the oestrous cycle is characterised by a
spontaneously active corpus luteum, progesterone levels generally
rise rapidly at the beginning of the cycle and remain elevated until
very near the end of the cycle when they decline sharply, often
reaching almost undetectable levels immediately prior to oestrus.
If the physiological requirement for an increase in the uterine out¬
put of PGF2a does involve a period of progesterone priming, followed
by oestrogen secretion, then plasma oestradiol levels should increase
prior to PGF2a release.
The utero-ovarian venous plasma levels of oestradiol are eleva¬
ted on Days 3 to 4, 10 to 12 and 14 to 16 of the sheep oestrous
cycle (Cox, Thorburn, Currie and Restall, 1974; Cox, Mattner and
Thorburn, 1971) PGF2a release first occurs around Days 12 to 13 and
thereafter continues to increase until Days 14 and 15. There
appears to be a good temporal relationship between oestradiol secre¬
tion and PGF2a release from the uterus from Day 13 onwards
(Barcikowski et ai. , 1974). The peak in oestradiol secretion
observed on Day 3 and 4 does not appear to be associated with an
increase in utero-ovarian venous plasma levels of PGF2a- This may
be because of the lack of adequate progesterone priming of the uterus
at this time (Moore, Barrett, Brown, Schindler, Smith and Smyth,
1969). Similarly in the cow peripheral plasma oestrogen increases
between Days 10 and 12 and in the 2-3 days preceding oestrus
(Shemesh, Ayalon and Lindner, 1972) when PGF2a levels also increase.
Again there is a small increase in oestradiol secretion between Days
4 and 6 but, unlike that in the sheep, it is associated with increased
levels of PGF2a in the utero-ovarian vein and is accompanied by a
transient decrease in utero-ovarian venous plasma progesterone
levels. This species difference may be due to the fact that, in
the cow, the uterus is exposed to a high level of progesterone
between Days 3 and 5. The transient decline in utero-ovarian and
peripheral plasma progesterone levels may reflect the presence of
a weak luteolytic stimulus (Nancarrow e~b ai. , 1973) . In the
guinea-pig, oestradiol levels increase after Day 10 and again after
Day 13(Joshi, Watson and Labhsetwar, 1973) while in the pig there is
a small peak in oestradiol levels between Days 4 to 8 which is then
followed by a steady increase from Day 12 until oestrus (Henricks,
Guthrie and Handlin, 1972). In both species the increase in
oestradiol levels after the middle of the cycle precedes the increase
in PGF2a in the utero-ovarian vein (Blatchley et at. , 1972; Gleeson
and Thorburn, 1973). In the pig, as in the sheep, the earlier peak
in oestradiol secretion is not associated with a significant increase
in uterine venous, plasma levels of PGF2a (Hunter and Poyser, as
reported by Horton and Poyser, 1976). In the pseudopregnant hamster
peripheral plasma oestradiol levels increase from Day 6 to reach peak
values on Day 8. Again, this increase precedes the increase in
peripheral plasma PGF2a concentration observed on Days 8 and 9
(Shaikh, Birchall and Saksena, 1973).
It would appear, therefore, that the increase in PGF2a in the
utero-ovarian vein seen towards the end of the oestrous cycle require
a period of progesterone priming followed by a 2 to 3 day exposure to
oestrogen. The duration of oestrogen exposure may also be important
Bolt and Hawk (1972b) have shown that the intravenous infusion of
oestradiol (10.4yg hr-1) will only induce luteolysis if infused for
a minimum of 24 hr. This could also explain why small increases in
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oestrogen secretion early in the cycle fail to stimulate adequate
PGF2a release to initiate luteolysis. It is also possible that the
susceptibility of the corpus luteum to PGF2a changes during the
oestrous cycle and that this too is under hormonal control.
Although the above evidence suggests that the luteolytic capa¬
city of the uterus is controlled by the sequential exposure of the
uterus to progesterone and oestrogen, there are certain observations
which are difficult to interpret on this basis. The most para¬
doxical of these is that in the pig (Gardner, First and Cas'ida, 1963),
Sheep (Piper and Foote, 1968; Denamur, Martinet and Short, 1970) and
guinea-pig (Illingworth and Perry, 1973) daily administration of
oestradiol towards the end of the cycle maintains luteal function.
Also, like hysterectomy, oestradiol treatment will maintain luteal
function in sheep following pituitary stalk transection (Denamur
et at. , 1970). This suggests that the oestradiol counteracts the
luteolytic presence of the uterus. Frank, Bazer, Thatcher and Wilcox
(1977) have shown that in the pig the administration of oestradiol
valerate (5mg day-1) on Days 11 to 15 of the cycle decreases the
number and amplitude of PGF2a peaks' in the uterine venous plasma and
maintains circulating progesterone levels above those observed in
untreated animals.
In all instances, however, the dose of oestradiol needed to
prolong luteal function is high and probably leads to plasma oestra¬
diol levels in excess of those occurring naturally. Moreover, since
oestradiol, in physiological doses, induces luteolysis in sheep when
given after Day 10 of the cycle (Stormshak et at., 1969; Barcikowski
et at. , 1974) it seems likely that, 'in vivo, the secreted oestrogen
will promote luteolysis rather than exert a luteotrophic effect.
More recently evidence has hegun to accumulate to suggest that
oxytocin may also be involved in the control of PGF2a release from
the uterus in the sheep. Fairclough, Moore, McGowan, Peterson,
Smith, Tervit and Watkins (1980) examined the temporal relationship
between plasma concentrations of oxytocin, as determined by measure¬
ment of plasma concentrations of oxytocin-associated neurophysins
I/II, and plasma concentrations of 13,14-dihydro-15-keto-PGF in sheep
over the time of expected luteolysis. They found that there was a
close temporal relationship between these two parameters. The
highest levels of neurophysin i/ll were recorded on Days 14 to 16
but peaks of neurophysin I/II were associated with small peaks in
13,14-dihydro-15-keto-PGF from Day 13 onwards. These results would
indicate that there is an increase in oxytocin release around the
time of luteolysis in the ewe. The possible involvement of oxytocin
in the control of luteolysis is also supported by the work of
Sheldrick, Mitchell and Flint (1980) who found that active immunisa¬
tion of sheep against oxytocin prolonged the luteal phase of the
oestrous cycle, as judged by oestrus behaviour and the circulating
levels of progesterone, by some 3-7 days.
Roberts, Barcikowski, Wilson, Skarnes and McCracken (1975) have
shown that infusions of oxytocin into the arterial supply of the
uterus evoke a substantial increase in PGF2a release from the uterus
when administered after Day 14 of the cycle. The ability of oxytocin
to stimulate PGF2a release closely parallels the ability of the endo¬
metrium to bind oxytocin (Roberts, McCracken, Gavagan and Soloff,
1976) and this, in turn is dependent on the hormonal state of the
animal. In the anoestrous ewe oxytocin will not stimulate the release
of PGF2q from the uterus unless the animal has been primed with
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oestrogen (Sharma and Fitzpatrick, 1974) . In experiments with ovari-
ectomised ewes with autotransplanted uteri, oestradiol-178 has been
shown to increase the number of oxytocin receptors in the uterus
within 6 hrs while the administration of progesterone (500yg hr-1,
i.v.) resulted in the uterus becoming refactory to oxytocin stimula¬
tion. When oestradiol-173 infusions were superimposed upon proges¬
terone treatment the ability of oestradiol-173 to stimulate oxytocin
receptor formation was not evident until after progesterone treat¬
ment had been continued for 10 days. The response of the uterus
to oxytocin challenge was then found to be 50 to 100 fold greater
than when oestradiol-173 was given alone (McCracken, Gammel, Glew and
Underwood, 1978). The period of progesterone priming therefore
appears to amplify the response of the uterus to oxytocin in terms
of PGF2ct secretion. The mechanism by which this is achieved is not
clear.
Whether oxytocin also plays an important role in regulating
uterine PGF2ct secretion in other species is not known although
Armstrong and Hansel (1959) have reported that oxytocin will induce
precocious oestrus in the cow when given on Days 2 to 6 of the cycle.
.The premature demise of the corpus luteum by such treatment is
associated with increased concentrations of PGF20C in the uterine
venous blood (Milvae and Hansel, 1980).
As previously mentioned prostaglandins are not stored intra-
cellularly but are synthesised de novo as required. This process
involves the release of arachidonic acid from tissue stores followed
by the enzymatic conversion of the precursor into the relevant
prostaglandin. An increase in PGF2a production could therefore be
effected by increasing the availability of the precursor, by
increasing the amount and/or rate of enzyme conversion of substrate,
either by activation of pre-existing enzyme or through de novo syn¬
thesis of new enzyme, or by a redirection of synthesis towards PGF2a
production (see Fig. I) . The in vitvo capacity of guinea-pig uteri to
synthesise PGF2a is approximately three fold higher on Days 14 and
15 than on earlier days of the cycle (Poyser, 1972). The addition
of arachidonic acid (0.5 or 2,5)jg ml-1) or phospholipase (5yg ml-1)
to incubates of Day 6 uterine homogenates failed to increase the
amount of PGF2a synthesised by these tissues (Poyser, 1972). This
suggests that the differences in the synthetic capacity of uterine
tissue on Days 6 and 14 of the cycle cannot be accounted for in
terms of lack of substrate. Using a partially purified prostaglandin
synthetase enzyme complex prepared from sheep vesicular glands, Lands,
Le Tellier and Vanderhoek (1973) observed that synthesis of the
'oxygenated' product from arachidonic acid ceased before all the
substrate had been utilised, and that the reaction could be restarted
if more enzyme was added. They therefore proposed that a self-
catalysed destruction of the enzyme occurred and that it was this
property of autocatalysis that determined the amount of product that
.could be synthesised by a given amount of enzyme. Oestrogen stimu¬
lates uterine growth and protein synthesis. The action of oestrogen
on PGF2a production could therefore be linked with fresh protein
synthesis. Oestradiol is believed to enter the cell via a specific
protein-mediated process (Milgrom, Atger and Baulieu, 1977) and to
become bound to a cytosolic receptor (Gorski, Taft, Shyamala, Smith
and Nolides, 1968). Once bound, the oestrogen-cytosol receptor
complex undergoes translocation to specific nuclear sites where it
stimulates RNA synthesis. The RNA in turn stimulates production of
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small amounts of a 'specific induced' protein. The synthesis of
specific induced protein occurs within one hour of oestrogen admini¬
stration and is blocked by actinomycin D, but not by puromycin or
cyclohexamide (De Angelo and Gorski, 1970). The induced protein
then stimulates the production of general RNA which is followed by
an increase in general protein levels and the accumulation of phos¬
pholipids (Mueller, Gorski and Aizawa, 1961). The intrauterine
administration of actinomycin D (500pg hom-1) to sheep on Day 11 of
the cycle inhibits luteal regression in a highly localised manner
and blocks the luteolytic effect of oestrogen (French and Casida,
1973). The initial DNA dependent synthesis of RNA therefore appears
to be important for the expression of the luteolytic effect of
oestrogen. However, whether oestrogen acts to increase prostaglandin
synthesis by increasing the amount of prostaglandin synthetase-present
is not clear. In the guinea-pig the intrauterine injection of
actinomycin D also significantly prolongs luteal function and oestrous
cycle length (Poyser, 1979). This effect is accompanied by a
decrease in the ability of the Day 15 uterus to synthesise PGF2a, an
effect which cannot be overcome by the addition of exogenous precursor
to the incubation medium or by in vivo oestrogen treatment. Since
the ability of the tissue to synthesise PGE is also decreased by
actinomycin D treatment, these results suggest that, in the guinea-
pig, oestradiol exerts its luteolytic affect by increasing prosta¬
glandin synthetase activity, via a DNA dependent mechanism, either by
inducing de novo prostaglandin synthetase synthesis or by activation
of the existing enzyme.
Using an immunochemical technique Huslig, Fogwell and Smith
(1979) have shown that there is a threefold increase in the specific
activity of the cyclo-oxygenase in caruncular microsomes from sheep
uteri on Day 14 of the cycle. Whether this occurs as a consequence
of the increase in oestradiol secretion from the ovary is not known.
Alwachi e~b at. (1979) have shown that the ability of the
uterine endometrium to synthesise PGF2a varies with the presence or
absence of the neighbouring ovary. In unilaterally ovariectomised
sheep endometrial tissue from the uterine horn adjacent to the ovary
synthesised significantly more PGF2a than endometrial tissue from
the contralateral horn. Naylor and Poyser (as reported in Horton
and Poyser, 1976) found that the administration of oestradiol
benzoate to guinea-pigs on Days 4 to 6 of the cycle did not increase
the synthesising capacity of the uterus on Day 7 of the cycle despite
the fact that this treatment stimulates PGF2a release from the uterus
(Blatchley et at., 1971; 1972). Oestrogen may therefore have both
a direct, immediate effect to initiate PGF2a release and a more
prolonged action to increase the synthetic capacity of the uterus.
In the rat, ovariectomy induces a ten fold increase in the
uterine tissue levels of PGE and a three fold increase in PGF levels.
Subsequent oestrogen treatment does not appear to affect the total
prostaglandin content but it does result in a decrease in PGE levels
and a concomitant elevation in PGF levels. The ability of isolated
uterine microsomes to biosynthesise prostaglandins when incubated
with arachidonic acid in the presence of co-factors, was also found
to be enhanced by in vivo oestradiol treatment. PGF2a was synthe¬
sised in preference to PGE (Ham, Cirillo, Zanetti and Kuehl, 1975).
These results suggest that oestradiol exerts a dual action
a) to increase the synthetic capacity of the uterus
and
b) to exert a directional influence on the products formed.
A similar pattern of changes in the endogenous levels of PGF and PGE
in the rat uterus throughout the oestrous cycle has been reported by
Poyser and Scott (1980), However, they were unable to support the
findings of Ham et at. (1975) that the increase in the ability of the
uterus to synthesise PGF at pro-oestrus and oestrus occured at the
expense of PGE synthesis and that, during dioestrus, the uterus syn-
thesises PGE in preference to PGF. In their study Poyser and Scott
(1980) found that the major prostaglandin to be synthesised by homo-
genates of the rat uterus ■in vitro was prostacyclin (PGI2)- Appre¬
ciable quantities of PGF2a/ PGE2 and PGD2 were also formed but PGF
production always exceeded PGE production and the ratio of the
amounts of prostaglandins formed remained fairly constant. The
reason for the differences in the findings of Ham et at. (1975) and
Poyser and Scott (1980) may be due to differences in experimental
design. Poyser and Scott (1980) measured the synthetic capacity in
uterine tissue homogenates in the absence of added arachidonic acid
whereas Ham et at. (1975) used a microsomal uterine tissue prepara¬
tion incubated in the presence of exogenous arachidonic acid, and
the co-factors hydroquinone and reduced glutathione which promote
PGE synthesis. The ability of guinea-pig uterine microsomes to
synthesise PGF2a from arachidonic acid also increases towards the
end of the cycle and after oestrogen treatment (Wlodawar, Kindahl
and Hamberg, 1976). Again it is not clear whether this is due to
an increase in prostaglandin synthetase or a directional influence,
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as is seen in the rat. However, Wlodawar et at, (1976) have also
reported that both cow and guinea-pig uteri contain an endogenous
inhibitor of cycloxygenase, The activity of this inhibitory factor
also alters during the cycle but these changes could not be measured
accurately enough to relate them to changes in the synthetic capacity
of the uterus during the oestrous cycle. The effect of oestrogen on
the 'activity' of this inhibitory factor was not studied.
Relatively little work has been carried out to investigate the
role of progesterone in controlling PGF201 secretion by the uterus.
In the castrate guinea-pig the in vivo administration of progesterone
does not appear to affect the ability of uterine tissue homogenates
to synthesise PGF2a in vitro nor to modify the increase in uterine
synthetic capacity induced by in vivo oestradiol treatment (Naylor
and Poyser, 1975). These results contrast markedly with those
obtained when exogenous oestradiol and progesterone, either alone or
in combination, are added in vitro to the incubation medium containing
homogenates of Day 7 guinea-pig uterine tissue. Oestradiol treatment
significantly increased PGF production while progesterone treatment,
which had no effect on its own, significantly reduced the response
to oestrogen. However, the concentrations of oestradiol and proges¬
terone used are high and may represent a pharmacological action.
In the castrate rat, progesterone treatment also has little effect on
prostaglandin synthesis when administered alone but substantially
reduces the total prostaglandin content and blunts the increase in
PGF levels induced by oestrogen treatment. This effect differs from
that of indomethecin treatment in that indomethecin reduces the total
endogenous tissue concentrations of PGE and PGF and completely
abolishes the 'directional' effect of oestrogen treatment (Ham et al.3
1975).
Like oestrogen, progesterone also binds to a uterine cytosolic
receptor which is then translocated to the nucleus, The ability of
a tissue to respond to either oestrogen or progesterone is presumably
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related to its ability to bind these hormones. In the human
(Bayard, Damilano, Robel and Baulieu, 1978), rat (Bhakoo and
Katzenellenbogen, 1977) and sheep (Koligan and Stormshak, 1977;
Zelinski, Hirota, Keenan and Stormshak, 1980), oestrogen appears to
stimulate the synthesis of its own receptor and of the cytosoloic
progesterone receptor (CPR), while progesterone exerts the opposite
effect (Milgrom, Thi, Atger and Baulieu, 1973). In the immature
rat, the administration of progesterone causes an increase in uterine
glucose metabolism and in the rate of DNA synthesis. When co¬
administered with oestrogen, progesterone decreases the uterine
responsiveness to subsequent oestrogen administration. This action
is accompanied by a decrease in the number of cytosolic oestrogen
receptors (CER) but does not appear to interfere with the trans¬
location of receptor-bound oestrogen to the nucleus. The admini¬
stration of either cycloheximide or actinomycin D between 0 to 6 hrs
following the injection of oestradiol induces a 60% decrease in CER
(Bhakoo and Katzenellenbogen, 1977). It has therefore been proposed
that CER replenishment is a dual process involving both receptor
recycling and de novo synthesis. Progesterone appears to inhibit
-idle latter process.
If oestradiol determines the amount of PGF2ot produced by the
uterus by regulating the amount and/or expression of the prostaglandin
synthetase enzymes, the increase in uterine secretion of PGF2a towards
the end of the oestrous cycle could arise in the following way.
Increased oestradiol secretion from the ovary after Day 10 of the
cycle would stimulate synthesis of CER and increase the amount of
oestradiol translocated to the nucleus, so stimulating RNA and
protein synthesis. This in turn would stimulate PGF2a production
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and the PGF2a would then act on the corpus luteum to decrease pro¬
gesterone secretion. The resulting fall in progesterone production
would then enhance the production and/or replenishment of CER
(Jacobson, Keyes and Bullock, 1972) and thereby further stimulate
PGF2a synthesis. As progesterone levels continue to fall and
oestrogen levels rise, the uterine levels of CER and CPR would
increase. Following ovulation oestradiol secretion would fall,
PGF2ct synthesis would no longer be stimulated and progesterone levels
would begin to rise and so bring about a decrease in uterine CER and
CPR. This type of positive feedback could explain the cyclical
changes in PGF2a secretion observed i-n vivo, The pulsatile nature
of the release could reflect the synthesis of a new 'batch' of
enzyme produced in response to an oestrogen surge.
Although the above theory may account for the increase in PGF2a
secretion at the end of the oestrous cycle it does not explain the
~tn VIVO requirement for a period of progesterone priming. It is
possible that progesterone is important in controlling the availa¬
bility of substrate. Following progesterone treatment there is an
increase in the number of lipid droplets in endometrial cells
-(Brinsfield and Hawk, 1973), The lack of effect of progesterone in
many of the vn vttvo studies may be due to the fact that these have
been performed in the presence of added substrate or in tissue
homogenates where the coherence of the intracellular structure has
been destroyed.
As previously mentioned there is now evidence to suggest that
oxytocin is also involved in controlling the uterine production of
PGF2a in the sheep. The ability of oxytocin to evoke PGF201 release
from the uterus closely parallels cha,nges in the endometrial oxytocin-
receptor concentration (Roberts et aZ,3 1976). By using the
oxytocin induced release of PGF2a as an in VX-VO marker for the
appearance of the oxytocin receptor, McCracken et at., 1978
have shown that in ovariectomised sheep, the infusion of
oestradiol into the arterial supply of the autotransplanted uterus,
results in an increase in uterine sensitivity to oxytocin within
6 hrs. Progesterone treatment on the other hand resulted in the
uterus becoming refactory to oxytocin treatment and initially blocked
the oestradiol-178-induced increase in uterine sensitivity to
oxytocin. This effect is probably due to the ability of progesterone
to inhibit CER replenishment (Koligan and Stormshak, 1977). However,
after 10 days of progesterone treatment, oestradiol-178 treatment
regains its ability to stimulate oxytocin receptor formation and,
following oxytocin challenge, the uterus secretes 50 to 100 fold more
PGF2ct than when oestradiol-173 is infused alone. The return of
uterine responsiveness to oestradiol is probably due to the fact that
progesterone catalyses the destruction of its own receptor (Vu Hai,
Logeat, Warernbourg and Milgrom, 1977) so that progesterone can no
longer inhibit CER replenishment. The reason for the amplification
of the uterine response to oxytocin following progesterone priming
and oestrogen treatment is not known but could be due to an increased
supply of lipid precursor (Brinsfield and Hawk, 1973).
When progesterone (500yg hr-1, i.v.) is infused systemically
into sheep bearing utero-ovarian transplants from Day 1 to 10 of the
cycle, spontaneous peaks of PGF2a of low magnitude (3 to 5 ng ml-1)
occurred in the uterine venous blood around Day 9 and 10, Following
cessation of the progesterone infusion, the magnitude of the peaks of
PGF2a began to increase in a fashion similar to that seen after the
onset of luteolysis in the normal cycle (McCracken et aZ, , 1978. )
Ottobre, Lewis, Thayne and Inskeep (1980) have also reported
increased levels of PGF2a in the uterine venous plasma of ewes
treated with progesterone 8 or 32 hrs after the onset of oestrus,
from Day 8 onwards. McCracken et aZ, (1978) have proposed that the
increase in PGF2ct secretion observed following the termination of
progesterone secretion may be due to an increase in oxytocin levels
following removal of the blockade of progesterone at the level of
the CNS (Blank and De Bias, 1977). The mechanism by which oxytocin
evokes the rapid release of PGF2a is not known, although it has been
proposed that it may precipitate PGF2ct synthesis by activating a
phospholipase. Although there is no direct evidence to support
this idea, such a mechanism seems possible in view of the evidence
that thyroid stimulating hormone regulates PG synthesis in thyroid
cells by stimulating phospholipase A2 activity (Haye, Champion and
Jacquemin, (1976). Obviously, the control of PGF2a synthesis by
the uterus is a complex process.
From the above evidence, PGF2a fulfils many of the previously
mentioned criteria for the role of a uterine luteolytic hormone in
several species of mammal, with the sheep and guinea-pig having been
studied in the greatest detail. PGF2a, secreted by the uterus in
greater amounts towards the end of the cycle than at earlier times,
acts directly on the corpus luteum to terminate its functional life
span. The trigger for the increase in uterine PGF2a production
appears to depend on the exposure of a progesterone primed uterus to
oestrogen and, in the sheep at least, to oxytocin. The question of
whether PGF2a also acts as the uterine luteolysin in other species
such as the rabbit, in which hysterectomy extends the length of
pseudopregnancy, still requires further clarification.
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Prostaglandin production by the uterus during early pregnancy
In many species progesterone is necessary for the maintenance
of pregnancy. In eutherian mammals, but not marsupials, the length
of gestation exceeds that of the oestrous cycle. In the rat,
hamster, rabbit, pig and cow, the maintenance of pregnancy is
dependent on ovarian progesterone. In the sheep and guinea-pig,
however, ovarian progesterone is only required for the first third
of gestation, after which time the placenta produces sufficient
progesterone to maintain pregnancy. In all instances, therefore,
the functional life span of the corpus luteum in the pregnant animal
must be prolonged. This means that, in those animals that secrete
a uterine luteolytic hormone, the effect of the uterus must be
negated if the pregnancy is to proceed to a successful conclusion.
Logically, the signal for luteal maintenance should come from the
'products of conception' and could be either luteotrophic, and
directly stimulate the corpus luteum, be anti-luteolytic, and
inhibit the production and/or action of the luteolysin, or be a
mixture of both.
In the guinea-pig, rat, rabbit and hamster, implantation occurs
at a time when the corpora lutea are still functional. In the
sheep, cow and pig, however, implantation occurs after the time at
which the corpora lutea of the cycling animal would normally have
regressed.
PGF2a output from the uterus begins to increase from Day 11 in
most species. If PGF2a is the uterine luteolytic hormone, then it
seems likely that the signal for luteal maintenance should occur
about this time.
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In the pregnant sheep, removal of the embryo up to and including
Day 12, allows regression of the corpus luteum to occur at the normal
time. Removal of the conceptuses after Day 12 however, results in a
marked extension of luteal function (Moor and Rowson, 1966a). Similarly,
the transfer of embryos to the non-pregnant sheep uterus up to Day 12
of the cycle will prolong luteal function. Transfers performed after
this time do not (Moor and Rowson, 1966b). The transferred embryos
are capable of maintaining the corpora lutea in both unilaterally and
bilaterally ovulating ewes irrespective of their position in the
uterus relative to the active corpus luteum, providing the lumen of
the two horns are contiguous (Moor, 1968; Moor and Rowson, 1966b).
In unilaterally ovulating ewes in which one horn has been transected
at the cervix, embryo transfer only results in luteal maintenance
when the corpus luteum is adjacent to the pregnant horn. This
suggests that the 'signal' for luteal maintenance acts locally on the
uterus, rather than systemically on the ovary. This idea is also
supported by the fact that the daily intrauterine infusion of homo-
genates prepared from Day 14 and Day 15 embryos into the uteri of
non-pregnant sheep, extends luteal function until Day 25, Extra¬
uterine administration of Day 14 or Day 15 embryo homogenates, or the
intrauterine infusion of Day 25 embryo homogenates is without effect.
This indicates that the antiluteolytic effect of the embryo is
extended for a limited period only (Rowson and Moor, 1967), In the
guinea-pig, grafts of Day 11 or Day 12 conceptuses to the spleen of
normally cycling animals le^d to luteal maintenance in 13 out of 25
animals. Grafts of Day 9 or Day 10 conceptuses, however, were
without effect (Bland and Donovan, 1969b). This suggests that, in
the guinea-pig, the 'signal' for luteal maintenance occurs after
Day 12 but, unlike that of the sheep, the 'signal' has a systemic
component. Unilateral pregnancy in the guinea-pig, as in the sheep,
results in bilateral luteal maintenance. In the pig, however,
unilateral pregnancy tends to result in pregnancy failure due to
luteal regression (Anderson, Rathmaker and Melampy, 1966). The
removal of the non-gravid horn permits pregnancy to continue and
results in the bilateral maintenance of the corpora lutea. In
bilaterally pregnant pigs, the removal of the embryos from one horn
up to Day 10 or Day 11 of pregnancy results in bilateral luteal
maintenance (Dhindsa and Dzuik, 1968). The 'signal' for luteal
maintenance in the pig therefore appears to be released around Days
lO to 12. Longenecker and Day (1972) have shown that the infusion
of saline extracts of Day 20 to Day 25 conceptuses into the non¬
pregnant horn of unilaterally pregnant pigs results in an increased
incidence of pregnancy maintenance of 57.1% of the animals as com¬
pared with non-treated, unilaterally pregnant pigs. If the infusion
was restricted to only a small area of the sterile horn, the preg¬
nancy rate at slaughter was only 16.7% greater than in the controls.
This suggests that the conceptuses and associated membranes act
directly on the uterus, and also that the 'anti-luteolytic' effect
of the embryo is still present after Day 20 of pregnancy. Inter¬
estingly, saline extracts of embryonic tissue collected on Days 26
to 40 of pregnancy, although capable of blocking the luteolytic
effect of a non-gravid horn in a unilaterally pregnant animal, will
not prevent luteal regression when infused into the uteri of non¬
pregnant pigs. The infusion of 14-day old pig embryos into the uteri
of non-pregnant sheep also failed to prevent luteal regression
(Rowson and Moor, 1967).
Prostaglandin secretion by the uterus in early pregnancy has
been studied in the sheep (Thorburn et at, , 1973) , mare (Douglas and
Ginther, 1976), cow (Lukaszewska and Hansel, 1980), pig (Moeljono,
Thatcher, Bazer, Frank, Owens and Wilcox, 1977) and guinea-pig
(Blatchley, Maule Walker and Poyser, 1975a). Using a chronic sampling
technique Thorburn et at. (1973) found that the large peaks of PGF2a
in utero-ovarian venous plasma observed on Days 15 and 16 of the
oestrous cycle are not present in the uterine blood of pregnant sheep.
These results were confirmed by Barcikowski et at. (1974) . However,
Pexton, Weems and Inskeep (1975), using an acute sampling technique,
found no significant difference in the levels of PGF2a in the utero-
ovarian venous plasma of pregnant and non-pregnant sheep on Days 13
to 15. These results were confirmed by Nett, Staigmiller, Akbar,
Diekman, Ellinwood and Niswender (1976) but, like Thorburn et at.
(1973) these authors also found that the 'peak' frequency of PGF2a
secretion was significantly lower in the pregnant animal as compared
to the cycling sheep. In an attempt to help to resolve the question
of whether PGF2a output from the ovine uterus is inhibited during
early pregnancy Peterson et at. (1976) measured the peripheral plasma
levels of 13,14-dihydro-15-keto-PGF2a- in the cycling animal, the
levels of 13,14-dihydro-15-keto-PGF2a increase towards the end of the
cycle with peaks being observed around the time of luteolysis. In
the pregnant sheep however, the metabolite levels were found to be
lower and no peaks were observed between Days 12 to 20. These
results, therefore, support the opinion that in the early pregnant
sheep PGF2a output from the uterus is suppressed. In the cycling
pig and cow the peripheral plasma concentrations of 13,14-dihydro-15-
keto-PGF2a also increase and exhibit peaks around the time of
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luteolysis (Shille et at, , 1979; Kindahl et at,, 1976), Again these
increases are thought to reflect the increased output of PGF2a from
the uterus (Shemesh and Hansel, 1975; Moeljono et at., 1977). As in
the sheep, these increases in metabolite levels are not found in the
pregnant animal (Kindahl et at,, 1976; Shille et at. , 1979) sugges¬
ting that PGF2a release is also suppressed during early pregnancy.
Lukaszewska and Hansel (1980) have recently reported that the con¬
centration of PGF2a in the uterine vein is significantly lower in
the pregnant cow on Day 18 than in the non-pregnant animal. Simi¬
larly in the guinea-pig, the levels of the main urinary metabolite
of PGF2a are also depressed in early pregnancy when compared with
those observed in the non-pregnant animal (Granstrom and Kindahl,
1976). These results are in agreement with those of Antonini,
Turner and Paverstein (1976) and Blatchley, Maule Walker and Poyser
(1975a) who have shown that the increase in utero-ovarian venous
levels of PGF2a seen on Days 14 to 16 of the cycle is not observed
in the pregnant animal. However, urinary metabolite levels of
PGF2a do begin to increase from Day 25 of pregnancy when the anti-
luteolytic effect of the conceptus is no longer evident (Bland and
Donovan, 1969).
In several species therefore it is apparent that decreased
secretion of PGF2a into the uterine venous drainage occurs during
early pregnancy at the time at which corpus luteyim regression would
normally be occurring in the non-pregnant animal. The mechanisms
by which this occurs again shows considerable species variation.
Maule Walker and Poyser (1974) have shown that uterine tissue
from bilaterally pregnant guinea-pigs synthesises significantly less
PGF2a, in vitro, on Day 15 of pregnancy than uterine tissue on Day
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15 of the cycle. In unilaterally pregnant guinea-pigs the amount
of PGF2ct synthesised by the pregnant horn is the same as the amount
synthesised by uterine tissue from a bilaterally pregnant animal.
The non-gravid horn, however, synthesises approximately twice as
much PGF2a as either the unilaterally pregnant or bilaterally
pregnant uterus but synthesises significantly less than the Day 15,
non-pregnant uterus. The mechanism by which the conceptus maintains
luteal function during early pregnancy therefore appears to be partly,
if not fully, via an antiluteolytic effect which possesses both a
systemic and local component. Further evidence for this suggestion
comes from studies involving guinea-pigs in which the luminal
continuity of the uterine horns has been disrupted by transection of
one of the horns. Following mating the ability of uterine tissue
from the transected horn to synthesise PGF2a, in vitro, on Day 15 of
pregnancy, although lower than that of the Day 14 non-pregnant uterus,
was three fold higher than that of the pregnant horn (cleared of
conceptuses and attached uterine tissue) and was also significantly
higher than PGF2a production by the sterile horn of spontaneous,
unilateral pregnancies. Peripheral plasma progesterone levels in
these animals showed that the corpora lutea were still functional but
the circulating level of progesterone was still significantly lower
than those observed in spontaneous, unilateral pregnancies or in
bilaterally pregnant guinea-pigs (Maule Walker, 1976), (These
findings contrast with those observed in the sheep where transection
of a sterile horn results in luteal regression in the adjacent ovary
(Rowson and Moor, 1967),)
In the sheep Ellinwood, Nett and Niswender (1979) found that
there was no difference in the amount of PGF2ct released from uterine
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tissue, in vitro, on Day 13 of either the oestrous cycle or pregnancy
while PGF2d release on Days 15 and 17 of pregnancy was significantly
greater than on Days 14 and 17 of the oestrous cycle. However, they
also reported that there was a marked increase in the concentrations
of PGF2a and PGE2 in the uterine flushings from pregnant animals on
Days 13, 15 and 17 and in the utero-ovarian venous plasma levels of
PGE2 on Days 15 and 17. It is possible that the presence of the
developing conceptus induces a shift in the direction of secretion
of PGF2a from the lamina propria to the uterine lumen. Bazer and
Thatcher (1977) have proposed a similar hypothesis to explain the
antiluteolytic effect of oestradiol in the pig and the decrease in
uterine venous plasma concentrations of PGF2a during early pregnancy.
However, whether the high levels of PGE2 and PGF2a in the uterine
lumen result from the accumulation of prostaglandins in blastocoelic
fluid, binding of prostaglandins to embryonic or uterine proteins or
de novo synthesis of prostaglandins by the embryo and/or endometrium
is not known. The amount of protein recovered from uterine flushings
on Day 13, 15 and 17 of pregnancy is greater than the amount
recovered from uterine flushings on the same days of the oestrous
cycle. This suggests that pregnancy-specific proteins may be
present in the uterine lumen as early as Day 13, and therefore these
could play a part in the mechanism of luteal maintenance which
becomes operational at this time (Moor, Hay, Short and Rowson, 1970),
The enhanced capacity of endometrial tissue to synthesise PGE2
on Day 15 and 17 of pregnancy (Ellinwood et aZ. , 1979) may also be
significant in terms of luteal maintenance. Experiments performed
by Mapletoft, Del Campo and Ginther (1975) suggest that, in the
unilaterally pregnant ewe there is also a locally mediated luteo-
45
trophic effect of the uterus, PGE2 counteracts the luteolytic effect
of PGF2a when infused simultaneously into the ovarian artery of
cycling ewes (Henderson, Scaramuzzi and Baird, 1977), The intra¬
uterine administration of PGE2 to cycling ewes also overcomes both
natural and oestradiol induced luteolysis (Magness, Huie and Weems,
1978; Colcord, Hoyer and Weems, 1978). The mechanism by which
PGE2 exerts this antiluteolytic/luteotrophic effect is not known.
It could be due to a vascular effect resulting from its potent
vasodilator properties (Bergstrom, Carlson and Weeks, 1968) and/or
its ability to elevate intracellular c-AMP and stimulate progesterone
production by luteal tissue (Marsh, 1971). It is possible that PGE2
is the luteotrophic substance produced by the pregnant uterus.
In the sheep Martal, Lacroix, Loudes, Saunier and Wintenberger-
Torres (1979) have identified a protein-like material secreted by the
trophoblast which is capable of maintaining luteal function when
injected for periods of 4 to 11 days into the uterus of normally
cycling ewes from Day 12 of the cycle. This principle., called
trophoblastin, appears to be secreted for a limited period only and
is no longer evident in homogenates of embryos and their membranes
from Day 21 to 23 of pregnancy. Removal of embryos on Days 21 to 23
of pregnancy also results in luteal maintenance for periods in excess
of 30 days in over 50% of the operated animals although luteal weight,
as compared to normal pregnancy, is reduced. The latter effect
probably reflects the absence of placental luteotrophic influences.
The mechanism by which trophoblastin secures luteal maintenance is
not known. Its action is essentially local (Moor and Rowson, 1966b)
but whether it acts to inhibit PGF2a synthesis and/or release or by
stimulating the production of a locally acting luteotrophin is still
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a matter of conjecture. Certainly it is present in the uterus at
the time that PGF2a output is reduced, but a purely antiluteolytic
effect would not explain the prolonged effect of trophoblastin on
luteal maintenance since the levels of progesterone in the peripheral
venous plasma of these animals are higher than those observed follow¬
ing hysterectomy in the non-pregnant animal. Such an effect is more
readily explained in terms of a luteotrophic effect and could involve
stimulation of PGE2 synthesis. In this respect it is interesting to
note that during early pregnancy there is some evidence to suggest
that the sensitivity of the uterus to luteolytic stimuli, such as
oestrogen or PGF2a treatment, is reduced (Kittock and Britt, 1977;
Pratt, Butcher and Inskeep, 1977) . As previously mentioned PGE2
has been shown to overcome both natural and oestradiol induced luteo-
lysis and to antagonise the effect of PGF2ct infusion (Magness et at.,
1978; Colcord et at., 1978; Henderson et at., 1977). Similarly,
in the guinea-pig there is evidence to suggest that the conceptus
also produces a luteotrophic hormone which acts locally between the
uterus and the ovary (see Poyser and Maule Walker, 1979) although
attempts to isolate such a factor have so far proved unsuccessful.
If oestrogen, acting in the presence of progesterone, forms
part of the physiological stimulus for the increase in uterine secre¬
tion of PGF2a which occurs towards the end of the oestrous cycle, then
it is of interest to know how the advent of pregnancy affects oestro¬
gen secretion. In the early pregnant sheep (Cox et at., 1974), cow
(Henricks, Dickey, Hill and Johnston, 1972), guinea-pig (Blatchley
et at., 1975), pig (Guthrie, Henricks and Handlin, 1972) and hamster
(Shaikh et at., 1973) the increases in oestradiol levels seen towards
the end of the oestrous cycle or pseudopregnancy do not occur. It
47
is possible therefore, that the developing embryo maintains luteal
function by inhibiting oestradiol output by the ovary.
In the guinea-pig, the administration of oestradiol (lOyg day-1)
from Day 10 of pregnancy results in a fall in plasma progesterone
from Day 12 onwards and termination of pregnancy occurs by Days 20 to
22 (gestation length 65 days). The uteri of these animals showed an
increased ability to synthesise PGF2a when compared to the uteri of
untreated, pregnant animals (Poyser and Maule Walker, 1979). However,
in one animal treated with oestradiol, the peripheral plasma levels
of progesterone continued increasing, instead of falling, after
Day 12, Abortion still occurred by Day 21 but in this animal the
conceptuses were still present in the uterus whereas in the other
animals they were in the vagina.
Oestradiol is also luteolytic in the pregnant cow (Wiltbank,
1966), sheep (Kittock and Britt, 1977) and the early pregnant hamster
(Greenwald, 1965). However, in the pig the blastocyst is capable
of synthesising oestrogens, principally oestrone, from Day 12 of
pregnancy (Perry, Heap and Amoroso, 1973; Perry, Heap, Burton and
Gadsby, 1976). Kraeling, Rampacek and Ball (1975) have reported
that the administration of oestradiol benzoate on Days 10 to 15 of
pregnancy, prolongs luteal function in unilaterally pregnant pigs and
blocks the luteolytic effect of PGF201 in hemi-hysterectomised,
pregnant sows. The dose of oestradiol benzoate required to overcome
the luteolytic effect of PGF2a was high (5 mg) and so may represent a
pharmacological effect rather than a physiological one. Treatment
with oestradiol valerate in non-pregnant gilts however, maintains
peripheral plasma progesterone levels above those of untreated
animals, PGF2a still appears to be secreted after Day 13 but the
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peak frequency is more erratic (Frank, Bazer, Thai and Wilcox, 1977).
Bazer and Thatcher (1977) have proposed that in the pregnant animal,
oestradiol exerts a luteotrophic effect, not by decreasing the amount
of PGF2a synthesised but by redirecting its secretion from the vas¬
culature to the uterine lumen, since the amount of PGF2a in the
uterine lumen of pregnant gilts, or in gilts treated with oestradiol
valerate, is significantly higher than in the untreated, non-pregnant
animal.
It is apparent therefore that in those species studied, the
mechanisms by which PGF2a secretion into the uterine vein during early
pregnancy is reduced, compared with the non-pregnant animal, vary
amongst the species (e.g. decreased uterine synthetase levels in the
guinea-pig; a redirection of secretion in the pig). This decreased
supply of PGF2a to the ovary may be the cause of luteal maintenance
during early pregnancy. However, it is apparent that in some species
{e.g. sheep) the embryos secrete a luteotrophic hormone (or cause such
a hormone to be secreted by the uterus) which also aids in maintaining
the corpus luteum during early pregnancy. The presence of concep-
tuses therefore greatly affects prostaglandin synthesis by and/or
release from the uterus.
Aims of the present Studies
The purpose of the experiments reported in this thesis was to
examine whether PGF2a could be the uterine luteolysin in the rabbit.
The rabbit, unlike the sheep, pig, cow and guinea-pig is a reflex
ovulator and, as such, does not exhibit an ovarian cycle characterised
by the presence of a spontaneously active corpus luteum. However,
the doe does show seasonal variation in mating behaviour and during
the breeding season shows oestrus activity. Oestrus lasts from 2 to
15 days. Cycles of oestrus activity of 4 to 6 days or 7 days, or
multiples thereof, have been reported (Asdell, 1964). Ovulation
occurs approximately 10 hrs after mating (Harper, 1961) and by Day 4
post coitus the corpus luteum is secreting substantial amounts of
progesterone (Challis, Davies and Ryan, 1973). Pregnancy lasts
approximately 32 days in the rabbit and is dependent upon pituitary
support (Smith and White, 1931) and ovarian progesterone (Allen and
Corner, 1930) throughout the whole of the gestational period. If
the mating is infertile, an active corpus luteum still forms but the
animal enters into a state of pseudopregnancy which lasts approxi¬
mately half as long as pregnancy (17 days). Luteal regression, as
determined by the appearance and weight of the corpora lutea and the
histology of the endometrium begins to occur from Day 12 of pseudo-
pregnancy. Ovarian progesterone secretion reaches peak values be¬
tween Days 8 to 14 of pseudopregnancy and then declines steadily from
Day 15 to Day 21. The decline in progesterone output is accompanied
by a marked increase in 20a-hydroxypregn-4-en-3-one (20a-0H) and a
significant increase in the 20a-0H : progesterone ratio (Hilliard,
Spies and Sawyer, 1968). There is a good correlation between corpus
luteum weight and progesterone secretion throughout pseudopregnancy.
In the pregnant rabbit the concentration of progesterone in the peri¬
pheral venous plasma reaches peak levels on Days 10 to 14 of pregnancy,
they fall abruptly on Day 15 to a lower level which is then maintained
for about 12 days when the levels fall again to reach pre-ovulation
values by the time parturition occurs (Fuchs, 1978) . On the other
hand, luteal weight increases to reach peak values between Days 15 to
20 and then maintains this weight until parturition, despite the fact
that progesterone secretion begins to decline by Day 28 (Hilliard
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et at., 1968). Also, unlike the pseudopregnant animal, the levels
of 20a-OH are similar to those of progesterone throughout pregnancy
and parturition and the ratio of 20a-OH : progesterone approaches
unity (Fuchs, 1978).
Implantation occurs around Day 6.5 to 8 post coitus (Steven, 1975)
and the placenta is established by Day 11. This coincides with the
time at which differences in luteal progesterone output in pregnant
and pseudopregnant animals occurs, suggesting that the placenta or
developing embryo is responsible for maintaining luteal function in
the pregnant animal.
Oestrogen appears to act as the ultimate luteotrophin in the
rabbit and is essential for the development, persistence and function
of the corpora lutea. Removal of the pituitary after ovulation
results in the rapid involution of the corpora lutea. This can be
prevented by the daily administration of 2yg oestradiol benzoate or
by low doses of luteinizing hormone (lOyg animal-1) (Hilliard,
Saldarini, Spies and Sawyer, 1971). As the luteotrophic effect of
luteinizing hormone (LH) does not occur following destruction of the
ovarian follicles (Rennie, 1968) the luteotrophic action of LH is
•thought to be mediated via its ability to stimulate oestrogen secre¬
tion from the follicles (Eaton and Hilliard, 1971).
The ovarian follicles are the principal source of oestrogen
since their destruction by cautery (Rennie, 1968), X-irradiation
(Keyes and Nalbandov, 1967) or luteinization in response to high doses
of LH (Stormshak and Casida, 1965) results in the rapid regression of
the corpora lutea unless exogenous oestrogen is administered.
However, the uterus also appears to play a role in regulating
the life span of the corpus luteum in the pseudopregnant animal.
Removal of the uterus - prior to ovulation increases the luteal life
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span by between 6 to 10 days (Asdell and Hammond, 1933) beyond its
normal duration. The degree of lengthening of pseudopregnancy has
been reported to be inversely related to the quantity of uterine tissue
remaining. However, no well defined unilateral relationship was evi¬
dent (Hunter and Casida, 1967). Scott and Rennie (1970) showed that
following the transfer of 2-day old corpora lutea from donor rabbits
to beneath the kidney capsule of recipient animals, the life span of
the transferred corpora lutea depended on the day of pseudopregnancy
of the recipient
)yon which transfer took place. In oestrus recipients, the life span
of the transferred corpora lutea was approximately 17 days whereas
in corpora lutea transferred to Day 12 pseudopregnant recipients, the
life span was reduced to approximately 11 days. In the latter
experiment, both ovarian and transferred corpora lutea regressed at
the same time. However, if the recipient animals were hysterecto¬
mised at the time of transfer, the two sets of corpora lutea regressed
assynchronously and had life spans of between 23 to 27 days. This
data suggests that the uterus secretes a luteolytic principle towards
the end of pseudopregnancy which is responsible for initiating luteal
regression. As regards the maintenance of luteal function beyond
Day 12 in the pregnant rabbit the induction of uterine deciduomata by
trauma in the pseudopregnant rabbit does not extend luteal function
(Hammond, 1917). This is in contrast to the rat (Velardo, 1955 ;
Hashimoto, Henricks, Anderson and Melampy, 1968), However, following
the post implantation destruction of the rabbit blastocyst on Day 8 of
pregnancy, the functional life span of the corpus luteum is extended
to a similar extent as produced by hysterectomy (Hoffman, Davies and
Davenport, 1973), The decidual reaction produced following removal
of the blastocyst closely resembles the maternal placenta of normal
pregnancy whereas decidual tissue induced by trauma does not and so
may account for the differences in the responses to these two treat¬
ments. However, neither hysterectomy or decidualisation results in
a condition of luteal maintenance equivalent to pregnancy. In the
rabbit therefore, it would appear that in the absence of a developing
embryo and its associated tissues, the uterus will curtail the func¬
tional life-span of the corpus luteum. However, in the pregnant
animal the presence of the developing embryo exerts both an anti-
luteolytic as well as a luteotrophic effect.
The next question which arises is whether PGF2a is the uterine
luteolytic principle involved. PGF2a is luteolytic in the pseudo-
pregnant (Carlson and Gole, 1978; Scott and Rennie, 1970) and pregnant
rabbit (Challis, Porter and Ryan, 1974), and inhibits the in vitro
synthesis of progesterone by rabbit corpora lutea (0'Grady et at. ,
1972). "Treatment with PGF2a is accompanied by a rapid decrease in the
peripheral plasma concentration of progesterone and an increase in
plasma levels of 20a-OH (Lau, Saksena and Chang, 1976), Morpho¬
logical regression occurs within 24 hr of PGF2a treatment (Koering,
1974).
Wilks, Hunter and Norland (1972) have shown that the rabbit
uterus is capable of synthesising PGF2a and that the amount of PGF2a
synthesised (per unit wt per hr) is higher in oestrus animals than on
Day 9 of pseudopregnancy,
The main evidence which suggests that PGF2a is the uterine luteo¬
lytic principle in the rabbit comes from studies involving the inhibi¬
tion of prostaglandin synthesis and the 'neutralisation' of its
effect. Subcutaneous administration of indomethacin (8 mg kg-1,
12 hr--1) from Day 12 of pseudopregnancy prolongs luteal function as
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determined by the measurement of peripheral plasma progesterone con¬
centrations until Day 24 post coitus (p.c.). The plasma levels in
treated rabbits is substantially higher on Day 13 than in untreated
animals. The concentration of progesterone in treated rabbits drops
significantly between Days 13 and 15 to plateau at a lower level of
about 4 ng ml-1 which is maintained until Day 22 when it then drops
again to reach 2 ng ml-1 by Day 24 (O'Grady et al, , 1972) . This
stepwise decrease in progesterone secretion seen around Day 15 is
similar to that observed in the pregnant animal although the concen¬
tration of progesterone in the peripheral plasma of indomethacin
treated animals is still lower than that observed in the pregnant
rabbit. Similar results are also obtained when the rabbit is immu¬
nised against PGF2ct (Caldwell, Auletta, Gordon and Speroff, 1972).
In the rabbit, therefore, PGF2a fulfils several of the previously
mentioned criteria for a luteolytic hormone. However, before such a
role can be unequivocally established, it is also necessary to show
that there is an increase in the uterine secretion of PGF2a imme¬
diately prior to the onset of luteal regression. The following
experiments were undertaken in an attempt to clarify the role of
PGF2a in controlling the function of the corpus luteum in the rabbit
and to determine the hormonal factors controlling its synthesis. The
effect of pregnancy on uterine prostaglandin production in the rabbit
has also been studied.
54
SECTION 1. MATERIALS & GENERAL METHODS
The work presented in this thesis has involved the measurement
of prostaglandin concentrations in rabbit plasma during pseudopreg-
nancy and pregnancy, and the ability of uterine tissue from pseudo-
pregnant and pregnant rabbits, and ovariectomised rabbits treated
with progesterone and oestradiol-178 (E2l7$), either alone or in com¬
bination, and of placental tissue, to synthesise, and metabolise,
prostaglandins. The methods of analysis involved the extraction of
prostaglandins from biological samples by organic solvents, further
purification by silicic acid, column chromatography and measurement
by radioimmunoassay. Prostaglandin identification was confirmed
whenever possible by combined gas chromatography and mass spectrometry
(g.c.-m.s.). The experimental work has been divided into several
sections but, as many of the analytical procedures used are common to
each section the details of such procedures are given in Section 1.
Solvents
Chloroform (analar) B.D.H. Chemicals Ltd,
*1,2-Dichloroethane (HPLC grade) Rathbone Chemicals,
*Ethanol (absolute alcohol) J. Boroughs Ltd., London.
*Ethyl Acetate (reagent grade) B.D.H, Chemicals Ltd.
*Heptane (reagent grade) Koch Light Laboratories Ltd.
*Methanol (reagent grade) Koch Light Laboratories Ltd.
*Petroleum Spirit, b.pt 40-60°C,
(reagent grade) B.D.H. Chemicals Ltd,
*Petroleum Spirit, b.pt 60-80°C,
(analar grade) B,D,H, Chemicals Ltd,
*Toluene Koch Light Laboratories Ltd.




[5, 6, 8,11,12 ,14 ,15 (n)-3H] Prostaglandin E£ (Sp, act, 160 Ci mmol-1)
Radiochemical Centre, Amersham,
[5,6,8,ll,12,14,15n-3H] Prostaglandin F2a (SP• act. 160 Ci mmol-1)
Radiochemical Centre, Amersham.
[1,2,6,7-3H] Progesterone (St. act. 110 Ci mmol-1)
Radiochemical Centre, Amersham,
3H-Progesterone was checked for purity on a column of Sephadex LH-20
(Pharmacia Fine Chemicals) run in Heptane : Chloroform : Ethanol
(200:200:1) saturated with water. It was then stored at 5.0yCi ml 1)
in ethanol at -20°C.
Radioactivity was monitored on a Mark II Nuclear Chicago liquid
scintillation counter.
Other Chemicals
Authentic prostaglandins E2, F2a and 6-keto-prostaglandin F^a were
the gift of Dr. J. Pike, Upjohn Company, Kalamazoo, U.S.A.
Arachidonic Acid Sigma Chemical Company.




Human chorionic gonadotrophin (HCG)-Pregnyl B.P.
Organon Laboratories Limited.
Urethane, Ethyl Carbamate May & Baker Limited
Heparin, Pu^larin Heparin inj B.P. Evans Medical Limited
Sagatal May & Baker Limited
Krebs' Solution was made up daily as required in 2 1quantities:-
*including deuterated 6-keto-Prostaglandin F1(X.
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13. 8g Sodium Chloride
4,2g Sodium dihydrogen phosphate
4.0g Glucose
2.8ml 10% Magnesium Sulphate
3.2ml 10% Potassium dihydrogen orthophosphate
7.0ml 10% Potassium chloride
5.04ml 1 M Calcium chloride
All reagents were supplied by BDH Chemicals Ltd.
Chemicals and Solutions for Radioimmunoassay (RIA)
Tris(hydroxymethyl)methylamine)Analar B.D.H. Chemicals Limited
Sodium azide Hopkin and Williams Limited
Gelatin B.D.H. Chemicals Limited
PPO(2,5-diphenyloxazole) Fisons
Butyl PBD (2-(4-tert-Butylphenyl)-5-(4-biphenyl)-1,3,4-oxadiazole)
Koch Light Laboratories Ltd.
Napthalene May & Baker Limited
The above chemicals were used to make up the following solutions.
Diluent 1 0.05m Tris buffer pH 8,0
O.lg l-1 Sodium azide
1.Og 1 1 Gelatin
Diluent 2 0,05m Phosphate buffer pH 7,5
O.lg 1_1 Sodium azide
l.Og l-1 Gelatin
Diluent 3 0.05m Tris buffer pH 6.8
0.1g l-1 Sodium azide
1, Og l-1 Gelatin
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Scintillant 1 10,5g PPO
1,5 1 Toluene
0.9 1 2 Ethoxyethanol
Scintillant 2 10.Og Butyl PBD
2.5 1 Toluene
Scintillant 3 112.5g Napthalene
10.5g PPO
1.5 1 Toluene
0.9 1 2 ethoxyethanol
Donkey anti-rabbit serum (DARS) Wellcome Reagents Limited
stored at 4°C in 25 ml aliquots
until use
Normal rabbit serum (NRS) - obtained from non-immunised New Zealand
white rabbits (male) by the method of Dighe Emslie, Henderson and
Simon, 1975. Stored in 1 ml fractions at -20°C. Prior to use the
serum was thawed and thereafter stored at 4°C. Dilutions of NRS
were made up in diluent 1 or diluent 2 as required.
Section 1,1a Experiment to check the purity of tritiated prosta¬
glandin E? and Fprc tracers.
Tritiated prostaglandin F2a (3H-PGF2a) and tritiated prostaglan¬
din E2 (3H-PGE2) were obtained from the Radiochemical Centre,
Amersham in quantities of 250yCi,
On arrival the radioactive prostaglandins (tracers) were taken
to dryness and resuspended in methanol to give a final dilution of
5.0yCi ml-1. This was stored in sealed vials containing 2 to 3 ml
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methanol and kept at -20°C until use.
Because of the high substitution of hydrogen atoms with tritium
and because PGE2 is liable to dehydration, the purity of the tracers
was checked periodically.
Method
Stock solutions of authentic PGE2 and PGF2ct at a concentration
of 5.0pg ml-1 were made up in methanol. 0.1 ml Authentic PGE2 or
PGF2a was spotted on to a 50 x 200 x 0.25 mm, precoated, silica gel
thin layer chromatography plate (Merck, precoated TLC plates without
fluorescence indicator) using a 100yl Hamilton syringe, to give an
origin 30 mm from the end of the plate. The spot was allowed to
dry and 0.1 ml of 3H-PGE2 or 3H-PGF2a (5yCi ml-1) spotted over it.
Control plates were spotted with lOOyl of cold standard only. All
plates were first developed in solvent F VI (Andersen 1969; a
mixture of ethyl acetate : acetone : glacial acetic acid, 90:10:0.1)
and then in solvent G.C.M. (Miller 1974; a mixture of ethyl acetate
: methanol : glacial acetic acid, 100:10:1). The plates were
developed to give a solvent front of 160 mm from the origin.
The radioactivity was localised using a Panax radio thin layer
chromatographic (T.L.C.) plate scanner, the position of the radio¬
active peaks relative to the origin measured and the Rf values
calculated. Control plates were visualised by spraying with a
saturated solution of phosphomolybdic acid in ethanol and heating at













Table 1. Comparison of the Rf values of 3H-PGE2 and
^H-PGF2a and the unlabelled standard (mean ±
standard error of the mean (SEM), n = 5)
When the tracer did not run as a single spot with the same Rf
value as the authentic standard, the remaining ampoules of that tracer
were pooled and the tracer purified by column chromatography on
Lipidex 1000 using the method of Brash and Jones (1974).
Section 1.1b Purification of 3H-PGE2 and 3H-PGF2« by Column
Chromatography
Method
20g Lipidex 1000 was placed in an excess of running solvent of
the following composition, Hexane : dichloroethane : ethanol : glacial
acetic acid (100:100:15:0.1%) and allowed to swell overnight. A
glass column of 300-400 mm length and 10 mm internal diameter, which
had a teflon wool plug covered with acidic, washed sand at the bottom
and a solvent reservoir to form a constant pressure head at the top
was used. The swollen Lipidex was poured into the column to a
height of 310 mm and left to wash overnight with a further 250 ml
running solvent.
The pooled tracer was evaporated to dryness at 45°C under
reduced pressure on a rotary evaporator, and drying was completed in
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a vacuum dessicator. The H-PGF2a was redissolved in 0,5 ml of
running solvent and applied to the column. The flask containing
the tracer was washed twice with a further 0.25 ml running solvent
and the washings applied to the column. The reservoir was filled
with 500 ml of running solvent and the column developed. The
column effluent was led via narrow bore Teflon tubing to the drop-
counting head of a L.K.B. ultronic fraction collector. Fractions
were collected on a fixed volume basis of 3 ml (150 drops) and the
height of the column outflow adjusted to give flow rates of 10 to
15 ml h-1.
20yl samples were removed from each fraction, transferred to
scintillation vials containing 13 ml of scintillant 1 and
monitored for radioactivity for 1 min. The relevant fractions
containing the purified tracer were pooled, taken to dryness at 45°C
on a rotary evaporator and drying was completed in a vacuum
dessicator.
The purified tracer was redissolved in 10 ml methanol and three
20yl amounts were transferred to scintillation vials containing 13 ml
scintillant I and monitored for radioactivity using the external
standards channels/ratio method. The total amount of radioactivity
present was calculated. The remaining tracer was taken to dryness
and redissolved in methanol to give a final dilution of 5.0yCi ml-1,
3H-PGE2 was purified by the same method but the running solvent
had the following composition; Hexane ; dichloroethane ; ethanol ;
glacial acetic acid (100:100:10:0,1%),
Following purification by the above method the purified tracers
were re-run on a TLC plate as described in section 1.1a and the Rf
value of the tracer compared with the Rf value of the authentic
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standard. Following purification tracers were reampouled and stored
as previously described.
Results
Both 3H-PGF2a and 3H-PGE2 ran as single spots with Rf values
comparable to the Rf values obtained for authentic standards follow¬
ing purification by the above procedure. 3H-PGE2 had to be purified
more frequently than 3H-PGF2ct-
Conclusion
3H-PGE2 is not as stable as 3H-PGF2a when stored at -20°C in
methanol and should be checked for purity on a regular basis.
Section 1.2a Extraction of Prostaglandins from Tissue Homogenates
Prostaglandins were extracted from rabbit uterine tissue homo¬
genates using the method described by Poyser (1972). Tissue
homogenates were adjusted to pH 4.5 by the dropwise addition of 0.5M
hydrochloric acid and extracted three times with five volumes of
ethyl acetate. The ethyl acetate fractions were combined and taken
to dryness at 45°C on a rotary evaporator. The residue was re-
dissolved in 20 ml of 67% aqueous ethanol (v/v), washed twice with
two 20 ml fractions of petroleum spirit (b.pt 60-80°C) and the
ethanolic fraction taken to dryness at 45°C on a rotary evaporator.
Drying was completed by placing the extract in a vacuum desslcator
for a minimum period of 5 min. The residue was redissolved in
10 ml ethyl acetate and samples stored at -20°C until assayed.
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Section 1,2b Determination of the recovery of trjtiated Prosta¬
glandins E? and F?ra from tissue Homogenates
Method
Two female New Zealand white rabbits were killed by stunning
and incising the neck. The uteri were removed and divided into
twelve segments each weighing approximately 1 g. Each segment was
homogenised in 5 ml Krebs' solution using a Fisons glass homogeniser
and the homogenate poured into a 50 ml conical flask. The homo¬
geniser was washed with two further 5 ml aliquots of Krebs1 solution
and the washings added to the flask. 50yl 3H-PGF2a (0.26yCi ml-1)
in saline was added to each of six flasks, and also to four liquid
scintillation vials containing 13 ml scintillant I which acted as
counting standards. 50yl 3H-PGE2 (0.26yCi ml-1) in saline was
added to each of the remaining six flasks and to another four scin¬
tillation vials containing 13 ml scintillant I. The homogenates
were incubated for 90 min at 37°C in a Grant automatic shaker and
gassed with a mixture of 95% O2 and 5% CO2. Following incubation
the homogenates were extracted as described in section 1.2a.
After vacuum dessication each sample was dissolved in 2 ml ethyl
acetate and transferred to a scintillation vial. The ethyl acetate
was evaporated off at 45°C under a jet of nitrogen. 13 ml
Scintillant I were added to each vial and all vials monitored for
radioactivity using the external standard/channels ratio method.
The percentage recovery was calculated from the expression
disintegrations per minute (dpm) per vial
% recovery = ][
6
x 100
Average dpm of counting standards
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Results
The average percentage recovery of added 3H-PGF2a an^ 3H-PGE2
was 91.97 ± 2.96 and 89.68 ± 1.75 respectively (mean ± SEM, n = 6).
Conclusion
These results indicate that the method described in section 1.2a
for the extraction of prostaglandins E and , as judged by the
q q
recovery of °H-PGE2 and H-PGF2a, gives high recovery values and is
very reproductible.
Concentrations of prostaglandins measured in tissue homogenates
have not been corrected for procedural losses.
O
Section 1.2c Determination of the percentage recovery of ^H-PGE?
and 3H-PGF?ra from Krebs' solution
Method
Flasks containing 10.0, 100.0 or 1000.0 ng authentic PGF2a were
set up in quadruplicate. 0.013yCi 3H-PGF2ct in saline were added to
each flask and to 4 scintillation vials containing 13 ml scintillant
I; these acted as counting standards. 15 ml Krebs' solution was
added to each flask and the flask contents extracted as described in
section 1.2a. After vacuum dessication each sample was dissolved
in 2 ml ethyl acetate and transferred to a scintillation vial. The
ethyl acetate was blown off at 45°C under a stream of nitrogen and
13 ml scintillant I added to each vial. All vials were monitored
for radioactivity using the external standard channels/ratio method
and the percentage recovery of 3H-PGF2a calculated.
q l
The recovery of JH-PGE2 from Krebs was determined as for
recovery of 3H-PGF2ct except that authentic PGE2 and 3H-PGE2 were




Table 2 shows the percentage recovery of H-PGF2a anc^ H-PGE2
from Krebs' solution over a range of concentrations of prostaglandin.
Cold PGE2 % Recovery Cold PGF2a % Recovery
ng 3H-PGE2 ng 3H-PGF2a
10 91.75 ± 4.92 10 97.00 ± 5.12
100 93.00 ± 4.74 100 96.25 ± 4.91
1000 97.25 ± 4.70 1000 92.00 ± 4.50
Table 2. Percentage recovery of 3H-PGE2 and 3H-PGF2a from Krebs'
solution in the presence of different quantities of
authentic PGE2 and PGF2ct (mean ± SEM, n = 4)
Conclusion
The method described here for the extraction of prostaglandins
from Krebs' solution gives a high percentage recovery of 3H-PGF2a
and 3H—PGE2 which remains constant over a wide range of concentrations.
Section 1.2d Recovery of tritiated 6-keto-prostaglandin F1a from
Krebs1 solution
A similar experiment to the one described above was performed
in this laboratory by Miss F. Housman to determine the percentage
recovery of tritiated 6-keto-prostaglandin F^ (3H-6-keto-PGF]_a) from
Krebs' solution. 0.5yCi 3H-6-keto-PGFja was added to three flasks
each containing lyg 6-keto-prostaglandin Fia (6-keto-PGF-La) in 15 ml
Krebs' solution and the flask contents extracted as described in
section 1.2a.
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The percentage recovery was 63.4 ± 2.5%. Lowering the pH of
the extraction process did not affect the percentage recovery of
3H-6-keto-PGFia but increasing the pH to pH 5.0 decreased the per¬
centage recovery. It was decided therefore that extractions should
be carried out at pH 4.5 as this yielded a high percentage recovery
of PGE2/ PGF2a and 6-keto-PGFia.
Section 1.3a Solvent extraction of Prostaglandins from rabbit
plasma
Method
Prostaglandins were extracted from rabbit plasma using a modifi¬
cation of the extraction procedure described by Bergstrom and
Samuelsson (1964), and outlined in Fig. 3.
10 ml of rabbit plasma were acidified to pH 5 with 0.5M hydro¬
chloric acid and washed three times with three volumes of ethyl
acetate. The combined ethyl acetate fractions were taken to dry¬
ness at 45°C on a rotary evaporator, the residue dissolved in 20 ml
ethyl acetate and extracted three times with an equal volume of
0.05 M phosphate buffer solution at pH 8.0. The aqueous phases
were pooled and acidified to between pH 4 to pH 5 by the dropwise
addition of concentrated hydrochloric acid. The aqueous phase was
washed three times with an equal volume of ethyl acetate (60 ml),
the ethyl acetate fractions pooled and evaporated to dryness at
45°C on a rotary evaporator. Drying was completed in a vacuum
dessicator. The residue was redissolved in 20 ml 67% aqueous
ethanol and washed twice with an equal volume of petroleum spirit
0 1
(b.pt 60-80 C). The aqueous ethanol fraction was evaporated to dry¬











Adjust to pH5 with 0.1 N HC1
Wash 3 times with 3 vol Ethyl acetate pooling ethyl
aqueous acetate fractions
phase
Reduce Ethylacetate to 20 mis on a rotary
evaporator
< Wash 3 times with 1 vol pH8 phosphate buffer
Pool buffer & reduce to pH 4-5 with conc. HC1
discard
pH8 < Wash 3 times with 60 ml Ethyl acetate
phase
Pool Ethyl acetate washes and reduce to dryness
and dessicate
Redissolve residue in 20 ml 67% aqueous ethanol
Wash 2 times with 20 mis 60-80 Petroleum Spirit
Reduce to dryness
and dessicate
Dissolve in 0.15 ml ethyl acetate : methanol
(29.9 : 0.1 v/v) add 0.35 toluene
Store at -20°C
Chromatography
Fig. 3 Extraction of Prostaglandins from Rabbit Plasma
67
of ethyl acetate and methanol (29,9 : 0,1), 0,35 ml of toluene was
then added and the sample stored at -20°C until chromatography.
Section 1.3b Separation of Prostaglandins of the E and F series by
silicic acid column chromatography: Characterisation
of silicic acid
Introduction
When rabbit plasma prostaglandin concentrations were measured by
RIA following solvent extraction only, the levels of PGF^ recorded
were approximately 50% higher than those obtained when the same
plasma was assayed after solvent extraction followed by silicic acid
chromatography and correction for procedural losses. This indicated
that some constituent of the rabbit plasma was interfering with the
assay. In order to avoid this interference all plasma samples were
subjected to silicic acid column chromatography following solvent
extraction.
The method used was first described by Samuelsson (1963) and is
a further modification of the method used by Downie, Poyser and
Wunderlich (1972). Batches of silicic acid were found to differ in
their chromatographic characteristics, an observation confirmed by
Kibbey, Brown and Minton (1971), such that the characteristics of
each batch were determined prior to use.
Method
10 ml rabbit plasma were extracted as previously described. The
residue was dissolved in 10 ml ethyl acetate and divided into two
5 ml fractions. 20 ng authentic PGF2a (0.2 ml of 100 ng ml-1 in
methanol) and 0,013yCi 3H-PGF2a (50yl of 0.26yCi ml"1 in methanol)
were added to one fraction while the other received the same quantities
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of cold and tritiated PGE2« Each sample was taken to dryness at
45°C on a rotary evaporator. Drying was completed in a vacuum
dessicator and the residue redissolved in 0.15 ml of a mixture of
ethyl acetate and methanol (29.9 : 0.1). 0.35 ml toluene was added
and the sample stored at -20°C overnight.
Two chromatography columns were prepared as follows:-
3.8 to 4,2g silicic acid, depending on the batch, were suspended in
10 ml of a mixture of methanol, ethyl acetate and toluene (0.1 : 29.9
: 70), Hereafter this mixture is referred to as Fl. The slurry
was poured into a glass chromatography column of 100 mm length,
10 mm internal diameter and possessing a glass scinter at its base.
Prior to use 0.25 mm acid washed sand was placed over the scinter
to protect it from becoming blocked by fine particles of silicic
acid. Columns were kept moist with Fl overnight. The following
morning the excess Fl was removed and the extracted plasma added to
the top of the. column. The flask containing the extracted plasma
was washed three times with 0.5 ml of Fl and the washings added to
the top of the column.
Columns were eluted under reduced pressure at a rate of approxi¬
mately 30 drops per minute using solvent mixtures of increasing
polarity as detailed in Table 4, Each fraction was taken to dryness
on a rotary evaporator and the residue dissolved in 0.5 ml methanol,
transferred to a scintillation vial containing 13 ml scintillant 1
and monitored for radioactivity using the external standard^ channels/
ratio method. The percentage of radioactivity recovered was cal¬
culated using the formula
«
dpm fraction-1
% recovery = x 100
£ dpm of all fractions
The ratio of methanol to ethyl acetate in fractions 3,4 and fraction
5 was adjusted to maximise the separation of prostaglandins of the E









1 40 29.9 70 0.1
2 40 39.9 60 0.2
3 120 64.4 35 0.6
4 30 64.4 35 0.6
5 150 79.0 20 1.0
6 40 98.0 - 2.0
Table 4, The solvent composition and volumes of fluid applied to
silicic acid columns made from silicic acid, Batch No.
2847.
the fractions in Table 4 fulfilled these requirements for Batch No.
2847. Fig. 4 gives a graphic representation of the separation of
PGE2 from PGF2a using this system.
Conclusion
As shown in Fig. 4 this system provided good separation of
prostaglandins of the E and F series, PGE2 being almost completely
eluted in fraction 3 and PGF2a i-n fraction 5. When this system was
used to purify plasma extracts prior to assay by RIA fraction 3 and
4 were run as a single fraction of 150 ml. New columns were pre-
«



















Section 1.3c Correction for procedural losses
Introduction
When a radioactive tracer is used as an internal standard to
monitor losses incurred during the preparation of samples to be
assayed by RIA it is important that the internal standard does not
contribute significantly to the mass and/or the radioactivity of the
tracer added for assay purposes. This requires that the internal
standard have a high specific activity such that a small mass pro¬
duces a sufficient number of counts.
PGF2oi
In order to correct for losses of PGF2a which occurred during
the extraction and purification of plasma samples, 0.0013yCi 3H-PGF2a
(3pg) was added to all plasma samples and to a counting standard
before extraction. Following chromatography fractions 3 and
fraction 5 were taken to dryness at 45°C on a rotary evaporator and
drying was completed in a vacuum dessicator. The residue was
redissolved in 10 ml ethyl acetate and stored at -20°C, Prior to
assay, 1 ml of fraction 5 was transferred to a scintillation vial,
the ethyl acetate blown off at 45°C under a jet of air and 13 ml
scintillant 3 added. The sample was monitored for radioactivity
for 100 min using the external standard channels/ratio method. The
percentage recovery of 3H-PGF2a from the plasma sample was calculated
by using the formula




The concentrations of PGF2tt in plasma given in the following sections
have been corrected for procedural losses.
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PGE2
As 3H-PGF2a was used to correct for procedural losses of PGF2a
extracted from plasma, it was considered unsuitable to use 3H-PGE2
as an internal standard to monitor losses of PGE2 as any incomplete
separation of tracers on the silicic acid column would lead to
spurious results concerning the calculation for correction for pro¬
cedural losses for each plasma sample. The average efficiency of
the extraction and purification procedure for PGE2 was therefore
determined and it was assumed that the recovery of PGE from subse¬
quent plasma samples did not differ greatly from this average.
Method
A New Zealand white female rabbit was anaesthetized by the
intravenous injection (i.v.) of urethane (7 ml kg-1 of a 25% solution
of ethyl carbamate in 0.9% saline, w/v). A mid-line abdominal
incision was made, the aorta exposed and cannulated. Blood was
collected in a glass beaker surrounded by crushed ice and containing
sufficient heparin to produce a minimum final concentration of
10 i.U. ml-1 of blood. Following collection the blood was centri-
fuged for 30 min at 4°C at 1300 x g in a MSE Coolspin centrifuge.
The plasma was decanted.
Known amounts of cold PGE2 in methanol were added to five conical
flasks. 0.013yCi 3H-PGE2 in methanol was added to each flask, and
also to four scintillation vials containing 8 ml scintillant 3. The
methanol was evaporated off at 45°C under a stream of nitrogen and
10 ml of aortic plasma added to each flask. The plasma samples were
extracted and purified by silicic acid column chromatography as pre¬
viously described. The 10 ml of ethyl acetate, containing the re-
dissolved residues of fraction 3, were transferred to scintillation
vials, the ethyl acetate evaporated off at 45°C under a stream of
nitrogen and 8 ml scintillant 3 added to each vial. All vials were
monitored for radioactivity using the external standard channels/
q
ratxo method. The percentage recovery of H-PGE2 was calculated
from the formula
dpm per sample
% recovery = x 100
Average dpm of the counting standards
Results
The percentage recovery of 3H-PGE2 from plasma containing 0 to
1000 ng of added PGE2 is shown in Table 5.
Cold PGE2 % Recovery
ng
0 49.4 ± 0.9
10 51.4 ± 2.6
100 52,6 ± 2.1
1000 50.1 ± 1.3
Table 5. Percentage recovery of 3H-PGE2 from rabbit plasma after
solvent extraction and silicic acid column chromatography
(mean ± SEM, n = 3)
Conclusion
The average percentage recovery of 3H-PGE2 from rabbit plasma
following solvent extraction and silicic acid chromatography is un¬
affected by the amount of cold PGE2 present and is about 50%. In
the following section the concentrations of PGE in plasma samples
are uncorrected for procedural losses.
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Section 1.3d Extraction' of progesterone from rabbit plasma
Method
0.05 to 0.2 ml of rabbit plasma was made up to a volume of
0.2 ml if necessary by the addition of redistilled water. In samples
in which the extraction was performed on undiluted plasma, a small
volume of ethanol (10 vol plasma + 1 vol ethanol) was added to improve
the consistency of progesterone recovery. Each sample was extracted
twice with 2 ml petroleum spirit (b.pt 40-60°C). The two petroleum
fractions were pooled and evaporated to dryness at 60°C under a jet
of air. The residue was dissolved in 1 ml diluent 2 and the amount
of progesterone per tube determined by RIA.
Section 1.4 Measurement of Prostaglandins and Progesterone by
Radioimmunoassay
Section 1.4a PGE Radioimmunoassay
Introduction
The concentration of PGE in rabbit plasma and tissue extracts
were routinely measured by RIA using an antibody supplied by Dr. K.K.
Dighe. The production of antisera to PGE2 from rabbits immunised with
PGE2~bovine thyroglobulin conjugate has been described by Dighe, Smith,
Ungar and Whelpdale, (1978). The process is not repeated here but, as
the particular bleed of antisera used had not been fully characterised
the developmental details of the assay are described in detail.
Dilution Curve
The purpose of this experiment was to determine the dilution of
antibody which will bind approximately 60% of the tritiated PGE2
added. The mass of tracer used was chosen to give approximately
20,000 counts over a period of four minutes and was 30 pg per tube.
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Method
^H-PGE2 (sp. act 160yCi mmol-1) was checked for purity and
stored as previously described. Before use the methanol was evapora¬
ted off at 45°C under a stream of nitrogen and redissolved in diluent
2 to give a final concentration of 0.26yCi ml (0.6 ng ml-1). This
solution is referred to as 'tracer' hereafter. 0.1 ml neat antibody
serum (Rabbit 8, 6th boost) was diluted in diluent 2 to give a stock
solution of a 1 in 100 dilution. This was then used to prepare a
series of two-fold dilutions (0.5 ml each) ranging from 1 in 800 to
1 in 12800.
50yl of tracer (30 pg) was added to all dilutions, and to 4
counting standards and 4 non-specific binding standards
containing 0.7 ml and 0.5 ml diluent 2 respectively. The solutions
were whirlimixed and allowed to incubate for 2 hr at room tempera¬
ture. After incubation 50yl of a 1 in 140 dilution of normal rabbit
serum (NRS) in diluent 2 was added to all tubes except the counting
standards and mixed. This ensures that at the higher dilutions of
antiserum there is sufficient Y-gl°bulin present for adequate pre¬
cipitation. 50yl of a 1 in 2 dilution of Donkey anti-rabbit serum
(DARS) in diluent 2 was added to the same tubes, the tubes whirli¬
mixed and left to incubate for a minimum of 16 hrs at 4°C. All
tubes were centrifuged at 1300 xg in an MSE Coolspin centrifuge for
30 min at 4°C, the supernatant, containing the unbound tracer,
decanted into vials containing 13 ml scintillant 1 and counted for
4 min.
The percentage of tracer bound by a given dilution of antibody
I
was calculated using the formula
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% bound = 100
sample counts
x 100
Average counting standard counts
A graph of percentage tracer bound v. dilution was plotted and the
dilution of antiserum binding 60% of the added tracer, calculated.
Results












, i i r t 1—■
1:200 1:400 1:800 1:1600 1:3200 1:6400 1:1280
Dilution of Antiserum
Fig. 5 Dilution curve for PGE2 antiserum obtained from rabbit 8 (6th
boost). Double antibody method using 0.013yCi ^H-PGE2
(30 pg)
Conclusion
The following conditions were found suitable. Final dilution of
antiserum binding 60% tracer was 1 in 3200
Reaction volume for assay was 0.65 ml
Volume antiserum added was 0.05 ml
Working dilution of antiserum was 1 in 250




A series of standard solutions of cold PGE2 ranging from 0.2 ng
ml-1 to 10.24 ng ml-1 were made up in diluent 2 from a stock solu¬
tion of lyg ml-1 in methanol. Tubes containing 0.5 ml of the above


















Table 6, Concentrations of PGE2 standards used in setting up the
PGE2 Standard Curve together with the volume of standard
and amount of PGE2 placed in each tube.
Counting standards and zero standards containing 0,6 ml and 0.5 ml
of diluent 2 respectively, and non-specific binding standards con¬
taining 0.5 ml of 100 ng ml--1 PGE2 in diluent 2, were set up in
quadruplicate. All tubes were then treated as shown in Fig, 6.
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Extracted tissue or plasma samples in
ethyl acetate
blow off ethyl acetate at 45°C under a
stream of air








Add 50yl PGE antiserum (1 in 250)
Counting Standards whirlimix & incubate for 2 hrs
at room temperature
Add 50yl 1:8 DARS
whirlimix and incubate for 16 hr at 4°C
Centrifuge at 1300 x g for 30 min at 4 C
decant supernatant into scintillation
vials containing 13 ml Scintillant 1
and shake
Monitor for radioactivity
Fig. 6 Method for setting up a PGE-Standard Curve and Assay
The counting standards give an estimate of the average number
of counts added to each tube. The zero standards indicate the
maximum binding of the tracer bound by the added antiserum in the
presence of cold prostaglandin E2. The non-specific binding stan¬
dards, which contain sufficient cold PGE2 to completely saturate the
added antiserum, provide a measure of the degree of binding of the
tracer by other components of the assay. If the non-specific bind¬
ing was greater than ten per cent the assay was judged to be
unacceptable.
The number of counts per vial were recorded on a paper punch
tape which was fed into a POP 8 computer programmed to calculate the
percentage binding of the tracer as previously described. The com¬
puter then applied the logistic curve fit formula of Parker and
WaUd (1971) to the observed values of percentage tracer bound in the
presence of different concentrations of cold PGE2 and calculated the
co-ordinates for the curve of best fit. The two sets of values,
observed and calculated, were compared and, if the variation between
them was less than 5% the calculated curve was judged to be acceptable.
Results
Fig, 7 shows the standard curve from eight consecutive assays
(mean ± SEM). The limit of sensitivity was defined as the con-
centration of cold PGE2 which produced a 10% decrease in the binding
from the zero standards. The limit of sensitivity of this assay
was 0.040 ng.
When this assay was used to measure the concentration of PGE
in extracts of biological samples, samples were assayed'in triplicate
at two different volumes. Extracted samples were stored in ethyl






transferred to assay tubes using fixed volume Eppendorf pipettes.
The ethyl acetate was evaporated off at 45°C under a stream of air.
0.5M diluent was added to each tube and all tubes treated as for the
standard curve. The number of counts per vial were recorded on
paper punch tape. Following calculation of the standard curve, the
computer programme went on to calculate the amount of PGE in each
tube and the coefficient of variation for each triplicate. Values
of PGE which did not lie on the linear portion of the curve were
reassayed using different volumes or dilutions of the sample. A
standard curve was included in all assays and only assays in which
the linear portion of the curve showed an 8.0 to 12.5% gradient, as
measured over a doubling of the concentration of PGE2 per tube, were
accepted. When the gradient is less than 8.0%, small changes in
the amount of PGE produced too small a change in the percentage
binding of tracer for accurate measurement of sample differences in
PGE concentrations to be made while too steep a gradient reduces the
working range of the assay to an unacceptable degree. These criteria
for the acceptance of a standard curve were applied to all assays.
The intra-assay coefficient of variation was calculated from the
formula




mean value of triplicate
, . - X 100
of variation
, , _ ...
total number of triplicates
For this assay the intra-assay coefficient of variation was
8.51 ± 0.28% (mean ± SEM f n = 8 )
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The accuracy of this assay was calculated by incorporating three
tubes containing an 'external standard' of 0,35 ng per tube. The
mean calculated value of the 'external standard' for 5 assays was
0.35 ± 0.02 ng (mean ± SEM).
The inter-assay coefficient of variation for this assay was
calculated using the formula below, and was found to be 8.7%.
standard deviation
inter-assay coefficient of variation = £ x 100
mean
Determination of the cross reactivity of the PGE antiserum of
rabbit 8, 6th boost
Method
A standard curve for PGE2 was set up in parallel with standard
curves for several other prostaglandins. The percentage cross
reactivity of the antiserum obtained from rabbit 8, 6th boost was
determined by finding the concentration of prostaglandin which pro¬
duced a 50% inhibition of binding of the tracer and then applying
the following formula.
Concentration of prostaglandin binding
50% of tracer
% Cross reactivity = x 100
Concentration of cold PGE2 binding 50%
of tracer
Results
Table 7 gives the percentage cross reactivity of antiserum from
rabbit 8, 6th boost with various prostaglandins. As shown in Fig. 8
the dose response curves of other prostaglandins which react with the
antiserum are not parallel to the PGE2 standard curve, the degree of
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cross reaction differs over its response curve. By measuring the
cross reactivity at 50% the values quoted represent the upper limits
of cross reaction.
Compound
% Cross Reactivity at













Table 7. Cross reactivity of antiserum from rabbit 8, 6th boost,
measured at 50% inhibition of binding of tracer.
Conclusion
The antibody showed high cross reactivity with prostaglandin B2
(PGB2) and prostaglandin Ej (PGEj). As all plasma samples were sub¬
jected to silicic acid column chromatography prior to radioimmuno¬
assay, any PGB2 present in the plasma would have been removed from
the extracted plasma prior to assay (Davies and Horton, 1972), The
chromatographic system used, however, did not permit separation of
84
_J J I I I I














. PGE} and PGE2 and the results obtained following measurements made
on samples of extracted plasma using this assay have been quoted as
concentrations of PGE present.
When this assay was used to measure the PGE content in tissue
extracts the chromatography step was omitted. Howeyer, in samples,
subjected to analysis by combined gas liquid chromatography - mass
spectrometry no PGB2 was detected consequently the measurements made
on extracted tissue homogenates are also expressed in terms of PGE
concentration.
Section 1.4b PGF?g Radioimmunoassay
Antisera to PGF2a were raised in rabbits immunised with a
prostaglandin F2g-bovine serum albumin conjugate as described by




3H-PGF2a 0.26yCi ml-1 in diluent 1
Antiserum R6 - 5th boost at a dilution of 1 in 1700 in diluent 1
1 in 140-dilution of NRS in diluent 1
1 in 15-dilution of DARS in diluent 1
Method
A series of standard solutions of PGF2g ranging from 0,1 ng ml-1
to 5.12 ng ml-1 were made up in diluent 1. Tubes retaining 0.5 ml
of the above standards were set up in triplicate. Counting stan¬
dards, non-specific binding standards and zero standards containing
0.65, 0.55 and 0.5 ml of diluent 1 respectively were set up in
quadruplicate. All tubes were treated as shown in Fig, 9.
Extracted tissue and plasma in
ethyl acetate
blow off ethyl acetate at 45°C under
stream of air












Add 50yl 1:1700 R6, 5th boost
Counting Stds.\^
whirlimix and incubate for 1 hr at
room temperature
Add 50yl 1 in 140 NRS
whirlimix
Add 50yl 1 in 15 DARS
whirlimix and incubate for 16 hrs at 4
Centrifuge at 1300 x g for 30 min at 4°C
decant supernatant into scintillation
vials containing 13 ml Scintillant 1
Monitor for radioactivity






























Fig. 10 shows the standard curve from nine consecutive assays
(mean ± SEM).
The limit of sensitivity was 0.024 ng.
The intra-assay coefficient of variation was 7.87%,
The inter-assay coefficient of variation was 7.90%.
An 'external standard' of 0.25 ng per tube was incorporated in all
assays. The mean calculated value for this standard as determined
over 9 assays = 0.247 ± 0.019 (mean ± SEM).
The cross reactivities of antiserum R-6, 5th boost with other
prostaglandins was determined by Ms. L. Simon and are shown in
Table 8.

















The antiserum showed negligible cross reaction with all pros¬
taglandins tested except PGFia with which it showed 100% cross
reaction. All measurements made using this assay are quoted as
concentrations of PGF present.
a
Experiment to determine the effect of the addition of 0.0013pCi
3H-PGF?rY on the PGF?a Standard curve
Introduction
The measurement of antigen by radioimmunoassay relies on the
observation that a given amount of antigen produces a given percen¬
tage inhibition of binding of radioactive antigen to antiserum
providing the amount of radioactive antigen and the dilution of
antiserum are kept constant. It is important therefore that when
a radioactive tracer is used as an internal standard in samples to
be assayed by RIA, the internal standard does not contribute sig¬
nificantly to the mass and/or radioactivity of the tracer added for
assay purposes.
Method
The maximum mass of ^H-PGF2a present in extracted plasma samples
-l -1 o
is 0.3 pg ml h A solution of 0.3 pg ml 3H-PGF2a i-n ethyl acetate
was prepared. 1 ml of this solution was placed in each of 42 assay
tubes. The ethyl acetate was blown off at 45°C under a jet of air
and the tubes used to set up a PGF2a standard curve as previously
described, A second standard curve was set up in parallel using
untreated assay tubes. Both standard curves were counted, the
curves calculated and each set of corresponding points analysed for


























Fig. 11 shows the effect of the addition of 0,0013yCi 3H-PGF2a
on the PGF2a standard curve. Although there was a slight decrease
in the percentage binding of the zero standards and a slight increase
in binding of the tracer at the lower end of the curve, the two
curves did not differ significantly (p >0.05) from one another.
Conclusion
The addition of 0.0013yCi 3H-PGF2a to rabbit plasma samples prior
to extraction does not interfere with the assay of these samples by
RIA.
Section 1.4c 6-Keto-PGFira Radioimmunoassay
The antiserum to 6-keto-PGFia, a stable metabolite of prosta¬
glandin I2 (PGI2), was raised in rabbits immunised against a conju¬





3H-6-keto-PGF2a ~ was synthesised from octa-tritiated arachidonic
acid incubated with a sheep uterus microsomal
enzyme preparation and purified as described by
Dighe, Jones and Poyser (1978). The tracer was
made up in diluent 3 at a concentration of
0.23yCi ml-1 (sp. act 150yCi mmol-1)
Antibody - Rabbit NP-1, 6th boost was used at a dilution of 1 in 650
in diluent 3
DARS - 1 in 8 dilution in diluent 3.
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Method
A series of standard solutions of cold 6-keto-PGFia ranging
from 0.2 ng ml-1 to 10.24 ng ml-1 were made up in diluent 3. The
assay was set up using the method previously described for the PGE2
standard curve.
Results
Fig. 12 shows the standard curve from seven consecutive assays.
The sensitivity was 70 pg.
The intra-assay coefficient of variation was 9.01%, as
measured over 7 consecutive assays.
The inter-assay coefficient of variation was 12.01%.
An 'external standard' of 0.2 ng per tube was incorporated in all
assays. The mean calculated value of the 'external standard' was
0.198 ± 0.240 (mean ± SEM):.,. This value also reflects the accuracy
and precision of the assay.
The cross reactivities of antiserum NP-1, 6th boost with other
prostaglandins were determined by Ms. I. Ramsay and are as shown in
Table 9.
Conclusion
Antiserum NP-1, 6th boost shows negligible cross reactivity
with all other prostaglandins tested and this together with the high

















Table 9. Percentage Cross Reaction of NP~1, 6th boost
Section 1.4d Progesterone Radioimmunoassay
The progesterone antiserum was supplied by Dr. K. Dighe and
Dr. W.M. Hunter and was raised in rabbits immunised with a conjugate
of lla-hydroxyprogesteronehemisuccinate-bovine serum albumin.
Details of the preparation of conjugate and testing of the antisera




3H-Progesterone - 0.07yCi ml-1 in diluent 2
N.R.S. - 1 in 140 dilution in diluent 2
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Reagents (continued)
D A R S - 1 in 15 dilution in diluent 2
Antibody R353, 5th bleed, was used at 1:2000 dilution in diluent 2
Method
Five standard solutions of progesterone, ranging from 0.1 ng ml-1
to 12.8 ng ml-1 were made up in ethanol and used to set up a series
of tubes as detailed in Table 10. Each standard was set up in
triplicate. Counting standards, non-specific binding standards and
zero standards containing 1.15 ml, 1.05 ml and 1.0 ml respectively
were set up in quadruplicate. The standard curve was set up as


















Table 10. Concentration of Progesterone standards used in setting
up the Progesterone standard curve together with the
volumes and amounts of each standard used.
96
3 x (200-20yl) Plasma ± Absolute alcohol
whirlimix
*Add 2 ml Petroleum Spirit (b.pt 60-40°C)
Vortex mix for 5 min
Freeze plasma and decant Petroleum Spirit
Set up Standards for
Standard Curve






Blow off solvent at 60°C under a jet of air
Add 1 ml diluent 2
Add 50yl ^H-Progesterone (3.5 * 10 ^ yCi)
r
-x. whirlimix
Add 50yl Progesterone Antibody (1:2000)
Non-specific




Add 50y1 NRS (1:140)
whirlimix
Add 50yl DARS (1:15)
whirlimix and incubate for minimum of
16 hrs at 4°C
Add 1 ml diluent 2
centrifuge at 1300 x g for 30 min at 4°C
Decant supernatant into scintillation vials
containing 10 ml Scintillant 2
shake for 2 min
Count
Fig. 13 Method for Progesterone extraction and setting up of
Standard Curve and Assay
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Results
The standard curve from eight consecutive assays is shown in
Fig. 14. The sensitivity of the assay was 18 pg. The intra-assay
coefficient of variation was 8.55% (n = 8). The inter-assay
coefficient of variation was 9.8% (n = 8). The cross reactivities
of this antiserum were determined at 50% inhibition of binding of the
tracer and were performed by Dr. K.K. Dighe; they are as shown in
Table 11.















Table 11. Cross-reactivity of progesterone antiserum as determined






































The progesterone antiserum shows high cross reactivity with
lla-OH-progesterone, ll$-OH-progesterone and Sa^Pregnane-3,20-dione.
However, it shows low cross reaction with 20a-hydroxypregn-4-en-3-
one which is the only other progestin found in the rabbit in any
appreciable amounts (Simmer, Hilliard and Archibald, 1963).
The progesterone antibody was therefore considered to be suitable
for the measurement on progesterone in rabbit plasma samples.
Measurement of the precision and accuracy of the progesterone RIA.
The efficiency of the extraction procedure was determined by
adding known amounts of progesterone to 0.2 ml of ear vein plasma
collected from an ovariectomised rabbit, and estimating the amount
of progesterone received.
Method
Two sets of tubes were set up in triplicate containing differ¬
ent amounts of progesterone in ethanol. The ethanol was evaporated
off at 60°C under a jet of air and 0.2 ml plasma was added to each
tube. In addition 0.07yCi 3H-Progesterone was added to one set of
tubes and to four scintillation vials containing 13 ml scintillant 3
which acted as counting standards. Both sets of tubes were extrac¬
ted as previously described in section 1.3d and the petroleum spirit
blown off. The residue from the tubes containing added tracer was
redissolved in 0.5 ml methanol, transferred to liquid scintillation
vials containing 13 ml scintillant 3 and counted. The residue from











































Table12.Comparisonfpercentagerecoveryofrogesteronedete mi dy RIAandrecoveryof3H-prog sterone
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Results
The amount of Progesterone in 1 ml of plasma was 0.57 ng ml-1.
Table 11 shows the amount of Progesterone recovered as measured by
RIA following solvent extraction. All values have been corrected
for a 'blank' value of 0.57 ng ml-*.
Conclusion
The percentage recovery of 3H-Progesterone is in good agreement
with the percentage recovery of progesterone as determined by RIA
and is unaffected by the amount of progesterone present. Moreover
the amounts of progesterone present, as determined by RIA show that
this assay exhibits a high degree of accuracy.
Section 1.5 Gas chromatography - Mass spectrometry
Introduction
Although radioimmunoassay offers a very sensitive method for
measuring small amounts of biologically active material on a routine
basis, it has the disadvantage that it does not provide a definitive
identification of the compounds measured. Within certain limits
the ability of the antisera to discriminate between the antigen to
which it has been raised and other structurally similar molecules
is determined from cross-reactivity studies. However, such studies
are confined to compounds already known to exist and which are
available in a pure form. Moreover, even when the cross reactivity
of the antiserum is known, the ability of the antisera to measure
the required antigen will depend on the relative amounts present of
the antigen and other substances with which it cross reacts.
i
Selective extraction procedures help to minimise this type of error
but cannot eliminate it. A more positive identification of a
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compound can be obtained from its mass spectrum.
As a detection system the mass spectrometer offers both high
sensitivity and high specificity especially when coupled to a gas
liquid chromatography system. Consequently following measurement
by RIA, extracts of plasma and tissue homogenates were deriv tized
and subjected to further analysis by combined gas-chromatography -
mass spectrometry (g.c. - m.s.).
The g.c. - m.s. data given in the subsequent sections were
obtained using a VG-Micromass 70-70F mass spectrometer coupled to a
Pye 204 gas chromatograph by means of a single stage glass separator.
The gas chromatograph was equipped with a 3m spiral glass column of
4 mm internal diameter, packed with 3% OVI on supelcoport 100-120
mesh (Supelco Inc., Bellefonte, Pennsylvania, U.S.A.). The oven
temperature was 265°C, and the carrier gas was Helium which flowed
at a rate of 30 ml min-1.
Typical operating conditions for the mass spectrometer were
Separator temperature 250°C
Ion source temperature 250°C
Electron Energy 22-70 eV
Accelerating Voltage 4 kV
Signal Amplification 5 x 10~6 amps
Mass spectra were recorded using a light beam oscillograph (S.E.
Labs, (EMI) Ltd,, Feltham, England). When there was insufficient
material present to obtain a full mass spectrum the V.G.-Micromass
70-70F was used in the selected ion monitoring mode (MID) with
fixed magnet current and voltage scanning. The exact mass measure¬
ment of the ion fragments from the OVI phase column bleed, determined
103
by using perfluorokerosene as a calibration standard, were used for
reference purposes. The mass spectrometer was tuned to the required
ion fragments for selected ion monitoring by reference of their
precise masses to the precise mass of the nearest column bleed ion
fragment. Single ion chromatograms were recorded on a multi-pen
recorder (Rikadenki, Mitsui Electronics (U.K.) Ltd.). A mixture of
straight chain saturated fatty acid methyl esters (lyg pi-1) were
used to calibrate the g.c. column. The retention time of each
standard fatty acid was plotted, on a logarithmic scale, against the
number of carbon atoms in the fatty acid used (Bergstrom, Ryhage,
Samuelsson and Sjovall, 1963) and the graph obtained used to convert
the observed retention times of the prostaglandins into carbon
values. This fatty acid mixture also provided an indication of the
chromatographic efficiency of the column and of the sensitivity of
the mass spectrometer prior to analysis of the samples.
Section 1.5a Derivatization of prostaglandins for combined gas
liquid chromatography - mass spectrometry
Introduction
The presence of carboxyl and hydroxyl groups in the free
prostaglandins make these compounds too polar to be run directly on
a gas chromatograph. Various derivatives therefore have been used
to reduce the polarity of these functional groups. Carbox^y^flic
acid groups on the prostaglandin molecules were protected by methyl
ester formation, free hydroxyl groups were protected by trimethyl-
silyl ether formation and free ketone groups were protected by
O-butyloxime formation. 6-Keto-PGF^a with four deuterium atoms
substituted at positions 4 and 5 (dij-6-keto-PGF^a) was used as an
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internal standard and also served to improve the sensitivity of the
g.c. - m.s. system.
Method
All reactions were performed in 1 ml Eppendorf tubes which had
previously been rinsed in chloroform and methanol. Extracted
samples and authentic prostaglandin standards in methanol were
transferred to the Eppendorf tubes and 500 ng d^-6-keto-PGFia (ie
lOOyl of a 5yg dLj-6-keto-PGFiQ ml-1 in methanol) was added to each
tube. The methanol was evaporated off at 45°C under a jet of air.
Two drops of methanol were added to each tube followed by the addi¬
tion of approximately 1 ml diazomethhne solution (9 parts diethyl-
ether : 1 part methanol). The contents were allowed to react for
5 min at room temperature. The solvent was removed at 45°C under
a stream of air and the process repeated. Following removal of the
solvent again, the residue was vacuum dessicated for 10 min.
n-Butyloxime formation
3-5 drops of 5 mg ml-1 O-butylhydroxylamine hydroxylchloride in
dry pyridine were added to all tubes, the tubes stoppered and left
at room temperature overnight. The following morning the samples
were heated for 15 min at 60°C to complete the reaction. The
pyridine was evaporated off under a jet of air and the sample vacuum
desiccated for 15 min.
Trimethylsilyl ether formation
10-30yl bis(trimethylsilyl)-trifluoroacetamide (BSTFA) were
added to each tube, the tubes stoppered and heated for 15 min at 60°C.
Samples were injected in the BSTFA into the gas chromatograph.
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Results
Fig. 15 and Fig. 16 show typical chromatograms obtained by
selected ion monitoring of authentic prostaglandin standards follow¬
ing derivatization and using the 503 column bleed ion fragment as
the "lock" peak. The carbon values of the various standards used
are shown in Table 13.
Compound Derivative Ion Monitored Carbon value Cv
PGF2ct Me,TMS 423 23.8
PGFla Me,TMS 425 24.4
d^-6-keto-PGFicx Me,BuO,TMS 495 26,4
6-keto-PGFia II 508 26.4
PGEi 1st isomer II 510 25.95
PGEi 2nd isomer II 510 26.25
PGE2 1st isomer II 508 25.52
PGE2 2nd isomer II 508 26,1
PGD2 1st isomer II 510 25.1
PGD2 2nd isomer II 510 25.8
Table 13, Carbon values for the methyl trimethylsilyl ether (Me,TMS)
and methyl, trimethylsilyl butoxime (Me,BuO,TMS)
derivatives of prostaglandin standards
Conclusion
The derivatization procedure and conditions of operation of the
g,c. - m.s. used gave a good separation of the different prostaglan-
«
dins in the gas chromatograph. Therefore, the detection in a sample
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prostaglandin provides further evidence for the presence of that
prostaglandin in the sample. The lower limit of sensitivity of
this system for the prostaglandin standards was approximately 20 ng.
Ideally, for absolute identification of a prostaglandin in an
extracted sample, a full mass spectrum should be taken and com¬
pared with the mass spectrum produced by the authentic compound.
However, this requires the presence of about 300 ng of the extracted
prostaglandin, especially when injected into the g.c. as an extract
rather than the pure compound. Consequently, it was not always
possible to obtain a full mass spectrum of the extracted prostaglan¬
din in all instances.
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SECTION 2. CONCENTRATIONS OF PGF?g AND PGE IN THE UTERINE VENOUS
PLASMA OF PSEUDOPREGNANT AND PREGNANT RABBITS
Section 2.1 Pseudopregnancy
Introduction
In certain sub-primate, mammalian species, removal of the uterus
prolongs the functional life span of the corpus luteum of the oestrous
cycle or of pseudopregnancy (Anderson, Bland and Melampy, 1969). In
the cycling sheep and guinea-pig there is strong evidence to suggest
that PGF2a acts as a uterine luteolytic hormone as discussed in the
general introduction. In both species hysterectomy prolongs luteal
function (Wiltbank and Casida 1956, Loeb, 1923) while the administra¬
tion of exogenous PGF2a induces luteolysis (Blatchley and Donovan,
1969; McCracken et at., 1970). Furthermore, the concentration of
PGF2a in the uterine venous plasma increases immediately prior to the
onset of luteal regression at the end of the oestrous cycle (Blatchley,
et at., 1972; Earthy et at., 1975; Bland, Horton and Poyser, 1971;
Thorburn et at. , 1972). Experiments designed to negate the luteolytic
effect of the uterus, either by inhibiting prostaglandin synthesis
with indomethacin (Lewis and Warren, 1975; Marley 1973; Horton and
Poyser, 1973) or, more specifically, by immunisation against PGF2a
(Horton and Poyser 1974, Scaramuzzi et at., 1974) result in a
lengthening of the oestrous cycle.
Unlike the sheep and guinea-pig, the rabbit is a reflex
ovulator and does not have an ovarian cycle. Under normal conditions
mating results in pregnancy5 however, if the mating is infertile the
rabbit enters into a state of pseudopregnancy which lasts for between
16 to 18 days, approximately half the length of the normal gestation
period. Chu et at. (1944) have shown that when hysterectomy is
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performed between Days 11 to 14 of pseudopregnancy the life span of
the corpora lutea is extended by some 11 to 18 days, and that this
effect is abolished by the presence of endometrial implants. PGF2a
is luteolytic in rabbits when administered either subcutaneously or
intravenously on 4 consecutive days of pseudopregnancy (Gutknecht,
Duncan and Wyngarden 1970). Following treatment with indometh cin
(8 mg kg--1 every 12 hr) from Day 12 of pseudopregnancy, the peripheral
plasma progesterone levels are significantly higher than those
observed in untreated rabbits from this time onwards and do not
return to basal levels until Day 26, approximately 10 days later than
in normal pseudopregnancy (O1Grady et al. , 1972). It has therefore
been suggested that PGF2a may also act as a uterine luteolysin in the
pseudopregnant rabbit. The purpose of the following experiments was
to investigate this hypothesis further and to determine whether the
onset of luteolysis is immediately preceded by an increase in the
concentration of PGF2a in the uterine venous plasma.
Section 2.1a Experiment to determine whether the onset of luteolysis
in the pseudopregnant rabbit is preceded by an increase
in the concentration of PGFpr, in the uterine venous
plasma
Method
Collection of blood samples
Forty-eight, female, New Zealand white rabbits were made pseudo¬
pregnant by the intravenous (i.v.) injection of 500 IU Human
chorionic gonadotrophin (HCG) into the marginal ear vein, between
15.00 and 15.30 hr. The day of injection was designated Day 0 of
pseudopregnancy. The animals were divided into 12 groups of 4
animals per group, and each group was sacrificed on a specific day
of pseudopregnancy.
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On the selected day rabbits were anaesthetised by i.v. injection
of urethane (7 ml Kg-1 of 25% solution of ethyl carbonate in 0.9%
saline) and fully heparinised by the concomitant injection of
1500 IU Heparin Kg-1. Blood samples were collected from the
marginal ear vein, the left and right uterine veins and the aorta.
A mid line abdominal incision was made to expose the uterus, and the
uterine veins were dissected free of fat. Care was taken to avoid
undue handling of the uterus and surrounding tissues. In the rabbit
the uterine vein has several prominent branches. The vessels
draining the caudal part of one uterine horn also drain the vagina
and show a large degree of anastomosis with vessels draining the
caudal part of the second horn (Del Campo and Ginther, 1972). Blood
samples were therefore collected from branches of the uterine vein
draining the cranial end of the uterine horn in an attempt to avoid
sampling the venous effluent from the vagina and the second horn.
Once exposed, therefore, an appropriate branch of the uterine vein
was cannulated using a 2 G IV' B.D. Yale microlance needle attached
to a 3" piece of narrow bore, teflon tubing. The blood was allowed
to flow freely and was collected in a glass vial surrounded by crushed
ice. In certain instances following cannulation, no blood flowed
through the cannula, possibly because the tip of the needle became
blocked during entry through the vessel wall or because the resis¬
tance to flow offered by the cannula was too great. Under these
circumstances the cannula was flushed with warm saline, but if this
failed to induce blood flow the cannula was withdrawn and the vein
recannulated. 20 ml blood was collected from the uterine vein on
each side. The ear vein sample (20m!)was collected by incising
the marginal ear vein with a scalpel and collecting the venous
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effluent, while the aortic sample (20 ml) was obtained by cannulation
of the aorta. In both instances the blood was collected in glass
vials surrounded by crushed ice. The animal was then killed by
exsanguination.
Blood samples were stored in crushed ice until the last sample
had been collected. They were then centrifuged at 4°C for 20 min
at 1300 x g on a MSE Coolspin centrifuge. The plasma was trans¬
ferred to universal bottles by means of a pasteur pipette and stored
at -20°C until extraction. Plasma samples were extracted within
1 week of collection.
All rabbits had their ovaries checked for the presence of
corpora lutea and if these were not present in both ovaries the
results from that animal were discarded and the animal replaced.
Extraction of blood samples
Prior to assay by RIA plasma samples underwent solvent extrac¬
tion followed by silicic acid column chromatography as described in
sections 1.3a and 1.3b. Following chromatography, fraction 3 (PGE)
and fraction 5 (PGF) were taken to dryness at 45°C on a rotary
evaporator, and drying was completed in a vacuum dessicator. The
residue in each fraction was redissolved in 10 ml ethyl acetate and
stored at -20°C until assayed for PGE and PGF , as described in
a
Sections 1.4a and 1.4b respectively (see Fig. 4 and Fig. 7). 1 ml
of ear vein plasma from each animal was extracted and assayed for
progesterone as described in sections 1.3d and 1.4d. All deter¬
minations were performed in triplicate at two dilutions.
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Identification of extracted plasma prostaglandins by g.c, - m.s.
Fractions 3 of the extracted ear vein plasma samples collected
throughout pseudopregnancy were pooled and taken to dryness on a
rotary evaporator. The residue was redissolved in 0.5 ml methanol
and transferred to an Eppendorf vial. The flask was washed with a
further 0.5 ml methanol and the wash added to the Eppendorf vial.
The methanol was blown off at 45°C under a jet of air. 500 ng
d^-6-keto-PGFia, in methanol, was added to each vial, the methanol
blown off and the sample derivatized as described in section 1.5a to
form the methyl ester, n-butyloxime, trimethylsilyl ether (Me,BuO,TMS
derivative). Similarly the following samples were pooled and
derivatized.
1) Fraction 3 extracted uterine vein plasma (left and right sides)
2) Fraction 5 extracted uterine vein plasma (left and right sides)
3) Fraction 3 extracted aortic plasma
4) Fraction 5 extracted aortic plasma
5) Fraction 5 extracted ear vein plasma
Trimethylsilyl ether formation was performed using 30yl BSTFA and
samples were injected into the g.c, in volumes of 5yl. The m.s,
was set up for MID as described in section 1.5a, using the 503 ion
fragment from the column bleed as the lock ion. Samples were
monitored for PGF2a (m/e 423), PGFia (m/e 425) , 6-keto-PGFia
(m/e 491), PGE2 (m/e 508), PGEX (m/e 510), PGDX (m/e 510).
Results
The concentrations of progesterone in the peripheral venous
plasma increased up to Day 7, remained elevated until Day 14, and
then declined steadily to reach pre-injection levels by Day 19
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peripheral venous plasmas showed little variation, remaining below
0.5 ng ml-1 throughout most of pseudopregnancy (Fig. 17). The con¬
centration of PGFa in the uterine venous plasma was higher than that
observed in either the aortic or peripheral venous plasma but re¬
mained low, approximately 0.75 ng ml--1- until Day 17 when it rose
significantly (p < 0.05) to a concentration of 4.51 ± 1.55 ng ml-1.
The concentration of PGFa on Day 18 of pseudopregnancy (2.34 ± 0.73
ng/ml) was significantly higher (p < 0.05) than on Day 16 but sig¬
nificantly lower (p < 0.05) than on Day 17. The mean concentration
of PGFa had returned to 'basal' levels by Day 19.
The concentrations of PGE in plasma from the ear vein, uterine
vein and aorta, remained low throughout pseudopregnancy and showed
no significant differences from each other although the mean con¬
centration of PGE in the uterine venous plasma tended to be higher
(Fig. 18). Analysis of the derivatized plasma samples by g.c. - m.s.
was inconclusive. The amounts of PGE and PGFa in the pooled, extrac¬
ted plasma samples of the marginal ear vein, the left and right
uterine veins and the aorta were found to be too low to be detected
against the background of impurities even when MID was used.
Conclusion
The concentration of progesterone in the peripheral venous
plasma had significantly decreased by Day 17, the time at which PGF^
levels in the uterine venous plasma increased. PGF released onr a
Day 17, therefore, may accelerate the decrease in progesterone pro¬
duction and so contribute to the final demise of luteal function at
this time. The low amounts of PGF2a present in the pooled uterine
venous plasma samples prevented the unequivocal identification of















Section 2.1b Experiment to determine the effect of hysterectomy
on the maintenance of the corpus luteum in pseudo-
pregnant rabbits
Introduction
If the decline of progesterone in the peripheral venous plasma
from Day 14 is independent of the release of PGFa from the uterus
then the removal of the uterus should not prevent the decline in
plasma progesterone observed at this time. However, if the release
of PGFa on Days 17 and 18 of pseudopregnancy contributes to the
cessation of luteal function then removal of the uterus should pro¬
long pseudopregnancy. The effect of hysterectomy on peripheral
plasma progesterone concentrations in pseudopregnant rabbits was
therefore examined.
Method
Eight New Zealand white, female, rabbits were divided into two
groups of four animals per group. Animals in Group 1 were used
intact while animals in Group 2 were hysterectomised prior to use.
Hysterectomy was performed under Nembutal anaesthesia (35 mg Kg-1).
Following the opening of the abdominal wall by a mid-line, abdominal
incision ligatures were placed round the oviducts, proximal to the
utero-oviductal junction, round the vagina, immediately below the
cervix and round the major blood vessels. The uterus was then
removed, the abdominal wall closed with cat gut sutures and the
skin with silk sutures. Animals were allowed to recover for 4 weeks
before use. Rabbits in both groups were made pseudopregnant by the
i.v, administration of HCG as previously described in section 2.1a.
Blood samples were collected from alternate ears, every second day
throughout pseudopregnancy. All animals underwent 2 pseudo-
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pregnancies. The ear was shaved and the blood vessels made to
dilate by the application of a small amount of xylene to the dorsal
surface. The marginal ear vein was incised with a scalpel and the
blood (2 ml) collected in a heparinized glass tube (10 IU Heparin
ml blood) . Immediately after collection blood samples were cen-
trifuged for 15 min at 4°C and 1300 x g in a MSE Coolspin centrifuge.
The plasma was transferred to universal bottles by pasteur pipette
and stored at -20°C until assayed for progesterone as described in
sections 1.3d and 1.4d. Determinations were performed in triplicate
at two dilutions.
Comparisons of the concentration of progesterone on different
days of pseudopregnancy in intact (Group 1) and hysterectomised
(Group 2) animals were made using the two tailed Students' 't' test.
Results
Fig, 19 shows the peripheral plasma profile throughout pseudo-
pregnancy in intact and hysterectomised pseudopregnant rabbits.
Results are expressed as the mean ± standard error of the mean of
four pseudopregnancies. In the intact animals the concentrations of
progesterone in the peripheral venous plasma increased steadily until
Day 8, remained elevated until Day 13 and then began to decline
steadily. By Day 20 they were no longer significantly (p > 0.05)
elevated above pre-injection levels. In fact there were no sig¬
nificant differences between the concentrations of progesterone on
Days 17, 18, 19 and 20, The mean plasma progesterone level observed
on Day 16 was significantly higher than on the following day
(p < 0,05). A similar, but not identical, profile was -observed in
hysterectomised animals. Plasma concentrations again increased
steadily until Day 8 and declined from Day 13 but the concentrations
119
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of progesterone observed in the hysterectomised animals were consis¬
tently higher than those observed in intact animals from Day 14
onwards. However, this difference was not statistically significant
until Day 17, 18 and 19 of pseudopregnancy (p < 0.05), the time at
which, as found in the previous experiment, PGFa release from the
uterus is increased. The sharp decline in plasma progesterone
levels on Day 17 in the intact animal is not observed. Instead
there is a steady but gradual decline from Day 16 until Day 20 when,
although the mean concentration of progesterone is not significantly
different from that observed on Day 20 in intact animals or from
pre-injection levels, it is still above 1 ng ml-1.
Conclusions
When the concentration of progesterone in the peripheral venous
plasma is used as an index of luteal function hysterectomy does not
appear to affect the time at which luteal function begins to
decline. However, the presence of the uterus does cause a more
abrupt fall in plasma progesterone concentration, especially on
Days 17 and 18 of pseudopregnancy.
These results support the earlier contention that the increase
in PGFa observed in the uterine venous plasma at the end of pseudo¬
pregnancy is not responsible for the initiation of luteolysis but





As already described in the general introduction and Section 2.1
there is strong evidence that PGF2ct acts as a uterine luteolytic
hormone in the cycling sheep and guinea-pig. In both these species
the maintenance of pregnancy is dependent upon progesterone secreted
from the corpus luteum until such time as the placenta can take over
(Deanamur and Martinet 1955; Heap and Deansley 1966). In both
species this change-over occurs after the time at which the corpus
luteum in the non-pregnant animal would normally have regressed.
This implies that, in the pregnant animal, a mechanism operates to
maintain luteal function during the early part of pregnancy. This
could be achieved, a) by the production of a luteotrophin which
overrides the effect of the luteolytic hormone, b) by inhibition of
luteolysin production and/or its release into the uterine vein or
c) by a combination of a) and b). Thorburn et al., (1973) have
shown that in the pregnant sheep the concentration of PGF in the
uterine venous plasma does not increase after Days 12 to 14 while,
in pregnant guinea-pigs the concentration of PGF2a in the utero-
ovarian venous plasma on Day 15 of pregnancy is significantly lower
than in the non-pregnant animal at this time (Blatchley et al.,
1975a). These observations suggest that, in these species, luteal
maintenance during early pregnancy is, at least in part, attributable
to a suppression of PGF2a release into the uterine venous blood.
In the rabbit the presence of a functional corpus luteum is
required throughout pregnancy. If PGF2a acts as a uterine luteolytic
hormone in the pseudopregnant animal, then some mechanism must operate
to neutralise its action during pregnancy. Therefore, the concen-
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tration of PGF in the uterine venous blood of the rabbit during
a
pregnancy was measured. The concentrations of progesterone in the
peripheral venous plasma and the concentrations of PGE in the uterine
venous plasma, aortic and peripheral venous plasma was also measured.
Section 2.2a Experiment to measure the concentrations of PGF_^ and
PGE in ear vein, aorta and uterine vein plasmas
throughout pregnancy.
Method
Mature, female, New Zealand white rabbits, all of which had
undergone at least one successful pregnancy prior to this experiment
were made pregnant by mating to buck rabbits of proven fertility.
The day of mating was designated Day 0 of pregnancy. Animals were
anaesthetised on selected days throughout pregnancy and blood samples
collected from the marginal ear vein, the left and right uterine veins
and the aorta as previously described in Section 2.1a. The blood
was centifuged and the plasma extracted and assayed for PGF^ and PGE
content as previously described (Section 2.1a). 1 ml of ear vein
plasma was extracted and assayed for progesterone as described in
sections 1.3d and 1.4d. Rabbits used on Days 6, 7 and 8 of pregnancy
had their ovaries checked for the presence of corpora lutea while in
animals used after Day 8, the number and state of the foetuses in
each uterine horn was noted. Results from rabbits in which the
corpora lutea were absent or in which no foetuses were present were
discarded and, whenever possible, the animals replaced.
Identification of extracted prostaglandins by g.c. - m.s.
4
Fractions 3 and fractions 5 from extracted plasma obtained from
the ear vein, the aorta and the left and right uterine veins were
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pooled and derivatised as described in Section 2.1a. Samples were
injected into the gas chromatograph in volumes of 5yl. The mass
spectrometer was run in the MID mode of operation but full mass
spectra were obtained when sufficient material was shown to be
present.
Results
Figure 20 shows the concentration of progesterone in the peri¬
pheral venous plasma throughout pregnancy. The results are expressed
as the mean ± SEM of four animals unless otherwise stated (numbers in
parenthesis over relevant column). There is one value per day from
each animal for ear vein and aorta, and two values per day from each
rabbit for the uterine vein (i.e. left and right sides). The con¬
centration of progesterone reached high values by Day 8, as observed
in the pseudopregnant animal and peaked by Day 16 to Day 17. It
fell on Day 18 to a lower level which was maintained until Day 30,
and then declined sharply on Day 31. A similar progesterone profile
has been reported by Fuchs (1978) in the ear vein plasma of pregnant
rabbits. The concentration of progesterone in the peripheral venous
plasma of one rabbit, Day 1 p.p., from which blood was collected
within 1 hr after delivery, was similar to that observed on Days 30
and 31.
The concentration of PGF in the aortic and ear vein plasma did
a
not differ significantly from the concentrations observed in similar
samples collected during pseudopregnancy. This was not true of the
concentration of PGF^ in the uterine venous plasma. The increased
concentrations of PGF^ observed on Days 17 and 18 of pseudopregnancy
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concentrations remained low, approximately 1 ng ml-1, until Day 24
when they rose significantly (p < 0,05), They reached peak values
on Day 25 and, although still elevated on Day 26, had returned to
'basal' levels by Day 27. The concentration of PGF on Day 25
a
(4.97 ± 0.22) was significantly higher (p < 0.05) than that observed
on Days 24 and 26 of pregnancy. Uterine venous PGF^ levels increased
again on Day 31 (2.30 ± 1.01) but this increase was not significant.
The concentrations of PGE in aortic and peripheral venous plasma
(Fig. 21) did not differ significantly from those observed during
pseudopregnancy (Fig. 18). The concentrations of PGE in the uterine
venous plasma on Days 6, 7 and 8, were similar to those observed in
the pseudopregnant animal at this stage. From Day 11 onwards,
however, the concentration of PGE in the uterine venous plasma rose
significantly. There was a wide variation among PGE levels in
animals of the same gestational age and even in the same animal between
the left and right uterine veins. Due to the wide scatter, it was
not considered valid to present the results as the mean ± SEM.
Therefore, each point in Fig. 21 (a) represents an individual measure¬
ment from either the left or right uterine vein of each rabbit.
Analysis of the number of foetuses per uterine horn and the concen-
tration of PGE in the uterine vein draining that horn using the x
test, shows that there is a positive correlation (p < 0.05) between
these two parameters. In the single post partum rabbit studied
( 1 p.p.) the concentration of PGE in the left and right uterine
venous plasma was not significantly different from that observed on
Days 6, 7 and 8 of pregnancy and throughout pseudopregnancy.
The amounts of PGE (fraction 3) and PGF (fraction 5) in the
a
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and aorta were found to be too low to be detected by MID in the
g.c. - m.s. The presence of PGE2, but not PGE^, in the extracted
uterine venous plasma was confirmed both by MID (Fig. 22) and by a
full mass spectrum taken at the relevant retention time. In
fraction 5 of the pooled uterine venous plasma extracts a m/e peak,
corresponding to the 423 ion of PGF2a, was observed at the correct
retention time for this compound. Similarly a m/e peak, correspon¬
ding to the 491 ion of 6-keto-PGFia, was also observed. In the
silicic acid column chromatography system described in Section 1.3b,
6-keto-PGF2a elutes in both fraction .3 and fraction 5. However,
no peak corresponding to 6-keto-PGFia was found in the pooled
fraction 3 of the uterine venous extracts from pregnant rabbits.
The low amounts of PGF2a present precluded a full mass spectra of
this compound from being obtained.
The pooled extracts of fraction 3 and fraction 5 showed no con¬
tamination by PGF^ and pGE respectively.
Conclusion
In the pregnant rabbit, the increase in PGF^ observed on Days
17 and 18 of pseudopregnancy is absent. This finding supports the
idea that the increase in PGF^ observed at the end of pseudopregnancy
contributes to luteal demise and that its absence in the pregnant
animal may aid in luteal maintenance. The significance of the
increase in the uterine venous plasma concentration of PGF2a on Days
24 to 26 of pregnancy is not known. However, it did not lead to a
fall in the peripheral plasma concentration of progesterone at this
time.
The high concentrations of PGE observed in the uterine venous




with those observed in the pseudopregnant animal. This finding,
together with the positive correlation between the number of foetuses
per uterine horn and the concentration of PGE in the uterine vein
draining that horn suggest that the rabbit foetal-placental unit may
be synthesising and releasing large amounts of PGE. ; This is further
supported by the observation that, in the post partum rabbit, the
concentration of PGE in the uterine venous plasma is similar to that
observed in the uterine venous plasma on Days 6, 7 and 8 of pregnancy,
prior to the formation of the foetal-placental unit. Also, the con¬
centration of PGE in the uterine venous plasma did not increase until
after implantation had occurred and the placenta had become estab¬
lished. The decline in peripheral plasma progesterone concentration
on Day 31 of pregnancy occurred independently of any significant
increase of PGF^ in the uterine venous plasma at this time, although
PGF^ levels did tend to be higher on Day 31. In two animals studied,
one on Day 31 and one on Day 32 of pregnancy, the cervix was dilated
and a foetus had already begun to move down into the vagina at the
time the blood samples were collected. In both animals the peri¬
pheral plasma progesterone was approximately 4 ng ml-1. The con¬
centrations of PGF in the uterine venous plasma from both the left
a
and right uterine veins were higher (2.75 and 4.92 ng ml-1 respec¬
tively on Day 31 and 1.67 and 1.21 ng ml-1 respectively on Day 32)
than those observed in Day 31 (0.31 and 1.19 ng ml-1 respectively)
and in Day 32 (.35 and .41 ng ml-1 respectively) rabbits in which
labour had not yet started. This finding suggests that there may
be an increase in PGF^ output by the uterus at the time of delivery.
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SECTION 3. MEASUREMENT OF THE ENDOGENOUS CONCENTRATIONS AND THE
ABILITY OF UTERINE TISSUE TO SYNTHESISE PGF , PGE AND
a
6-KETO-PGF1a, IN VITRO, ON SELECTED DAYS OF PSEUDO-
PREGNANCY AND DAY 17 OF PREGNANCY
Section 3.1a Experiment to determine the effect of homogenisation
on uterine tissue production of PGF^, an<3
6-keto-PGF]n
Introduction
In this section the synthetic capacity of rabbit uterine tissue
to synthesise prostaglandins at different stages of pseudopregnancy
and pregnancy has been investigated using incubates of uterine tissue
homogenates. As mechanical stimulation of many tissues is known to
cause prostaglandin synthesis and release, the following preliminary
experiment was performed to determine the effect of the process of
homogenisation on uterine tissue prostaglandin production.
Method
Three female, New Zealand white rabbits were killed by stunning
and incising the neck. The uteri were removed, and one horn from
each animal was divided into three segments and each segment weighed.
Segment 1 was used to determine the 'endogenous' prostaglandin con¬
tent of the uterine tissue. It was homogenised in 5 ml ethanol
using a Fisons glass homogeniser and the homogenate was poured into
a lOO ml round bottom flask. The homogeniser was washed with two
further 5 ml portions of ethanol and the washings added to the homo¬
genate, which was then allowed to stand for 90 min, with occasional
shaking. At the end of this period the ethanol was evaporated off
under reduced pressure at 45°C on a rotary evaporator. The residue
was resuspended in 15 ml Krebs' solution and extracted as described
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in Section 1.2a. Segments 2 and 3 of the uterine horn were homo¬
genised separately in 15 ml Krebs' solution as described in Section
1.2b. Following homogenisation, segment 2 was immediately solvent-
extracted, using the method described in Section 1.2a, while segment
3 was incubated for 90 min at 37°C, as described in Section 1.2b and
then solvent-extracted. All samples were assayed for PGFa» PGE and
6-keto-PGFlct by RIA.
Results
The concentrations of PGF , PGE and 6-keto-PGFn„ in uterine
a 1U
tissue samples of ethanolic homogenates (endogenous concentration)
and of Krebs' solution homogenates, pre- and post-incubation, are























Table 14. Amount of PGF^, PGE and 6-keto-PGFia in uterine tissue
samples following homogenisation in ethanol and in Krebs'
solution and following incubation of the Krebs' solution
homogenates (mean ± SEM, n = 3)
Comparisons of the amounts of PGFa» PGE an<3 6-keto-PGF^a in
ethanolic homogenates and Krebs' solution homogenates, £>re- and post-
incubation, were made using Students' 't" test for paired data.
There was no significant difference between the concentrations of PGE
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and 6-keto-PGFlct in ethanolic homogenates and pre-incubation, Krebs'
solution homogenates. The increase in the concentration of PGF^
following homogenisation in Krebs' solution, however, was signifi¬
cant (p < 0.05). Following incubation of Krebs' solution homo¬
genates the concentrations of PGF^, PGE and 6-keto-PGFpx were signi¬
ficantly higher than those observed in pre-incubation, Krebs' solu¬
tion homogenates, or ethanolic homogenates.
Conclusion
Although PGF^ concentrations increased significantly following
the homogenisation of uterine tissue in Krebs' solution the increase
was low when compared to the increase observed after these homo¬
genates had been incubated for 90 min. The process of homogenisa¬
tion did not appear to stimulate PGE and 6-keto-PGFja synthesis to
any significant extent. It was, therefore, considered that the
difference between endogenous PGF^, PGE and 6-keto-PGFpx concentra¬
tions and the concentrations of PGF , PGE and 6-keto-PGFia following
a
incubation, reflected the synthetic capacity of the uterine tissue
for each of these prostaglandins and was not attributable to the
effects of mechanical stimulation alone.
Section 3.1b Experiment to investigate the ability of the rabbit
uterus to synthesise PGF_^, PGE and 6-keto-PGF±a on
selected days of pseudopregnancy
Introduction
In the cycling sheep, guinea-pig and cow the endogenous concen¬
tration of PGF2a in the endometrium is higher at the end of the cycle,
«
when luteal regression occurs, than earlier in the cycle (Wilson et at.,
1972; Poyser, 1972; Shemesh and Hansel, 1975). Moreover in the
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guinea-pig and sheep the ability of the uterus to synthesise prosta¬
glandins, "in vitvo, is also increased at this time (Poyser 1972;
Wlodawar et aZ., 1976; Alwachi et aZ., 1979). In the guinea-pig
this increase appears to be related to a genuine increase in the
synthetic capacity of the uterus, as opposed to reflecting a decrease
in metabolism or an increase in the availability of substrate
(Mitchell, Poyser and Wilson, 1977; Maule Walker and Poyser, 1978),
and is probably responsible for the increased levels of PGF£a observed
in the uterine vein at this time.
In the following experiment, therefore, the endogenous prosta¬
glandin content and the synthetic capacity of uterine tissue homo-
genates on selected days of pseudopregnancy has been measured. The
effect of the addition of excess arachidonic acid to the incubation
medium has also been studied.
Method
Twenty, mature, New Zealand white female rabbits, of proven
fertility, were divided into five groups of four animals per group.
Animals in the first group acted as controls, and received 0.5 ml
saline into the marginal ear vein, while animals in the remaining
four groups were made pseudopregnant by the intravenous injection of
500 IU of HCG in 0.5 ml saline into the marginal ear vein between
15.OO to 15.30 hr. The day of injection was designated as Day 0
of pseudopregnancy. On the day of sacrifice 2 ml of blood was
collected from the marginal vein as previously described in section
2.1b. The blood was centrifuged and the plasma solvent extracted
and assayed for progesterone as described in Section 1.4d. Animals
were killed by stunning and incising the neck. Control animals
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were sacrificed the day after injection and animals in the remaining
four groups were sacrificed on Days 4, 7, 11 and 17 of pseudopregnancy.
The uterus was exposed by making a mid-line, abdominal incision. The
two uterine horns were severed on the uterine sides of the utero-
oviductal junction and cervix, and transferred to a beaker of ice
cold Krebs' solution. Each uterine horn was opened longitudinally
and cut into segments each of approximately lg, wet weight. Three
segments were then blotted dry and weighed and cut into small pieces
with a pair of scissors. The remaining tissue was left on ice
cooled Krebs' solution and retained for further incubation studies
and metabolism studies (see Section 5).
Segment 1 was used to determine the endogenous prostaglandin
content of the uterine tissue as described in Section 3.1a. Segment
2 was used to measure the ability of homogenised, uterine tissue to
synthesise prostaglandins in vitvo, and was homogenised in 15 ml
Krebs' solution and incubated for 90 min as described in Section
1.2b. The third segment was used to determine the effect of the
presence of excess arachidonic acid on prostaglandin production by
the uterus and was treated as segment 2, except that 75yg arachidonic
acid was added to the homogenate (final concentration 5-Oyg ml--1)
immediately prior to incubation. Following incubation both segments
were extracted as described in Section 1.2a. All samples were
assayed for PGF^, PGE and 6-keto-PGFja content by RIA, as previously
described (Sections 1.4a, b and c). Results were compared using
Students' 't' test for unpaired data unless otherwise stated.
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Identification of extracted prostaglandins by g.c. - m.s.
Following the measurement of PGFa/ PGE ant^ 6-keto-PGFja by RIA
the extracts from ethanolic homogenates of the 4 control animals
were pooled and taken to dryness on a rotary evaporator. The
residue was redissolved in 1 ml methanol, transferred to an Eppendorf
vial and derivatised to form the Me,BuO,TMS derivative as described
in Section 2.1a. The extracts from the uterine incubates of the
control animals were also pooled and derivatised as were the extracts
from uterine homogenates, incubated with excess arachidonic acid.
Extracts from ethanolic homogenates, and homogenates incubated in the
absence and presence of arachidonic acid from Days 4, 7 and 11 of
pseudopregnancy were similarly pooled and derivatised to form the
Me,BuO,TMS derivatives. Trimethylsilyl ether formation was per¬
formed using 30yl BSTFA and samples were injected into the gas
chromatograph in volumes of 2 or 3pl. The mass spectrometer was
set up for MID using the m/e 503 ion from the column bleed as the
lock ion as previously described (Section 1.5a). Samples were
monitored for PGF2a (m/e 423), PGF(m/e 425), 6-keto-PGFja (m/e
508) , dit-6-keto-PGFia (m/e 495) , PGE2 (m/e 508) , PGE^ (m/e 510) and
PGD2 (m/e 510). Because of the high cross reactivity of the anti-
sera used in the PGE RIA with PGB2, samples were also monitored for
the presence of PGB2. The mass spectrometer was again set up for
MID as previously described (Section 5.1a) but using the m/e 281
fragment of the column bleed as the lock ion. PGB2 was monitored
using the m/e 321 and m/e 349 ions. When the m/e 508 and m/e 5lO
ions were used to monitor for the presence of PGE2, PGD2 and 6-keto-
«
PGF^a in samples it became difficult to monitor PGE2 as the first






time as the second isomer of the. MefB.uQ,TMS derivative of PGD2/ and
the second isomer of the Me,BuO,TMS derivative of PGE2 had the same
retention time as the first isomer of the Me,BuO,TMS derivative of
6-keto-PGFia (Fig. 23). The presence of PGE2 was, therefore,
verified by monitoring the m/e 295 ion, which is not present in
either the Me,BuO,TMS derivative of PGD2 or in the Me,BuO,TMS deriva¬
tive of 6-keto-PGFia, at the same time as monitoring for PGB2 (Fig.
24) .
Results
The concentration of progesterone in the peripheral venous
plasma on different days of pseudopregnancy is shown in Table 15.
Progesterone increased until Day 11 of pseudopregnancy but had
returned to pre-injection levels by Day 17.
Day of Pseudopregnancy Concentration of Progesterone
ng ml-1 of plasma
Control .553 ± .039
4 10.60 ± 0.50
7 27.03 ± 3.29
11 38.21 ± 2.57
17 0.793 ± 0.053
Table 15. Concentration of progesterone in peripheral venous plasma
(ear vein) on selected days of pseudopregnancy (mean ± SEM,
n = 4)
The analysis of samples incubated in the absence or presence of
arachidonic acid by g.c. - m.s. using MID showed that each sample
«
contained PGF2a* PGE2, PGD2 and 6-keto-PGFja. N° PGB2 or PGFja
was detectable. Fig. 25 shows a typical trace obtained when recor-
in
* Voltage gain
I=PGF2a, II=PGD2, m= 6-keto-PGFla
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ding the m/e ion at 423, 491, 495, 508 and 510, The peaks shown
confirm the presence of PGF2a (I), PGD2 (XI) and 6-keto-PGFia (III).
For reasons stated in the introduction the presence of PGD2 and
6-keto-PGF^a masked the presence of PGE2. Fig. 24 shows the mass
fragmentation of authentic PGE2 monitored by the ion at m/e 295, and
also of authentic PGB2 by monitoring of the ions at m/e 321 and m/e
349. By subjecting the samples to this further analysis, the
presence of PGE2 was confirmed but PGB2 was not detected. Since no
PGFja or PGB2 could be detected it is probable that the RIA's for
PGE and PGF^ were measuring PGE^and PGF2a respectively. Results
from these studies will henceforward be described in terms of PGF2a,
PGE2 and 6-keto-PGFlct.
The endogenous concentration of PGF2a in uterine tissues was
higher on Day 17 of pseudopregnancy than on any other day studied
(p < 0.05) (Fig. 26). The endogenous levels of PGE2 (Fig. 27) and
6-keto-PGF2a (Fig. 28) were also significantly higher (p < 0.05) on
Day 17 of pseudopregnancy than on Days 4, 7 and 11 of pseudopregnancy,
but did not differ significantly from those observed in control
animals, although they did tend to be higher.
Following homogenisation and incubation in Krebs' solution there
was a significant increase in the prostaglandin concentration in all
uterine tissue homogenates when compared to uterine tissue homogenised
in ethanol. The amounts of PGE2 and PGF2a produced on Days 4, 7,
11 and 17 of pseudopregnancy, showed no significant differences but
all were significantly higher than the amounts of PGE2 and PGF2a pro¬
duced during incubation of uterine tissue homogenates from control
<
animals. The mean concentration of PGF2ct observed on Day 17 of
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pregnancy but this is probably due to the high endogenous concentra¬
tion of PGF2a observed in uterine tissue at this time. The major
prostaglandin produced during incubation was 6-keto-PGFia. The
amount of 6-keto-PGF^a produced during incubation of uterine homo-
pseudopregnant
genates from \ animals tended to increase up to Day 7 and then
decline until Day 17 but the only significant difference was between
control and Day 4 values (p < 0.05). The addition of 5yg ml-1 ara-
chidonic acid to the incubation medium tended to increase the amounts
of PGF2ct, PGE2 and 6-keto-PGFpj formed during incubation on all days
studied, but these increases were only significant (p < 0.05) in
control animals and also for PGF2tx on Day 4 of pseudopregnancy. In
control animals the addition of arachidonic acid to uterine tissue
homogenates increased the amounts of PGF2a and PGE2 formed during
incubation to the amounts produced by uterine tissue homogenates
from pseudopregnant animals when incubated in the absence of added
arachidonic acid. There was no significant difference between the
amounts of 6-keto-PGFia formed by uterine tissue from control animals
and the amount produced by uterine tissue from pseudopregnant rabbits
when incubated in the presence of excess arachidonic acid. The mean
amount of 6-keto-PGF^a produced by uterine tissue incubated in the
presence of 5yg ml-1 arachidonic acid on Day 7 of pseudopregnancy was
greater than on any other day studied but, because of the wide varia¬
tion between individual animals, this difference was not significant:.
Conclusion
The presence of PGF2a, PGE2, PGD2 and 6-keto-PGFia in uterine
tissue homogenates incubated in the absence or presence'of excess
arachidonic acid was confirmed by g.c. - m.s. using MID.
The endogenous concentration of PGF2a in the rabbit uterus was
significantly higher on Day 17 of pseudopregnancy than on any other
day studied. The endogenous concentrations of PGE2 and 6-keto-PGFja
were also significantly higher on Day 17 than on any other day of
pseudopregnancy but did not differ significantly from the endogenous
concentrations of PGE2 and 6-keto-PGFia observed in uterine tissue
of control animals. On each day studied the major prostaglandin
formed during incubation was 6-keto-PGFja. The ability of the
uterine tissue to synthesise PGF2a, PGE2 and 6-keto-PGFja did not
appear to change significantly throughout pseudopregnancy although
uterine tissue from pseudopregnant rabbits produced significantly
more PGF2ct, and PGE2 than uterine tissue from control animals. This
difference could be due to a lack in the availability of precursors
as the addition of excess arachidonic acid to the incubation medium
increases the amount of PGE2 and PGF2a formed, to that produced by
uterine incubates from pseudopregnant animals. Incubates of rabbit
uterus were also found to synthesise PGD2 but this was not realised
until after samples had been analysed by g.c. - m.s. using MID. The
significance of this observation is not known, however it would be
interesting to measure the amounts of PGD2 produced by the rabbit
uterus. Since g.c. - m.s. data of uterine tissue homogenates and
uterine-venous plasma (Section 2.2a) show that only PGF2a and PGE2
are present, the amounts of PGF and PGE measured by RIA will be
■ a
expressed as PGF2a and PGE2 hereafter.
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Section 3. 2a —' PGE ar"^ 6-keto-PGF j a production by the Day 17
pregnant rabbit uterus.
Introduction
In both the pregnant sheep and guinea-pig, the increase in
PGF2a concentration in the uterine venous plasma around Day 15 of the
oestrous cycle is not observed on Day 15 of pregnancy (Thorburn et at.,
1973; Blatchley et at., 1975a). In the previous section, it was
similarly found that the increase in the uterine venous plasma con¬
centration of PGF2d in the pseudopregnant rabbit on Day 17 is absent
on Day 17 in the pregnant animal.
Maule Walker and Poyser (1974) have shown that the Day 15 preg¬
nant, guinea-pig uterus synthesises significantly less PGF2a than
uterine tissue on Day 15 of the oestrous cycle. This decrease in
PGF2a production was not due to increased metabolism, lack of sub¬
strate or the redirection of synthesis towards PGE (Maule Walker and
Poyser, 1978). The authors, therefore, suggest that the lower level
of PGF2a production by the pregnant uterus may account for the reduced
output of PGF2a observed at this time and thereby result in the
maintenance of the corpora lutea beyond Day 15 in the pregnant
animal. In the following experiment, therefore, the amounts of
PGF2a/ as well as PGE2 and 6-keto-PGFia, present in, and produced by,
uterine tissue on Day 17 of pregnancy, have been measured.
Method
Four, female, New Zealand white rabbits of proven fertility were
mated with a fertile, buck rabbit. The day of mating was designated
Day O of pregnancy. On Day 17 of pregnancy, 2 ml blood were collec¬
ted from the marginal ear vein of each rabbit as previously described
(Section 2.1b). The blood was centrifuged, and the plasma was
14 7
solvent-extracted and assayed for progesterone as previously described
in Sections 1.3d and 1.4d. Each animal was then killed by stunning
and incising the neck. The uterus was exposed and extirpated as
described in Section 3.1b. The number and state of the foetuses in
each horn was noted. The uterus was opened longitudinally and freed
of any placental and embryonic tissue. These tissues were placed in
ice-cold, Krebs' solution and retained (Sections 4,1a, 4.1b and 5). The
uterine tissue appeared to consist of two 'types'; tissue which had
surrounded a developing foetus, which had a.'stretched' appearance
and an apparently thin layer of endometrium, and tissue from between
developing foetuses, which appeared 'unstretched' and had a thick,
spongey, endometrium. The uterine tissue was, therefore, divided
into 'stretched' and 'unstretched' tissue. Each type of tissue was
further divided into segments of approximately lg, wet weight. Each
segment was blotted dry and weighed. One segment from each tissue
type was used a) to determine the endogenous prostaglandin content
of the tissue, b) the, in vitvo, synthetic ability of the uterine
tissue to produce prostaglandins and c) the effect of the presence
of excess arachidonic acid on the synthetic capacity of the tissue,
as previously described in Section 3.1b. Any remaining uterine
tissue was replaced in ice-cold, Krebs' solution and retained
(Sections 4.1b and 5). Following extraction, samples were
assayed by RIA for PGF^, PGE^and 6-keto-PGF}a as previously described
(Sections 1.4a, b and c).
Results
The average litter size was 9.3 ± 1.3 foetuses per rabbit. The
large litter size meant that the amount of 'unstretched' uterine
tissue available was limited. In three of the four rabbits studied
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it was not possible to measure the effect of excess arachidonic acid
on prostaglandin production by incubates of 'unstretched' uterine
tissue. The amounts of PGF2a, PGE2 and 6-keto-PGFia present in
alcoholic homogenates of 'unstretched' and 'stretched' uterine tissue
and in homogenised tissues, incubated in the absence and presence of
added arachidonic acid are shown in Fig. 29. Results are expressed
as the mean ± SEM of 4 animals, unless otherwise stated (number over
relevant columns).
The endogenous concentrations of PGF2a in 'unstretched' and
'stretched' uterine tissue on Day 17 of pregnancy showed no signifi¬
cant differences. Similarly, the endogenous concentrations of PGE
and 6-keto-PGFia in 'unstretched' and 'stretched' uterine tissue did
not differ significantly. The endogenous concentration of PGE2 and
6-keto-PGFia in 'unstretched' and 'stretched' Day 17 pregnant uterine
tissues were not significantly different from those in Day 17 pseudo-
pregnant, uterine tissue. However, the endogenous concentration of
PGF in both 'unstretched' and 'stretched' uterine tissue on Day 17
la
of pregnancy was significantly lower (p < 0.05) than the endogenous
concentration of PGF2a in uterine tissue on Day 17 of pseudopregnancy
(Fig. 30). Following incubation of both 'unstretched' and 'stretched'
Day 17 pregnant, uterine tissue, there was a significant increase in
the amounts of PGF2a, PGE2 and 6-keto-PGFja in each homogenate
(p < 0.05) when compared with endogenous levels. The amounts of
PGF2a formed were not significantly different and did not differ
significantly from the amount produced during incubation of Day 17
pseudopregnant, uterine tissue. There was no significant difference
between the amounts of PGE2 and 6-keto-PGFia produced by 'unstretched'



















































tissue, but both were significantly lower than the amounts of PGE2
and 6-keto-PGFja produced during incubation of 'stretched', Day 17
pregnant, uterine tissue (Fig. 30) . The addition of 5yg ml-1 ara-
chidonic acid to incubates of 'stretched' uterine tissue incubates on
Day 17 of pregnancy, increased the amounts of PGF2a and PGE2 formed
and slightly decreased the amount of 6-keto-PGFja formed. These
changes, however, were not significant (Fig. 21). The amounts of
PGF2a, PGE2 and 6-keto-PGFja formed during incubation of 'stretched',
Day 17 pregnant, and Day 17 pseudopregnant, uterine tissue in the
presence of 5yg ml-1 arachidonic acid did not differ significantly
from the amounts of PGF2ct, PGE2 and 6-keto-PGF^a formed by these
tissues when incubated in the absence of added arachidonic acid.
Conclusions
The endogenous concentration of PGF2a in both 'unstretched', and
'stretched^ uterine tissue homogenates on Day 17 of pregnancy is
significantly lower, than in uterine tissue homogenates on Day 17 of
pseudopregnancy. This lower, endogenous level of PGF2a DaY
17 pregnant, animal is unlikely to be due to a decrease in the syn¬
thetic capacity of the tissue as the amounts of PGF^ produced by both
'unstretched', and 'stretched', Day 17 pregnant, and Day 17 pseudo-
pregnant, uterine tissue are not significantly different. Instead,
it may reflect a decrease in the synthesis of PGF2a, in vivo, when
the cellular integrity of the tissue may be an important feature in
controlling prostaglandin biosynthesis. "Stretched', Day 17 pregnant,
uterine tissue synthesises significantly more PGE2 and 6-keto-PGFia
than either 'unstretched', Day 17 pregnant, or Day 17 pseudopregnant,
uterine tissue. This increase may be related to the close proximity
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foetus and may contribute to the increase in PGE2 and 6-keto-PGFla
observed in the uterine venous plasma of pregnant rabbits.
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SECTION 4. ENDOGENOUS LEVELS AND IN VITRO PRODUCTION OF PGF?a,
PGE2 AND 6-KETO-PGF^ a BY PLACENTAL TISSUE ON DAY 17 OF
PREGNANCY AND THE EFFECT OF THE PRESENCE OF PLACENTAL
TISSUE ON PROSTAGLANDIN PRODUCTION BY UTERINE TISSUE
Section 4.1a Experiment to determine the endogenous levels and
in vitvo production of PGF2a, PGE? and 6-keto-PGFja
by placental tissue on Day 17 of pregnancy.
Introduction
In the pseudopregnant rabbit the concentration of pGF^ in the
uterine venous plasma remains low until Day 17 of pseudopregnancy
when it increases significantly. It is still elevated on Day 18,
but has returned to basal levels by Day 19. The concentration of
PGE2 in the uterine venous plasma however, remains low throughout
pseudopregnancy. In the pregnant animal the increase in PGF2ct out¬
put by the uterus on Days 17 and 18 of pseudopregnancy is not ob¬
served, but there is a significant increase in the uterine venous
plasma concentration of PGE2 from Day 11 of pregnancy onwards. This
increase in the concentration of PGE2 in the uterine vein occurs at
the time when the placenta becomes established (Lutwak-Mann, 1971)
and is positively correlated with the number of foetuses present in
the uterine horn.
When extracts of uterine venous plasma from pregnant rabbits
were derivatised and analysed by g.c. - m.s. using MID, they were
found to contain an ion fragment, at the correct retention time,
which corresponded to the m/e 491 ion of 6-keto-PGF2ct. No such ion
fragment was detected in extracts of uterine venous plasma from
pseudopregnant rabbits.
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These findings suggest that the foetal-placental unit may syn-
thesise PGE2 and 6-keto-PGF. In the following experiment the
ability of placental tissue homogenates, from Day 17 pregnant rabbits,
to synthesise PGE^and 6-keto-PGFia has been measured.
Method
Placental tissue was obtained from the animals used in Section
3.2a as previously described. The placenta, consisting of the
maternal decidua and the foetal-placenta, was dissected free of the
myometrium and freed of the embryonic sac and its contents. The
placental tissue from each animal was divided into segments of
approximately Ig weight. Each segment was blotted dry and weighed.
The endogenous prostaglandin content of the tissue and the amounts
of PGF2a, PGE2 and 6-keto-PGFja produced during a 90 min incubation
period, in the absence, or presence, of 5yg ml~* arachidonic acid,
was measured as described in Section 3.1b. In three animals there
was sufficient placental tissue present for some of it to be divided
into its maternal and foetal components. The endogenous concentra¬
tion and the amounts of PGF2cl, PGE2 and 6-keto-PGFja produced by the
materhal-decidua and foetal-placenta, when incubated in Krebs1 solu¬
tion, was measured as described in Section 3,1b. The placental
tissue remaining was replaced in ice-cold Krebs' solution and re¬
tained (Sections 4,2a and 5) . The amounts of PGF2(X, PGE2 and
6-keto~PGFia in the solvent-extracted tissue homogenates were
measured by RIA as previously described (Section 1.4a, b and c),
Results
The amounts of PGF2a, PGE2 and 6-keto-PGFja in ethanolic homo¬
genates of placental tissue, and in homogenates of placental tissue
incubated in Krebs1 solution, in the absence or presence of 5yg ml-1
6-keto-PGFla





















arachidonic acid, are shown in Fig, 31, The results are expressed
as the mean ± SEM of placentae from 4 animals. The endogenous levels
of PGF2a, PGE2 and 6-keto-PGFia were 1.57 ±0.31, 44.33 ± 23.12 and
5.72 ± 1.92, ng 100 mg * tissue, respectively. Following incubation
there was a significant increase in the amounts of PGF2a# PGE2 and
6-keto-PGFia in each homogenate (p < O.Ol). Approximately 3.5 times
as much PGE2 was produced as PGF^ or 6-keto-PGFja. The addition of
5yg ml-1 arachidonic acid to the incubation medium significantly
increased the amount of PGF2a and PGE2 formed (p < 0.05) but had no
significant effect on the amount of 6-keto-PGFja produced, although
the mean amount of 6-keto-PGFia synthesised was higher. The ratio
of PGF2a to PGE2 to 6-keto-PGFia synthesised was 1.5 : 5.9 : 1.0.
The amounts of PGF2a, PGE2 and 6-keto-PGFla in ethanolic homo-
genates of the maternal-decidua and foetal-placenta, and the amounts
of these compounds produced by these tissues during incubation, are
shown in Table 16. The results are expressed as the mean ± SEM of
3 animals.
The endogenous levels and the amounts of PGF2a, PGE2 and 6-keto-
PGFja produced during incubation of the maternal-decidua, were con¬
sistently lower than those of the foetal placenta. In both tissues
the endogenous concentration of PGE^was higher than the endogenous
concentration of PGF or 6-keto-PGF^a. The foetal-placenta produced
7.8 times more PGF2a, 18.3 times more PGE2 and 1.7 times more 6-keto-
PGFia than the maternal-decidua during a 90 min incubation period.
The major prostaglandin produced by the foetal-placenta was PGE2 while
the maternal-decidua produced approximately twice as much 6-keto-PGFja














1.52±0.08 9.42±6 51 1.96±0.64
31.82±4.44 28.82±5.28 58.67±6.32
2,68±0.01 56.66±13. 5.22±0,85
246.60±77.95 527.61±181. 7 98.75±57 07
Table16.ConcentrationfPGF2a,GE2and6-k to-PGFlaie hanolichomoge ates(end g nou )f maternal-deciduafoet l-placentaoD y17fregnancy,andhmountsPGF2a, PGE2and6-keto-PGFia,producedbythesiss sfoll wingh mogenisationaincubatio inKrebs"solution(mean±SEM,=3).
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Conclusion
Placental tissue, on Day 17 of pregnancy, has a high endogenous
concentration of PGE2. During incubation placental tissue homogenates
synthesise approximately 3.5 as much PGE2 as PGF2cx or 6-keto-PGFia.
The addition of 5yg ml-1 arachidonic acid to the incubation medium
had little effect on the ratio of the amounts of PGF2ot to PGE2 pro¬
duced but increased the ratio of PGF2a to 6-keto-PGFia from 1 to 1.5
and of PGE2 to 6-keto-PGFfrom 3.5 to 5.9. This suggests that,
in the presence of excess arachidonic acid, PGE2 and PGF2a are syn-
thesised in preference to 6-keto-PGF^a.
The foetal component of the placenta synthesises larger amounts
of PGF2ct, PGE2 and 6-keto-PGFia, in Vitro, then the maternal-decidua.
The major prostaglandin to be synthesised by the foetal-placenta is
PGE2 while 6-keto-PGFja is the major prostaglandin to be synthesised
by the maternal-decidua.
The high endogenous levels of PGE2 and the large amounts of PGE2
and PGF2ct produced during incubation of the placenta as a whole, are
probably due to the presence of the foetal-placenta. The high level
of PGE2 in the uterine venous plasma of pregnant animals from Day 11
of pregnancy onwards is also probably due to the production of PGE2
by the foetal placenta, although 'stretched' uterine tissue from
round the developing foetus may also contribute (see previous section).
The presence of 6-keto-PGF}a in uterine venous plasma of pregnant,
but not pseudopregnant, rabbits, is probably due a) to the presence
of the placenta and b) to the increased ability of 'stretched',
pregnant uterus, to synthesise larger amounts of 6-keto-PGFthan
pseudopregnant, uterine tissue.
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Section 4.1b Experiment to determine the effect of the presence
of placental tissue homogenates on the amounts of
PGF?a, PGE? and 6-keto-PGFin formed by uterine tissue
homogenates on Day 17 of pregnancy
Introduction
Maule Walker and Poyser (1974) have shown that uterine tissue
from bilaterally pregnant guinea-pigs synthesiser significantly less
PGF2a on Day 15 of pregnancy than uterine tissue on Day 15 of the
oej/strous cycle. In the unilaterally pregnant guinea-pig the amount
of PGF2a synthesised by the pregnant horn is the same as the amount
synthesised by uterine tissue of the bilaterally pregnant animal
while the non-pregnant horn synthesises approximately twice as much
PGF2a as either the unilaterally pregnant, or bilaterally pregnant,
uterus. The amount of PGF2a synthesised by the non-pregnant horn
in the unilaterally pregnant animal however, is still significantly
lower than the amounts synthesised by the Day 15, non-pregnant uterus
(Blatchley et al. , 1975b). These results suggest that the conceptus
supresses prostaglandin production by the uterus and that this effect
has both a local and systemic component. In the pregnant sheep,
removal of the embryo up to Day 12 of pregnancy results in a return
to oestrus by Day 18, while removal of the embryo on Days 13, 14 and
15 of pregnancy prolongs the functional life span of the corpus
luteum until Day 25 (Moor and Rowson, 1956a). Similarly, if embryos
are transferred to the uteri of normally cycling sheep by Day 12 of
the cycle the corpus luteum is maintained and becomes established as
the corpus luteum of pregnancy (Moor and Rowson, 1956b). Therefore,
if the corpus luteum of the oestrous cycle is to become established
as the corpus luteum of pregnancy, the embryo, or its secretions
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(Moor and Rowson, 1967) must be present in the uterus at the time at
which, in the non-pregnant animal, the levels of PGF2a in the uterine
venous plasma would normally begin to increase (Thorburn et al. , 1972).
In the pregnant sheep, however, the increase in PGF2a in the uterine
venous plasma seen on Days 14 to 16 of the oestrous cycle, is not
observed. This suggests that in this species, as in the guinea-pig,
the presence of the developing embryo in some way inhibits the syn¬
thesis and/or release of PGF2a into the uterine vein.
In the pregnant rabbit the increase in PGF2a in the uterine
venous plasma observed on Days 17 and 18 of pseudopregnancy is absent.
In the following experiment the effect of incubating pregnant uterine
tissue in the presence of placental tissue, on Day 17 of pregnancy,
has been measured to determine whether the presence of the placental
tissue affects the synthetic capacity of the uterine tissue.
Method
'Stretched' uterine tissue and placental tissue from Day 17
pregnant rabbits was obtained from animals used in Section 3.2a.
Placental tissue (i.e. maternal-decidua and foetal-placenta) was
disected free of adhering uterine tissue and of the embryonic sac
and its contents. Segments of 'stretched' uterine tissue and placen¬
tal tissue, each weighing approximately lg wet weight were prepared,
blotted dry and weighed. l.Og 'stretched' uterine tissue, and l.Og
placental tissue, from the same animal were homogenised together in
a total of 15 ml Krebs' solution using a Fissons glass homogeniser
as previously described in Section 1.2b-. All homogenates were in¬
cubated for 90 min at 37°C as previously described (Section 1.2b).
Homogenates were then solvent-extracted for prostaglandins (Section
1.2a) and assayed for PGF2a, PGE2 and 6-keto-PGFja by RIA as
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previously described. All determinations were performed in tripli¬
cate at two dilutions.
Results
The amounts of PGF2a, PGEg and 6-keto-PGFia produced when homo-
genates of uterine and placental tissues, from Day 17 pregnant rabbits,
are incubated together are shown in Fig. 32. Open bars represent
the amounts of PGF2ct' PGE2 and 6-keto-PGFia which were produced during
the incubation period, expressed as ng IOO rag"1 of uterine/placental
tissue. The amounts of PGF2a, PGE2 and 6-keto-PGFia which would
have been expected to be produced had the two tissue types been
incubated separately and the products of the two incubations combined
were calculated from the results of Section 3.2a and Section 4.1a
(and, expressed as ng 100 mg-1 of uterine/placental tissue) are
represented by the hatched bars in Fig. 32. When the 'observed'
and 'expected' amounts of PGF2a> PGE2 and 6-keto-PGF^a were compared
using Students' 't' test for both paired and unpaired data, there
were no significant differences between the 'observed' and 'expected'
amounts of PGF2a and 6-keto-PGFia formed although the mean amount of
6-keto-PGFla formed was higher than the calculated mean amount of
6-keto-PGF}a. The amount of PGE2 formed during incubation of uterine
tissue with placental tissue was significantly higher than the calcu¬
lated amount of PGE2•
Conclusion
The addition of placental tissue homogenates to incubates of
uterine tissue from Day 17 pregnant rabbits does not significantly
affect the amounts of PGF2a and 6-keto-PGFia produced but does appear









The reason for this increase in PGE2 output is not clear. The
addition of arachidonic acid to incubates of placental homogenates
significantly increased the amounts of pGFa and PGE^formed during
incubation but had no significant affect on the amounts of PGF2a, PGE2
or 6-keto-PGFja produced during incubation of 'stretched', uterine
tissue homogenates. The addition of homogenised, 'stretched',
uterine tissue to the placental tissue homogenate may, therefore,
increase the amount of arachidonic acid available and thereby con¬
tribute to the increase in PGE2 production.
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SECTION 5. EXPERIMENT TO MEASURE THE ABILITY OF UTERINE TISSUE ON
SELECTED DAYS OF PSEUDOPREGNANCY AND OF UTERINE AND
PLACENTAL TISSUE ON DAY 17 OF PREGNANCY, TO METABOLISE
3H-PGF?„.
Introduction
In the previous sections the ability of pseudopregnant and preg¬
nant uterine tissue, and of placental tissue to synthesise PGF2a< PGE2
and 6-keto-PGFia have been measured. In all these studies the amounts
of prostaglandins produced represent the total amount of prostaglandin
synthesised minus the amount of prostaglandin metabolised by these
tissues during the incubation period. In the following experiment
the ability of pseudopregnant and pregnant uterine tissue and placen¬
tal tissue on Day 17 of pregnancy to metabolise PGF2cx ^as heen
measured.
Method
Segments of uterine tissue (approximately lg wet weight) from
control and pseudopregnant rabbits (Section 3.1b) and from Day 17
pregnant rabbits (Section 3.2a) and placental tissue from Day 17
pregnant rabbits (Section 3.2a) were used. Each segment was blotted
dry, and weighed and homogenised in 15 ml Krebs' solution as pre¬
viously described (Section 3.1a). Nicotinamide adenine dinucleotide
-f- q
(NAD , to give a final concentration of 2.0 mM) , O.SyCi ;SH-PGF2a
(sp. act 160yCi mmol-1) and lOyg authentic PGF2a were added to each
homogenate. All homogenates were incubated for 90 min at 37°C as
previously described (Section 1.2b). Two further homogenates, one
of uterine tissue from a Day 7 pseudopregnant rabbit, and one of
placental tissue from a Day 17 pregnant rabbit, were also prepared
as described above except that no NAD+ was added to the incubation
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medium. Following incubation all homogenates were solvent-extrac¬
ted as previously described (Section 1,2a) and the residue redissolved
in 200yl methanol and subjected to thin layer chromatography.
3H-PGF2a and non-radioactive marker standards (lOyg each of PGF2a,
15-oxo-PGF2ct an<3 13,14-dihydro-15-oxo-PGF2a) were applied to 5
separate control plates. All plates were run first in solvent F VI
(Andersen, 1969) and then in solvent system GCM (Millar, 1974) as
previously described (Section 1.1a). Non-radioactive control plates
were visualised by spraying with a saturated solution of phospho-
molybdic acid in ethanol and heating at 110°C for lO min, and the Rf
values of the standards were calculated. Samples and marker stan¬
dards containing radioactive material were scanned using a Panax
radio thin-layer chromatographic plate scanner. The positions of
the radioactive bands were identified from the scans and their
positions relative to the solvent front recorded. The radioactive
bands were then each scraped off and washed three times with 3 ml
methanol. The washings were combined and transferred to scintilla¬
tion vials. The methanol was evaporated off under a jet of air at
45°C and the dry residue was redissolved in 13 ml Scintillant. All
samples were then monitored for radioactivity as previously described
(Section 1.la).
Results
The Rf values for the non-radioactive marker standards are shown
in Table 17. Metabolism was calculated as a percentage of the total
radioactivity recovered from each plate. Correction was made for
the loss of tritiated hydrogen atoms. The results are expressed
as the mean ± SEM of four animals and are shown in Table 18. The
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Table 17. Rf values for non-radioactive marker standards
15-oxo-PGF2a, 13,14-dihydro-15-oxo-PGF2a an^ a third, unidentified
product with an Rf value of 0.16. The percentage conversion of
3H-PGF2a to this last product is included in the total percentage









Control 68.29 ± 3.25 31.71 ± 3.25 n.d.*
Day 4 70.55 ± 6.06 29.65 ± 6.06 n.d.
Day 7 66.67 ± 7.92 35.70 ± 2.14 3.5 ± 2.14
Day 11 59.29 ± 5.02 40.54 ± 5.06 27.18 + 12.86
Day 17 71.53 ± 4.78 28.47 ± 4.78 19.53 ± 1.01
Day 17 Pregnancy 66.80 ± 5.16 33.20 i 6.06 16.OO ± 2.98
Day 17 Placenta 35.29 ± 3.09 64.72 ± 3.09 14.23 ± 0.17
Table 18. Percentage metabolism of 3H-PGF2ct by uterine tissue on
selected days of pseudopregnancy, and by uterine and
placental tissue on Day 17 of pregnancy (mean ± SEM,
n = 4) *n.d. non-detectable.
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also produced another metabolite at Rf 0,24 which is included in
Table 18.
Approximately 60-70% of added 3H-PGF2a was recovered unchanged
following incubation with uterine tissue homogenates on selected days
of pseudopregnancy and on Day 17 of pregnancy. In control animals
and on Days 4 and 7 of pseudopregnancy the major radioactive metab¬
olites had Rf values corresponding to 15-oxo-PGF2a and 13,14-dihydro-
15-oxo-PGF2ct. However, from Day 7 onwards there was a steady in¬
crease in the percentage metabolism of 3H-PGF2a which was recovered
as the unidentified metabolite (Rf value 0.16). The ratio of the
percentage of 3H-PGF2a converted into 15-oxo-PGF2a an(3 13,14-dihydro-
15-oxo-PGF2c( to the percentage of 3H-PGF2a recovered as the uniden¬
tified metabolite changed from 9.2 : 1 on Day 7, to 1 : 2 on Days 11
and 17 of pseudopregnancy, and to 1 : 1 on Day 17 of pregnancy.
Following incubation with placental tissue only, 35% of the added
q
QH-PGF2a was recovered in the unchanged form. The percentage of
q
H-PGF2a metabolised by placental tissue incubates on Day 17 of preg¬
nancy was significantly higher than that metabolised by any other
tissue studied (p < 0.05). Approximately 14.23% of the metabolised
q
H-PGF2a was recovered as the unidentified metabolite (Rf value 0.16)
and 11.92% as another unidentified metabolite with an Rf value of
0.24. The ratio of the percentage of 3H-PGF2a converted to 15-oxo-
PGF2a and 13,14-dihydro-15-oxo-PGF2a to the percentage of 3H-PGF2a
recovered as the unidentified metabolites, Rf values 0.16 and 0.24
respectively was 3.2 : 1.2 : 1.
In the two incubates, one of placental tissue and the other of
uterine tissue, in which no NAD+ was added to the incubation medium,
the radioactive material recovered ran as single spots on the TLC
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plates, both spots having Rf values corresponding to PGF2a-
Conclusion
There is no significant difference in the ability of uterine
tissue homogenates from control animals and on Days 4, 7, 11 and 17
O
of pseudopregnancy, and Day 17 of pregnancy, to metabolise °H-PGF2a.
The increase in PGF2a concentration in the uterine venous plasma of
pregnant rabbits on Days 17 and 18 of pseudopregnancy, therefore,
cannot be attributed to a decrease in the ability of the uterus to
metabolise PGF2a- However, although the total percentage metabolism
of 3H-PGF2a by uterine tissue homogenates did not change throughout
pseudopregnancy or on Day 17 of pregnancy, there was a steady increase
in the amount of 3H-PGF2a converted into the unidentified metabolite,
Rf value 0.16, and a steady decrease in the percentage of JH-PGF2ct
recovered as 15-oxo-PGF2a and 13,14-dihydro-15-oxo-PGF2a• Powell
(1978) found that following incubation of microsomal fractions of
rabbit lung or liver with PGF2a in the presence of reduced nicotin¬
amide adenine dinucleotide (NADH), a compound was produced which was
more polar than PGF2a anc^ which was identified as 20-hydroxy-PGF2a.
The 20-hydroxylation activity of rabbit lung and, to a lesser extent,
liver microsomes, increased dramatically during pregnancy, pseudo¬
pregnancy and following progesterone treatment of virgin female
rabbits. The increase in 20-hydroxylation activity lags several
days behind the increase in ovarian progesterone production and lasts
several days longer. Powell has also reported that the rabbit
placenta can convert PGF2a to its 20-hydroxy derivative, although it
is not as active as the lung or liver in this respect. The lung
homogenates from pregnant rabbits also convert 13,14-dihydro-15-oxo-
pgf2cx to its 20-hydroxy derivative in the presence of NADH (Powell &
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Solomon, 1978). Although the identity of the two polar metabolites,
Rf values 0.16 and 0.24 respectively, formed during incubation of
O
JH-PGF2a with homogenates of uterine or placental tissue in the
presence of NAD+ were not identified, it is probable that they are
the 20-hydroxylation products of 3H-PGF2a and of 13,14-dihydro-15-
oxo-PGF2a.
When uterine or placental tissue is incubated in the absence of
+ q
NAD , there is no detectable metabolism of °H-PGF2a. As the same
enzymes are responsible'for the metabolism of PGF2a an^ PGE2, the
amounts of PGF2a and PGE^synthesised by uterine tissue and placental
tissue homogenates in Sections 2, 3, 4 and 6 reflect the total syn¬
thetic capacity of these tissues as the amount of loss of PGF£a and
PGE_2_through metabolism is negligible.
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SECTION 6. ENDOGENOUS LEVELS AND IN VITRO PRODUCTION OF PGF?ri,
PGE2 AND 6-KETO-PGF-| n BY UTERINE TISSUE FROM OVARIEC-
TOMISED RABBITS TREATED WITH PROGESTERONE AND OESTRADIOL-
17B, EITHER ALONE OR IN COMBINATION
Introduction
In the normally cycling sheep, cow and guinea-pig, treatment
with oestrogen or progesterone can result in a shortening of the
oestrous cycle. Oestrogen is luteolytic on the cow when given on
Days 2-12 of the cycle, in sheep when given after Day lO, and in the
guinea-pig when given on Days 4 to 6 (Greenstein et at. , 1958;
Stormshak et at., 1968; 1969; Bland and Donovan, 1968; Choudary
and Greenwald, 1968). Progesterone treatment, begun on Day 1 of
the cycle and continued for several days, also decreases cycle
length in the sheep, cow and guinea-pig (Loy et at., 1960; Woody
et at., 1967). The luteolytic action of both these hormones appears
to be mediated via the uterus as hysterectomy abolishes their luteo¬
lytic effect (Stormshak et at. , 1968, 1969; Bland and Donovan 1970;
Rowlands, 1962; Brunner et at., 1969; Kaltenbach et at., 1964;).
Moreover, in the hemi-hysterectomised sheep and cow, and hemi-
hysterectomised and hemi-ovariectomised guinea-pig, progesterone and
oestrogen will only shorten the length of the oestrous cycle when the
retained horn is ipsilateral to the ovary containing the active
corpora lutea (Stormshak et at. , 1968, 1969, Bland and Donovan 1970;
Brunner et at., 1969; Ginther 1968, 1969; Woody, Ginther and
Casida 1967; Woody, Ginther and Pope, 1968).
Blatchley et at. , (1972) showed that the concentration of PGF2a
in the utero-ovarian vein of the guinea-pig fluctuates during the
oestrous cycle. The highest concentrations of PGF2ct in the utero-
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ovarian venous plasma were recorded on Day 15 when the levels of
progesterone were low but those of oestradiol are high. In contrast,
in the pregnant animal in which the levels of progesterone are still
elevated, the utero-ovarian venous plasma levels of PGF2ct and oestra¬
diol are low (Blatchley et at., 1975a). The in vivo treatment of
normally cycling guinea-pigs with lOyg oestradiol benzoate on Days 4
to 6 of the cycle results in an increase in the concentration of
PGF2a in the utero-ovarian venous plasma, as measured on Day 7 of
the cycle (Blatchley et at., 1971). The injection of oestradiol
benzoate, either alone or in combination with progesterone into
ovariectomised guinea-pigs also increases the concentration of PGF2ct
in the utero-ovarian venous plasma and also increases the ability of
the uterine tissue to synthesise PGF2a (Blatchley and Poyser, 1974;
Naylor and Poyser, 1975). These findings suggest that the increased
ability of the uterus to synthesise PGF2(X at the end of the oestrous
cycle is responsible for the increase in the uterine venous plasma
levels of PGF2a observed at this time and is under the hormonal con¬
trol of oestrogen and progesterone.
In the sheep there is an increase in the concentration of
oestradiol in the ovarian plasma between Days 10 and 12 and Days 15
and 16 of the cycle. Both increases precede an increase in PGF2a
output by the uterus (Cox et at., 1974). The infusion of oestra¬
diol into the uterine arterial blood supply of ewes in which the
uterus has been transplanted to the neck, also increases the level
of PGF2ct in the uterine venous effluent providing the animal has
previously been primed with progesterone (Barcikowski et at. , 1974;
Scaramuzzi, Boyle, Wheeler, Land and Baird, 1973). During the
cycle PGF2a synthesising capacity increases three days before oestrus
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in the sheep, at a time when plasma oestradiol concentrations are
increasing (Alwachi et aZ., 1979).
In the following experiment, the endogenous content and the
ability of the rabbit uterus to synthesise PGF2a, PGE2 and 6-keto-
PGFja following the in vivo treatment of ovariectomised rabbits
with oestradiol and progesterone, either alone or in combination,
has been measured, to investigate whether ovarian steroid hormones
regulate uterine prostaglandin synthesising capacity in the rabbit.
Method
Twenty mature female New Zealand white rabbits were anaesthe¬
tised with sodium pentobarbitone (35 mg kg-1). Following the opening
of the abdominal wall by a mid-line, abdominal incision, ligatures
were placed round the major ovarian blood vessels and the ovaries
excised and removed. The abdominal wall was closed with cat-gut
sutures and the skin closed with silk sutures. A month after
ovariectomy, the rabbits were randomly divided into five groups of
four animals per group and received daily injections of 0.5 ml
arachis oil (vehicle), containing steroids, as follows
Group 1-0.5 ml vehicle, for 10 days
Group 2 - 0.5 ml vehicle containing progesterone (10 mg) s.c. for
lO days
Group 3 - 0.5 ml vehicle: containing progesterone (10 mg) s.c. twice
daily for 10 days
Group 4 - 0.5 ml vehicle containing oestradiol-170 (E2~17(3, 2.0ug)
for 10 days
Group 5 - 0.5 ml vehicle containing progesterone (lO mg) twice daily
for 7 days followed by 0.5 ml vehicle containing E2-17B
(2.0yg) for 3 days
173
All injections were given subcutaneously (s.c.). Single injections
of vehvcle alone or veh\cle containing progesterone or E2~173 were
given between 09.00 hr and 09.30 hr. Animals in Group 3, receiving
two injections of progesterone (10 mg per injection) were injected
between 09.OO and 09.30 hr and between 16.45 hr and 17.15 hr. The
single daily injection of progesterone (10 mg) produced a mean con¬
centration of progesterone in the marginal ear vein plasma which was
similar to the physiological concentrations of progesterone observed
during pseudopregnancy and pregnancy. Animals in Group 3 received
a pharmacological dose of progesterone. The amount of E2~17g injec¬
ted (2.0yg per day) is the amount required to sustain pregnancy in
hypophysectomised rabbits, or in pregnant rabbits which have had
their follicles destroyed (Keyes & Nalbandov, 1967) .
On the 11th day after starting treatment, 2 ml blood were col¬
lected from the marginal ear vein of each rabbit as previously
described (Section 2.1b). The blood was centrifuged, and the
plasma was solvent-extracted and assayed for progesterone as pre¬
viously described (Sections 1.3d and 1.4d). Each animal was killed
by stunning and incising the neck. The uterus was removed, blotted
dry and weighed. The two uterine horns were opened longitudinally
and three segments, of approximately lg wet weight each, were cut.
Each segment was weighed and then used to determine one of the
following:
(a) the endogenous uterine tissue prostaglandin level
(b) the in vitro ability of the uterine tissue to syn-
thesise prostaglandins or
(c) the effect of the presence of excess arachidonic
acid on the synthetic capacity of the tissue,
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as previously described in Section 3.1b. Following solvent-
extraction, samples were assayed by RIA for PGE^and 6-keto-
PGFla as described in Sections 1.4a, 1.4b and 1.4c. Comparisons
of endogenous prostaglandin levels and the amounts of prostaglandin
synthesised by uterine tissue, in the absence and presence of added
arachidonic acid, in the five treatment groups studied, were per¬
formed using Students' 't' test for unpaired data unless otherwise
stated.
Results
The concentration of progesterone in the marginal ear vein
plasma and the effect of the various hormonal treatments on the
weight of the uterus, in the different groups, are shown in Table 19.
Uterine tissue from animals in Group 4 and 5 weighed significantly
more (p < O.OOl) than uterine tissue from animals in Groups 1'and 3,
but did not differ significantly from each other. Treatment with
progesterone alone (Group 3) also significantly increased the weight
of the uterus when compared to uteri from control animals (p < 0.05).
The endogenous levels of PGF2a, PGE2 and 6-keto-PGFia, and the
i/n vitro capacity of the uterine tissue from animals in Groups 1 to
5 to synthesise these prostaglandins, in the absence or presence of
excess arachidonic acid, are shown in Figs. 33, 34 and 35. Results
are expressed as the mean ± SEM of four animals (n = 4) except in
Group 2 where one animal died before treatment was completed (n = 3).
The endogenous level of PGE2 in uterine tissue in animals in
Group 1 (control) were significantly higher than in Group 2 (p < 0.02),
Group 3 (p < 0.05), Group 4 (p < 0.05) and Group 5 (p < 0.02). The
*
endogenous level of PGE2 in uterine tissue from animals receiving
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Group No Wt. of uterus
g
Concentration of Progesterone
in ear vein plasma
ng ml-1
1 1.79 ± 0.26 0.64 ± 0.07
2 n.m. 19,08 ± 5,09
3 3.82 ± 0.45 60.32 ± 7.04
4 11.12 ± 1.40 less than 0.4
5 11.95 ± 1.62 28.82 ± 7,60
Table 19. Concentrations of progesterone in ear vein plasma, and
the weight of uteri in ovariectomised rabbits treated in
the following way (mean ± SEM).
Group 1 - 0.5 ml arachis oil (vehicle) s.c. for 10 days
Group 2 - 0.5 ml vehicle containing progesterone (10 ml) s.c. for
10 days
Group 3 - 0.5 ml vehicle containing progesterone (lO mg) s.c. twice
daily for 10 days
Group 4 - 0.5 ml vehicle containing E2~173 (2jjg) s.c. for 10 days
Group 5 - 0.5 ml vehicle containing progesterone (10 mg) s.c. twice
daily for 7 days followed by
0.5 ml vehicle E2~17B (2yg) s.c. for lO days
n.m. = not measured
n = 4 for all Groups except Group 2 where n = 3.
progesterone followed by E -1 (Group 5) , was also significantly
lower than the endogenous level of PGE2 in animals receiving pro¬
gesterone only (Groups 2 and 3), but did not differ significantly
from the endogenous level of PGE2 in uterine tissue from animals
treated with E2~17fB alone (Group 4) . The endogenous concentration
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of PGF2a in uterine tissue from animals in Group 1 was significantly
higher than the endogenous levels of PGF2a in uterine tissue from
animals in Group 3 and Group 5. There were no significant differ¬
ences between the endogenous levels of PGF2a in uterine tissues of
animals in Groups 2, 3, 4 and 5. There were no significant
differences in the endogenous uterine tissue levels of 6-keto-PGFia
in any of the five treatment groups studied.
Following incubation there was a significant increase in the
amounts of PGF2a, PGE2 and 6-keto-PGFja produced per unit weight of
uterine tissue compared to the endogenous tissue concentrations of
these three compounds. The amounts of PGE2 synthesised by uterine
tissue from control animals (Group 1) were significantly higher
(p < 0.05) than the amounts of PGE2 synthesised by animals receiving
E2-17g, either alone or following progesterone pre-treatment (Groups
4 and 5), but did not differ significantly from the amounts of PGE2
produced by uteri from animals receiving progesterone alone (Groups
2 and 3). The amounts of PGE2 synthesised by uterine tissue from
Groups 2 and 3 also tended to be higher than the amounts synthesised by
uterine tissue from Groups 4 and 5, but these differences were not
significant. Uterine tissue from control animals also tended to
synthesise more PGF2a than uterine tissue from the other treatment
groups but the large variation between individual animals from the
other treatment groups and the large viariation between individual
animals in Group 1 meant that the results were not significant. The
amount of PGF2a produced by uterine tissue from animals in Groups 2
and 3 were significantly higher (p < 0.05) than the amounts syn¬
thesised by uterine tissue from animals in Groups 4 or 5. There were
no significant differences between the amounts of 6-keto-PGFia
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synthesised by uterine tissue from any of the five treatment groups
studied.
When Students' ' t' test for paired data was used to compare results
the addition of 5yg ml-1 arachidonic acid to the incubation medium
significantly increased the amounts of PGF2a synthesised by uterine
tissue from animals in Group 1 (p < 0.02), Group 4 (p < O.Ol) and
Group 5 (p < O.Ol) but, although it tended to increase the amounts
of PGE£ and 6-keto-PGFia formed by uterine tissue from all five
groups, these increases were not significant. The mean amounts of
PGF2cx and PGE2 synthesised by uterine tissue in the presence of
exogenous arachidonic acid from animals in Group 1 were higher than
in any other treatment group. However, the results were only sig¬
nificant when comparing pGF^ production in Group 1 with PGF^ produc¬
tion by uterine tissue from animals in Group 2 (p < 0.05) and Group
4 (p < 0.05).
The mean amounts of PGE2 produced by animals receiving pro¬
gesterone only (Groups 2 and 3) were higher than the amounts of
PGE2 synthesised by uterine tissue from animals receiving E2~17f3,
either alone (Group 4) or following a period of progesterone priming
(Group 5) but, because of the wide variation in animals in Groups 2
and 3, this difference was only significant when comparing values in
Group 2 with values in Group 4 (p < 0.05). There were no signifi¬
cant differences in the amounts of PGF2a produced by uterine tissue
from Groups 2, 3, 4 and 5.
The addition of 5yg ml~* arachidonic acid to the incubation
medium did not significantly affect the amounts of 6-keto-PGFia
formed by uterine tissue in all treatment groups. The mean amount
of 6-keto-PGFia synthesised by uterine tissue from animals in Group 3
was higher than in any other group studied, but this difference was
not significant, probably because of the wide variation in individual
animals within many of the groups. The major prostaglandin to be
produced during incubation in all groups studied, however, was
6-keto-PGFlct.
Conclusion
In the ovariectomised rabbit, the uterine tissue is capable of
synthesising quite large amounts of PGF2a/ PGE2 and 6-keto-PGFia. In
vivo treatment with progesterone, at both physiological or pharma¬
cological doses, did not significantly affect the capacity of the
uterine tissue to synthesise PGF2ct, PGE2 or 6-keto-PGF^a, in vitro,
whereas the administration of E2-17g (2.0)jg per day) for 10 days
decreased the amounts of PGF2a and PGE2 synthesised per unit weight
of uterine tissue. E2-17g administered after a period of progesterone
priming also decreased the amount of PGE2, but not PGF2a, synthesised
by uterine tissue in vitro. This decrease in PGF2a and PGE2 produc¬
tion following treatment with E2-178 could be related to a decrease
in the availability of precursor as the addition of excess arachi-
donic acid to the incubation medium increased the amount of PGF2a
and, to a lesser extent, the amount of PGE2 produced by uterine
tissue from animals treated with E2~17g alone or following a period
of progesterone priming. The in vivo treatment of rabbits with
progesterone and E2-17g, either alone or in combination, did not
affect the capacity of uterine tissue to synthesise 6-keto-PGFia.
Although the in vivo treatment of ovariectomised rabbits with
E2-17g, either alone or after a period of progesterone priming,
decreased the amounts of PGF2ct and PGE2 formed per 100 nig uterine
tissue, the increase in uterine weight following E2-17g treatment,
Group 1 Group 3 Group 4 Group 5
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means that the total amount of prostaglandin synthesised by the
uterus as a whole is highest in those animals receiving E2-17(3.
Fig. 36 shows the total amount of PGF2a, PGE2 and 6-keto-PGFja
synthesised by the whole uterus in Groups 1, 2, 3, 4 and 5. The
amount of PGE produced by the uterus as a whole was not altered
significantly by any of the hormone treatments studied. However,
the amounts of PGFj^ and 6-keto-PGF^a synthesised by whole uteri in
Groups 4 and 5 were significantly higher than the amounts syn¬
thesised by uteri from control animals (p < O.Ol). The mean amount
of PGF2ct synthesised by uteri from animals receiving both proges¬
terone and E2-173 (Group 5) was higher than the amount synthesised
by uteri from animals receiving only progesterone or E2-173- The
amount of 6-keto-PGFia synthesised.by uteri from animals in Group 3 was
significantly lower than the amount synthesised by uteri from animals
in Group 4 (p < 0.02) and Group 5 (p < 0.05). The addition of
5yg ml-1 arachidonic acid to the incubation medium significantly
increased the amounts of PGF2a produced by uteri from animals in
Groups 4 and 5. It is possible that the increased amount of PGF2a
synthesised by uteri in Group 5 (when compared to Group 4) could be
caused by an increase in arachidonic acid availability since pro¬
gesterone treatment has been reported to increase the number of lipid
droplets in endometrial cells (Brinsfield and Hawk, 1973). The mean
amount of 6-keto-PGFla synthesised by uteri from animals receiving
progesterone only (Group 3) was still significantly lower than the
amounts synthesised by uteri from animals in Group 4 and 5 in the
presence of added arachidonic acid. These results suggest that, as
in the sheep and guinea-pig, the maximum potential for uterine PGF2ct




Scott and Rennie (1970) have shown that in the pseudopregnant
rabbit, as in the cycling sheep, cow, pig and guinea-pig, and in the
pseudopregnant rat and hamster, the functional lifespan of the corpus
luteum is determined, at least in part, by the uterus. This effect
is mediated via a uterine luteolytic hormone and, in the sheep and
guinea-pig, there is now strong evidence to suggest that PGF2cx is the
luteolytic principle involved.
As outlined earlier, in order for a compound to be ascribed the
role of a uterine luteolysin it must fulfil certain minimum criteria.
More specifically, if PGF2a is the agent involved then these criteria
can be stated as follows.
1) PGF2ct should be luteolytic in vivo when administered in doses
that fall within the physiological range.
2) PGF2a should be present in the uterine vein at the time of
luteal regression.
3) Indometha.cin, at low doses (0.17 - 38,OyM) which specifically
inhibit the cycloxygenase enzyme in the prostaglandin syn¬
thetase system (Flower, 1974) , should prolong luteal function.
4) Immunisation against PGF2a should also prolong luteal function.
PGF2a is luteolytic in both the pseudopregnant and pregnant
rabbit when administered in vivo, either subcutaneously at doses of
1 to 5 mg kg-* day-1 (Gutknecht et a~l. , 1970; Carlson and Gole, 1978)
or via an intra-arterial or intravenous infusion of lOpg hr_1 (Challis
, oet at., 1974; Laudahski, Batra and Akerlund, 1979). Subcutaneous
administration of indomethacin (8 mg kg-1 12h_1) or immunisation
against PGF2a also prolongs luteal function in the pseudopregnant
rabbit (O'Grady et at., 1972; Caldwell et at., 1972). PGF2a
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therefore possesses several of the properties of a uterine luteolytic
hormone in this species. However, before PGF2a can be identified as
a uterine luteolytic hormone in the rabbit it is necessary to show
that the onset of luteolysis is immediately preceded by an increase
in the uterine secretion of PGF2a»
In the rabbit the corpus luteum is the major source of proges¬
terone (Keyes and Nalbandov, 1967; Eaton and Hilliard, 1971). During
pseudopregnancy and pregnancy the metabolic clearance rate of proges¬
terone remains fairly constant (Thau and Lanman, 1976) so that peri¬
pheral plasma concentrations reflect progesterone secretion by the
luteal tissue and can be used as an index of the functional state of
the corpus luteum. In the pseudopregnant animal the concentration
of progesterone in the peripheral venous plasma was found to increase
up to Day 7, remain elevated until Day 14 and then decline steadily
to reach pre-injection levels by Day 19 (Fig. 17). A similar profile
of peripheral plasma progesterone levels has been reported by other
workers although the absolute values reported by them tend to be lower
(Harrington and Rothermel, 1977; Miller and Keyes, 1976; Browning,
Keyesand Wolf, 1980). These differences are most probably due to
the higher dose of HCG used to induce pseudopregnancy in this study.
Harrington and Rothermel (1977) have reported that following the
induction of pseudopregnancy with 50-100 i.v. HCG, the plasma pro¬
gesterone levels observed on Days 8 through to Day 13 were signifi¬
cantly higher than the levels recorded in animals mated to vasecto-
mised males. The dose of HCG used does not appear to alter the
initial number of ovulation points but higher doses of HCG do appear
to cause the subsequent luteinization of non-ovulated follicles,
possibly because of the long half life of HCG, It is also possible
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that the HCG could affect the 'absolute' secretion rate of proges¬
terone by the corpora lutea. In experiment 2.1b, however, in which
the same dose of HCG was used to induce pseudopregnancy in intact
and hysterectomised animals, the range of progesterone concentrations
in the peripheral venous plasma is lower than in Fig. 17 and is simi¬
lar to that reported elsewhere (Miller and Keyes, 1977) . The reason
for this discrepancy is not known.
The concentration of PGF2a in the uterine venous plasma remained
low until Day 17 of pseudopregnancy when it rose significantly to
reach peak values of 4.51 ± 1.55 ng ml-1. It was still elevated on
Day 18 (2.34 ± 0.73 ng ml-1) but had declined to 'basal' levels by
Day 19. As this increase in uterine venous PGF2a concentration was
not seen in either the aortic or peripheral venous plasma levels, it
seems likely that the increase is due to a specific release of PGF2ct
from the uterus and is not a consequence of a general increase in
prostaglandin synthesis and/or release within the animal as a whole.
The increase in uterine PGFa output occurs 2 to 3 days after the mean
peripheral plasma progesterone levels have begun to decline. This
suggests that although PGF2ct released from the rabbit uterus after
Day 16 may contribute to luteal demise, it is unlikely to initiate
it. Failure to detect an increase in uterine PGF2a secretion prior
to Day 17 may have been due to the sampling technique used. The
large volumes of blood needed for assay purposes precluded the taking
of serial blood samples. Therefore, if PGF2a release from the
rabbit uterus occurs in a pulsatile fashion, as has been reported in
the sheep (Thorburn et at, , 1973), cow (Nancarrow et at. , 1973) and
pig (Gleeson and Thorburn, 1973), it is possible that an increase in
uterine PGF2a output would escape detection until such time as pulse
frequency and height led to gross changes in the uterine venous
plasma concentration of PGF2a. Another point that should be taken
into consideration is that the concentrations of PGF2a recorded here
do not take into account changes in uterine venous blood flow.
During collection of the blood samples it was noted that the diameter
of the uterine vein increased in size as pseudopregnancy progressed
and was accompanied by a tendency to shorten the time required to
collect 20 ml of blood. Measurements of uterine blood flow were not
made, however, since the method of collection and the anatomy of the
uterine vasculature would have made it difficult to relate these to
the overall output of PGF2a from the uterus. It is possible that,
had PGF2a release been expressed in terms of ng ml--'- min-^, an in¬
crease in uterine PGF2a output may have been observed prior to Day
17 of pseudopregnancy. If such a release did occur, and if it was
important for the initiation of luteolysis, then the decline in
peripheral plasma progesterone levels observed after Day 14 of pseudo¬
pregnancy should not occur in the hysterectomised, pseudopregnant
rabbit. As can be seen from Fig. 19, this decline did occur and the
concentration of progesterone in the peripheral venous plasma declined
from Day 13 onwards in both intact and hysterectomised rabbits and,
although the concentrations of progesterone in the hysterectomised
animal tended to be higher than those observed in the intact animal,
this difference was not significant except on Days 17, 18 and 19 of
pseudopregnancy (p < 0.05), the time at which PGF2a release from the
in the intact animal-
uterus was found to increase^ These results, therefore, support
the earlier hypothesis that PGF2a of uterine origin is unlikely to
be responsible for the initiation of luteolysis but does contribute
to the more rapid and final demise of luteal function after Day 16.
188
The increase in PGF2a on DaY 17 and 18 of pseudopregnancy coincides
with the onset of the morphological regression of the corpora lutea
reported by Scott and Rennie (1970).
Carlson and Gole (1978) have also tried to correlate changes in
the plasma progesterone levels with changes in the levels of PGF in
the posterior vena cava. As in the present study, evidence of func¬
tional regression of the corpus luteum, as determined by measurement
of the venous plasma progesterone levels, occurred between Days 14
and 15 of pseudopregnancy.- However, they found no significant
increase in PGF concentrations in the posterior vena cava, either at
this time or on later days of pseudopregnancy. Their failure to
detect the increase in PGF2a secretion observed in the present study
may have been due to a dilution effect since blood from the vena cava
is comprised of the venous effluents of a number of tissues besides
that of the uterus. This could also explain why the levels of PGF
recorded by Carlson and Gole (1978) tend to be slightly higher than
the basal levels observed in the uterine venous plasma in this study.
Moreover, Carlson and Gole (1978) measured the levels of PGF by radio¬
immunoassay of solvent-extracted blood samples. As mentioned in
Section 1.3b, it was found that rabbit plasma contained a constituent
which interfered with the assay. In order to avoid this interference,
all plasma samples in the present study were subjected to silicic acid
column chromatography following solvent extraction prior to being
assayed by radioimmunoassay. The omission of a chromatographic step
could also help to explain why the levels of PGF in the posterior vena
cava reported by Carlson and Gole (1978) were higher than those
observed in the uterine vein, aorta and ear vein in this study between
Days 6 to 16 of pseudopregnancy.
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In the pregnant rabbit, the presence of a functional corpus
luteum is required throughout pregnancy. If PGF2a is responsible
for terminating luteal function at the end of pseudopregnancy, then
some mechanism should operate to negate its effect in the pregnant
animal. In the sheep and guinea-pig, the presence of the developing
embryos results in a decrease in PGF2a output from the uterus in the
early pregnant animal (Thorburn et at., 1973; Nett et at., 1976;
Poyser and Maule Walker, 1979; Antonini et at., 1976). In the
pregnant sow, PGF2a output from the uterus is still fairly high
during early pregnancy but is still lower than in the non-pregnant
animal and appears to be accompanied by a redirection of PGF2a secre¬
tion away from the vasculature towards the uterine lumen (Moeljono
et at. , 1977).
The increase in PGF2a concentrations in the uterine venous
plasma seen on Days 17 and 18 of pseudopregnancy is not observed in
the pregnant rabbit. The concentrations of PGF2a remains low,
approximately 1 ng ml-1, until Day 24 when they rise significantly
(p < 0.05). They reached peak values on Day 25 (4.97 ± 0.22 ng ml-1)
and, although still elevated on Day 26 (2.0 ng ml-1) had returned to
'basal' levels by Day 27. The suppression of uterine PGF2a secre¬
tion on Days 17 and 18 of pseudopregnancy may be important in main¬
taining the function of the corpora lutea of pregnancy. However,
other factors of embryonic and placental origin are also involved
(Laudanski et at., 1979; Holt and Ewing, 1974; Fuchs and Beling,
1974; Singh and Adam, 1978).
It would appear, therefore, that PGF2a does act as a uterine
luteolytic hormone in the pseudopregnant rabbit. However, the rabbit
differs from other species in which PGF2a acts as a uterine luteolysin
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in several respects
(1) The release of PGF2a from the rabbit uterus, although res¬
ponsible for terminating luteal function, does not appear to initiate
it.
(2) The rabbit lacks the well defined unilateral, utero-ovarian
pathway observed in such species as the sheep, guinea-pig, cow and
pseudopregnant rat and hamster. Del Campo and Ginther (1972, 1973)
have shown that in those species in which there is a well defined
'unilateral' effect of the uterus on the ovary, the anatomy of the
uterine vasculature is such as to permit a counter-current mechanism
of transfer to operate, similar to that proposed for the sheep and
cow. In the rabbit, however, the anatomy of the uterine vasculature
is sufficiently independent from the ovarian vasculature to make such
a mechanism of transfer unlikely. It is possible that some PGF2a
of uterine origin could reach the ovary via the ovarian artery since
branches of the ovarian artery and vein, which are closely apposed to
one another, also supply and drain the cranial section of the uterine
horn. The amount of PGF2a which could be transferred in this way,
however, is likely to be small and, since such a system would give
rise to a 'unilateral' effect, it is probable that PGF2a transferred
by this route is insufficient to terminate luteal function. Scott
and Rennie (1970) have shown that when corpora lutea are grafted to
beneath the kidney capsule of a pseudopregnant rabbit, they regress
at the same time as the ovarian corpora lutea unless the recipient
doe has been previously hysterectomised. These results suggest that
the mechanism by which the uterus controls the functional life span
of the corpus luteum has a systemic component. The ability of the
lungs to metabolise prostaglandins makes it unlikely that such an
effect is mediated via the circulation but it is possible that PGF2a
from the uterus could reach the ovaries by way of the lymphatic sys¬
tem. The possible involvement of the lymphatic system is the trans¬
fer of PGF2ct from the uterus to the ovary has so far been ignored and
is in need of investigation. At present, however, it is difficult
to see how PGF2a from the uterus reaches the ovary in sufficient
amounts to induce luteolysis in the rabbit.
(3) In the cycling sheep, guinea-pig and cow, there is an in¬
crease in the endogenous tissue levels of PGF2a towards the end of
the oestrous cycle at the time luteal regression occurs (Wilson
et at., 1972; Poyser, 1972; Shemesh and Hansel, 1975). Since this
increase appears to coincide with the increase in utero-ovarian
plasma levels of PGF2a (McCracken et at., 1972; Blatchley et at.,
1972, Shemesh and Hansel, 1975) it is probable that the endogenous
tissue levels reflect the synthetic activity of the uterine tissue
■in vivo. Similarly in the rabbit the endogenous uterine tissue
levels of PGF2a on Day 17 of pseudopregnancy are significantly higher
than in uterine tissue from rabbits on Days 4, 7 and 11 of pseudo-
pregnancy and from control rabbits not injected with HCG. The
endogenous uterine levels of PGE2 and 6-keto-PGFja are also signifi¬
cantly higher on Day 17 of pseudopregnancy than on any other day
studied suggesting that there is a general increase in prostaglandin
synthesised at this time. In the guinea-pig (Poyser, 1972) and
sheep (Huslig et at., 1979; Alwachi et at. , 1979) the increase in
uterine venous plasma levels and uterine tissue levels of PGF2a is
correlated with an increase in prostaglandin synthetase levels.
However, experiments with uterine tissue homogenates showed that
although uterine tissue from Day 17 pseudopregnant rabbits does tend
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to synthesise slightly more PGF2a than uterine tissue on Days 4, 7
and 11 of pseudopregnancy, there is no significant change in the
ability of the uterine tissue to synthesise (or metabolise) PGF2a
during pseudopregnancy. The increase in uterine PGF2a output on
Day 17 of pseudopregnancy, therefore, does not correlate with changes
in the prostaglandin synthesising capacity of the uterus. A similar
observation has been made in the rat where increased levels of PGF
in the uterine venous plasma during dioestrus appear to be unrelated
to changes in the uterine capacity to synthesise prostaglandins
(Saksena, Shaikh and Shaikh, 1973;. Poyser and Scott, 1980). Also
there is no increase in the prostaglandin synthesising capacity of
the rat uterus at the end of pseudopregnancy (Fenwick, Jones, Naylor,
Poyser and Wilson, 1977).
(4) Uterine tissue homogenates from pseudopregnant rabbits syn-
thesises significantly more PGF2a and PGE2 tn vitro than uterine
tissue from non-pseudopregnant rabbits. Since the addition of exo¬
genous arachidonic acid to the incubation medium increases the amount
of PGE2 and PGF2a formed to that produced by uterine incubates from
pseudopregnant animals the reduced ability of uterine tissue from
non-HCG injected rabbit to synthesis prostaglandins may be due to a
lack in substrate availability. The increase in uterine PGF2a out¬
put on Days 17 and 18 of pseudopregnancy, however, cannot be due to
an increase in substrate availability since the addition of ara¬
chidonic acid to the incubation medium does not increase the amount
of PGF2a synthesised to any significant extent. However, it is
possible that when the cellular integrity of the uterus is maintained
the tissue may preferentially synthesise PGF2a towards the end of
pseudopregnancy. It should also be pointed out that in the rabbit
there is a substantial increase in uterine weight during pseudo-
pregnancy and the increase in uterine mass could also help to account
for the increase in uterine PGF2a output on Days 17 and 18 of pseudo-
pregnancy.
(5) In the pregnant sheep (Thorburn et at., 1973) , guinea-pig
(Blatchley et at., 1975a), cow (Kindahl et at., 1976; Lukaszewska
and Hansel, 1980) and pig (Moeljono et at., 1977; Shille et at.,
1979) the increase in uterine venous PGF2a observed towards the end
of the oestrous cycle is not observed in the pregnant animal.
Similarly in the pregnant rabbit the increase in uterine venous
plasma levels of PGF2a seen on Days 17 and 18 of pseudopregnancy is
not observed. Unlike the guinea-pig, however, this decrease in
uterine PGF2a output is not associated with a decrease in the ability
of the uterine tissue to synthesise PGF2a, in vitro, or with an
increase in its ability to metabolise PGF2a. However, since the
endogenous concentration of PGF2a in both 'unstretched' and 'stretched'
uterine tissue on Day 17 of pregnancy is significantly lower than in
uterine tissue on Day 17 of pseudopregnancy, it is possible that, in
Vt-VOi the pregnant uterus does in fact synthesise less PGF2a than
the pseudopregnant uterus. On the other hand, it is also possible
that, as has been proposed for the pregnant pig (Bazer and Thatcher,
1977) and sheep (Ellinwood et at. , 1980) that PGF2a released by the
pregnant rabbit uterus instead of entering the vascular system, is
secreted into the uterine lumen. The concentration of PGF2a in
uterine flushings from pregnant rabbits has not been measured.
(6) The rabbit uterus also shows some differences in its res¬
ponse to oestrogen and progesterone when compared to such animals as
the sheep and guinea-pig. In the ovariectomised guinea-pig
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the injection of oestradiol, either alone or in combination with
progesterone, increased the ability of the uterus to synthesise
PGF2a' in vitro (Naylor and Poyser, 1975). In the ovariectomised
rabbit, however, oestradiol treatment significantly reduced the
ability of uterine tissue to synthesise PGF2a when compared to pro¬
gesterone treatment. The reduction in PGF2a synthesising ability
induced by oestrogen treatment is probably due to lack of substrate
since it is abolished by the addition of exogenous arachidonic acid.
In the progesterone primed, oestrogen treated rabbit, the ability of
the uterus to synthesise PGF2a from endogenous arachidonic acid is
similar to that observed in progesterone only treated animals.
However, unlike progesterone only treated animals, the addition of
arachidonic acid to the incubation medium significantly increases
the amount of PGF2a synthesised. This suggests that, as in other
species (see Introduction) the maximum potential for uterine PGF2a
synthesis occurs after a period of progesterone priming followed by
exposure to oestrogen. In the pseudopregnant rabbit, the peripheral
plasma concentration of oestradiol-17f3 increases steadily from Day 12
of pseudopregnancy until oestrus (Browning et at., 1980), while in
the pregnant rabbit, although the circulating levels of oestrogen
remain fairly constant there is a steady increase in the ratio of
progesterone to oestradiol-178 from Day 21 (Challis Davies and Ryan,
1973). This increase in oestrogen and/or in the progesterone :
oestrogen ratio may be important in controlling uterine prostaglandin
synthesis.
It is clear, therefore, that the factors responsible for con¬
trolling prostaglandin production by the uterus in the pseudopregnant
and 'early' pregnant rabbit are different from those observed to
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operate in other species such as the sheep and guinea-pig.
The significance of the increase in the uterine venous plasma
concentration of PGF2a on DaY 24, 25 and 26 of pregnancy is not known.
It does not appear to induce luteolysis since the increase in PGF2a
levels is not accompanied by a decrease in peripheral plasma pro¬
gesterone levels. Chiboka, Casida and First (1977) have shown that
foetectomy in Day 25 pregnant rabbits (leaving the placentae in situ)
does not prevent delivery of the placentae from occurring at the
normal time. When foetectomy is performed on Day 21, however, pla¬
cental delivery is inhibited. These results imply that between Days
21 and 25 of pregnancy, the placentae receive a signal from the foetus
which confers autonomy on the placentae to initiate their own delivery.
Whether the increase in uterine venous plasma PGF2a levels on Days 24
to 26 of pregnancy forms part of the signal or arises as a consequence
of it requires further investigation. Elzayat and Stylos (1974) have
reported that when rabbits immunised against PGF2q are made pregnant,
abortion occurs around Day 24. In these animals pregnancy progressed
as normal until Day 14 but thereafter signs of retarded embryonic
growth and placental insufficiency were evident. The reasons for
these observations is not known but the results imply that PGF20C may
be involved in maintaining placental function. Challis, Davies and
Ryan (1975) have shown that when indomethacin is administered either
orally, from Day 20 to term, or subcutaneously from Days 23 to 28 of
pregnancy, parturition is delayed by up to two days whereas indome-
tha_cin treatment on Days 29 to 31 does not prolong gestation to any
significant extent. These results also imply that prostaglandin
secretion between Days 23 to 28 of pregnancy is important in deter¬
mining the time of delivery. As the above treatment did not affect
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the decline of peripheral plasma progesterone levels, the effect on
the time of delivery is unlikely to be related to the luteolytic
properties of PGF2a. As in several other species, glucocorticoid
treatment during the latter stages of pregnancy has been reported to
shorten the length of gestation in the rabbit. In this respect it
is interesting to note that the single injection of dexamethasone
into the amniotic sac will only induce premature delivery when given
on Day 25 of pregnancy (Kendall and Liggins, 1972). Whether this
is related to the 'signal' which passes from the foetus to the
placenta at this time and/or to the increase in uterine PGF£a output
is not known and requires further investigation. Premature delivery
can also be induced by the continuous infusion of Cortisol
(Nathanielsz and Abel, 1973) or by the daily administration of
dexamethasone (Challis et at. , 1975) from Day 21 of pregnancy and
does not appear to be affected by indomethacin treatment (Davies,
Yoshinaga and Ryan, 1976). It is clear that further work must be
performed if the importance of the increase in uterine PGF£ct secre¬
tion on Days 24 to 26 of pregnancy on the parturient process is to
be elucidated.
Although this study was not concerned with a detailed investi¬
gation into the uterine output of PGF2a term, it was noted that
the uterine venous plasma concentrations of PGF2a were higher in the
two rabbits which were in the early stages of labour than in rabbits
of the same gestational age in which labour had not yet started
(3,84 ± 1.53 Vs 0.75 ± 0.62 ng ml--'-, Day 31; and 1,44 ± 0.33 Vs
0.38 ± 0.04 ng ml-1, Day 32). Challis et at,. (1973) found that there
was a significant increase in the peripheral plasma concentration of
PGF between Days 21 and 30 of pregnancy, and this increase occurred
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immediately prior to, or coincident with the decline in progesterone
levels. The levels of PGF in the peripheral venous plasma reported
by Challis et aZ. (1973) are in good agreement with those reported
here. However, no significant increase in the peripheral plasma
levels of PGF2ct towards the end of pregnancy was observed.
In the pregnant rabbit the uterus remains relatively quiescent
throughout gestation until about 48 hr before delivery. The increase
in uterine activity which occurs at this time is coincident with an
increase in uterine sensitivity to oxytocin. Characteristically,
delivery is achieved with a sudden outburst of strong uterine con¬
tractions and the entire litter is delivered within 11.5 ± 2 min
(Fuchs, 1964; Fuchs, 1978). It is possible that the uterine output
of PGF2ct does increase during delivery. However, it is unlikely
that such an increase would be detected in the peripheral venous
plasma because of the rapid inactivation of prostaglandins by the
lung. If measurements of uterine PGF2a output during the delivery
period are to be made, it would be more sensible to look at the peri¬
pheral plasma levels of PGF2a metabolites in plasma obtained from
conscious animals at this time. Fuchs (1978) has suggested that
PGF2a may play a role in the parturient process by virtue of its
luteolytic properties. The experimental data on which this
'hypothesis' is based relies on the fact that, following indomethacin
treatment, plasma progesterone levels have been claimed to decrease
more slowly than in untreated animals (Davies et aZ., 1976). The
results reported in Section 2.2a do not support this idea since the
decline in peripheral plasma progesterone levels occurred indepen¬
dently of any increases in uterine PGF2a output. Moreover, since
indomethacin also blocks phosphodiesterase activity at similar
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concentrations to those at which it inhibits cyclo-oxygenase activity,
it is possible that the slowed decrease in plasma progesterone levels
observed by Davies et aZ. (1976) is due to the accumulation of intra¬
cellular c-AMP. PGF2a may contribute to the activation of the
myometrium during the delivery period since the levels of PGF2a in
the uterine venous plasma of the rabbit were found to be elevated
during the early stages of labour.
The concentrations of PGE2 were low and varied little in plasma
from the aorta and ear vein during pseudopregnancy and pregnancy,
and from the uterine vein during pseudopregnancy. In the pregnant
rabbit, however, the concentrations of PGE2 in the uterine venous
plasma were markedly elevated after Day 11. Similarly high levels
have been reported by Venuto, O'Dorisio, Stein and Ferris (1975) and
by Meese, Fischer, Hoffman and Frolich (1980). The PGE2 appears to
be of foetal-p]acental origin since in rabbits made unilaterally
pregnant by ligation of the oviduct prior to mating, the levels of
PGE2 in the uterine venous plasma on the sterile side are apprixi-
mately 77% lower than the levels of PGE2 in the uterine venous plasma
collected from the intact, pregnant side (Frolich, Whorton, McKenna
and Hoffman, 1978). Moreover, in the present study there is a posi¬
tive correlation between the uterine venous plasma levels of PGE2 and
the number of foetuses present in the uterine horn. The endogenous
levels of PGE2 in the foetal-placental tissue, and the ability of
this tissue to synthesise PGE2, in vitro is also very high when com¬
pared to the endogenous levels and synthetic ability of the maternal
decidua and Day 17 pregnant uterine tissue to synthesise PGE2.
The significance of this large output of PGE2 has not been
studied in any detail. Elzayat and Stylos (1974) have shown that
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when rabbits immunised against PGE are made pregnant, the doe dies
shortly after mid-pregnancy. Post mortem studies have shown that
the corpora lutea and ovaries appear to be functioning normally but
that the placentae show infarcts, thromboses and haemolysis. This
suggests that, like PGF2a, PGE2 may be important in maintaining
placental growth and function.
Since PGE2 is known to elevate ovarian c-AMP levels and to stimu¬
late progesterone production in a number of species, including the
sheep (Marsh, 1971), pig (Kolera and Channing, 1972), human (McNatty,
Henderson and Sawyers, 1975) and cow (Speroff and Ramwell, 1970), it
is possible that PGE2 may form part of the placental luteotrophic
stimulus in the rabbit. However, since plasma progesterone levels
decline at the end of pregnancy at a time when PGE2 output is still
high, it seems unlikely that ovarian progesterone secretion is con¬
trolled by PGE2- Also, in rabbits immunised against PGE2, the
corpora lutea did not regress (Elzayat and Stylos, 1974). It seems
more likely that PGE2 released locally by the placenta is important
in maintaining placental vascular patency. A similar mechanism for
PGE2 in regulating the ventillation-perfusion ratios in the lungs of
dogs, swine and lambs has been proposed (Kadowitz, Joiner and Hyman,
1975; Orehek, Douglas, Lewis and Bouhuys, 1973). Whatever the
action of PGE2 it is presumably of a local nature since the large
increases found in uterine venous plasma are not observed in the
aortic plasma. This implies that the lungs remove PGE2 from the
venous blood. The enhanced ability of the rabbit lung to inactivate
PGE2 during pregnancy (Bedwani and Marley, 1975), due to a 20-fold
increase in lung prostaglandin dehydrogenase activity (Surv <xrA Armour,
1974), may be of importance in this respect.
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In summary, therefore, the results of the experiments presented
in this thesis suggest that PGF2a of uterine origin is important in
terminating luteal function in the pseudopregnant rabbit. The
increased output of PGF2a from the uterus on Day 17 of pseudopregnancy
does not appear to be related to an increase in the ability of uterine
tissue homogenates to synthesise PGF2a in vitro, nor to the availa¬
bility of substrate. However, it is possible that in vivo PGF2a maY
be synthesised preferentially at this time. The capacity of the
uterus to synthesise PGE2 and PGF2a is affected by the hormonal status
of the animal and, as in other species in which PGF2a acts as a uterine
luteolysin, the synthetic potential of the uterus is greatest follow¬
ing the sequential exposure of uterine tissue to progesterone followed
by oestrogen.
In the pregnant rabbit, the increase in the uterine venous plasma
levels of PGF2a seen at the end of pseudopregnancy is not observed.
This cannot be attributed to a decrease in the ability of uterine
tissue to synthesise prostaglandins, although the reduction in the
endogenous levels of PGF2a at this time may reflect a decrease in
PGF2a synthesis in vivo. However, prostaglandin production by the
pregnant uterus and/or its contents does appear to be important in
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